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ABSTRACT
Cancer is one of the leading causes of death in the western world today. This work
looks at first the development of modern anticancer drugs and their drawbacks. The
need for research into new and more efficient drugs is highlighted. Traditional
anticancer drugs such as alkylating agents have targeted cell DNA causing cell death.
Our approach however was to target a key enzyme, phospholipase D (PLO), in the
cell signalling transduction pathway thus inhibiting cell division.
The natural products wortmannin I and demethoxyviridin II have been shown to
inhibit PLO and so provide a basis for the development of novel anticancer drugs. A
series of furan and thiophene derivatives modelled on the suspected pharmacophore
have therefore been synthesised.
o
o
II
A number of routes towards the synthesis of fused systems III and IV with
carbonyls in conjugation with a furan ring were investigated.
o
(co o o
III IV
IV
Subsequent to this several 3,5-disubstituted furan and thiophene derivatives V were
synthesised from 3-furoic acid and thiophene-3-carboxylic acid.
o
"\..
/'"o
X = 0 or S
o v
Various esters were made and a carbonyl group added at the 5-position using Friedel-
Crafts acylation and Vilsmeier-Haack formylation. This basic structure represents the
simplest form of the active component of wortmannin I. Further elaboration of the
formyl group by reaction with vinylmagnesium bromide and oxidation with
manganese dioxide introduced a,~-unsaturation analogous to that found in
wortmann in I. Diels-Alder cyclisation with various dienes then gave a number of
compounds with bulky side chains. These novel heterocyclic compounds are now
undergoing biological evaluation for inhibition of phospholipase D.
v
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CHAPTER 1
This chapter describes the background of cancer and the development of treatments.
Problems associated with current chemotherapy are discussed in detail highlighting
the need for new and better anticancer drugs.
1.1 THE CANCER PROBLEM
Cancer is an ancient disease dating as far back as the dinosaurs (paleopathologists
have found cancerous lesions on dinosaur bones). Egyptians also drew examples of
breast cancer in their hieroglyphics on papyrus, and by the 4th century B.c. many
types of tumours such as stomach and uterine cancer had been described.
In 1775 Percivall Pott, a London physician, linked the incidence of scrotal cancer in
men to their jobs as chimney sweeps when they were young boys. It was not,
however, until the 19th century that scientists began to study cancer systematically,
looking at what causes cancer and how it can be cured. I
Today, cancer is one of the leading causes of death in the western world. Although
commonly associated with ageing it affects people of all ages and all parts of the
body.
1.2 CAUSES OF CANCER
Causes of cancer are many and varied. Tobacco and bad diet (including alcohol) are
believed to be the two top causes accounting for almost two thirds of all deaths from
cancer.? Ironically these are the most avoidable. Enviromental carcinogens include
industrial pollutants, sunlight and other sources of radiation. Exposure to carcinogens
can also vary according to occupation e.g. painters have a high exposure to benzene, a
known human carcinogen. Inherited genetic defects may also give a person a
predisposition towards developing cancer. This does not mean that an individual will
definitely develop cancer but it does mean that the chances of developing cancer are
increased. There is, however, considerable research into the identification of faulty
genes to allow early detection and thus prevention of cancet.'
1.3 DEVELOPMENT OF CANCER IN THE BODY
When a cell mutates it does not form a tumour instantaneously. The cell must go
through a variety of other transformations which will result in further changes. This
section deals with how a cell can become damaged to initially give a mutated cell and
then further how a mutated cell progresses to give a tumour.
The development and invasion of cancer in the body can be broken down into three
main areas - initiation, promotion and progression (scheme 1.1)4,5
When a carcinogen is introduced into the body a cancerous cell will not immediately
result. This is due to the "latency effect" where a period of time elapses before there
is growth of the tumour. The initial application of a carcinogen will result in the
formation of an irreversible initiated cell. Time may then elapse before a second
agent, known as the promoter, will act reversibly on the initiated cell giving a
premalignant lesion. Changes in the premalignant lesion, such as increased growth
rate, increased invasiveness and metastases, result from the third stage of this process
known as progression. These changes are usually associated with a change in the
number and arrangement of genes which encode for various proteins.
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Scheme 1.1: Development of Cancer in the Body
Several animal experiments have been carried out to demonstrate this sequence of
events.' The first experiments started over 40 years ago with a single application of a
carcinogen to the skin of a mouse. No effect was observed until a second agent was
chronically applied to the same site. Even when the application of the secondary agent
was one year after the initial application 100% incidence of tumour formation
occurred. Animal experiments also demonstrated that promotion was reversible.
Removal of the secondary agent before the appearance of neoplastic lesions caused the
delay or prevention of the lesions appearing. A human example of this process would
be in the development of lung cancer in smokers. Smoking produces benz[a]pyrene
1, a polycyclic hydrocarbon, which is a chemical carcinogen and an initiating agent.
Activation of polycyclic hydrocarbons e.g. 1by the liver will form the epoxydiol 2
which will bind to the base pairs in DNA by intercalation, leading to mutation.
3
Prolonged or repeated exposure to this chemical carcinogen or the application of a
secondary agent (a promoter) may indeed induce a tumour.
ACTIVATION
BY LIVER
1
OH
2
BINDING
TO DNA
MUTATION .......11-------
INTERCALATION
BETWEEN BASE
PAIRS
Scheme 1.2: Interaction Between Polycyclic Hydrocarbons and
DNA
However, by stopping smoking the risk of former smokers developing lung cancer
reduces each year after having stopped.
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1.4 ANTICANCER DRUG DEVELOPMENT
Cancer treatment involving chemicals dates back over 500 years when preparations
involving zinc, silver and mercury were used. However, the first documented case of
a drug being used to treat cancer was in 1865 when Lissauer gave potassium arsenite
(Fowlers' solution) to a patient with leukaemia and noted a positive effects. It was
not however until 80 years later that the first effective anticancer drug was developed
by Adair and Bagg.? Since then, time, money and manpower have been invested by
pharmaceutical companies and universities into the discovery of new and more
effective drugs.
1.4.1 ALKYLATING AGENTS
The development of nitrogen mustards as potential anticancer agents dates back to
1917 when sulfur mustard bis(p-chloroethyl)sulfide 3, was used as a tool in chemical
warfare.f Although side effects of sulfur mustard were known to be burning in the
eyes, skin and respiratory tract, other toxic side effects," such as damage to the bone
marrow and lymphoid tissue were not observed until World War I was over.
Cl
~
S
~
Cl
3
Figure 1.1: Bis( f3-chloroethyl)sulfide
In 1931 Adair and Bagg 7 examined the effect of sulfur mustard on humans when
injected directly into tumours. Although initially good signs were observed. such as
the shrinkage of tumours, the bad side effects previously mentioned prevailed and the
drug was considered to be too toxic for further use.
5
Attention was then turned to the nitrogen analogues of the sulfur mustards. Animal
studies during World War II demonstrated that heavy exposure to the nitrogen
analogues, bis(~-chloroethyl)amino compounds, destroyed lymphoid tissue. In the
late 1930's Gilman and co-workers, knowing the effect that sulfur mustard had on
tumours, investigated the effect of nitrogen mustard on mice with lymphosarcoma. A
positive effect was observed and in 1942 the first clinical trial involving the
administration of a nitrogen mustard to a patient with lymphosarcoma was carried out.
Results of this trial were not made public until 1946 when Gilman and Philips
published a review!" on its success. Although highly successful in shrinking
tumours of patients with lymphosarcoma and Hodgkin's disease the drugs were
found to damage the bone marrow so this damage became a limiting factor in their
use.
One of the first nitrogen mustards shown to be effective as an anticancer drug is the
bifunctional alkylating agent mechloroethamine 4 also known as mustine. It is still in
use today as part of a 4-drug cocktail for Hodgkin's disease. I I
Figure 1.2: Mechloroethamine
Alkylating agents generally function by chemically interfering with DNA replication.
First the nitrogen on the alkylating agent attacks the electropositive carbon next to the
chlorine to form the highly reactive aziridinium ion 5. This will now be very
susceptible to nucleophilic attack as shown in scheme 1.3.
6
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Schemel.3: Attack of Nucleophile on Bifunctional Alkylating Agent
In cells nucleophilic attack will usually be from the N7 of guanine (or in some cases
attack occurs from the N3 of adenine) and a process of de-purination may occur. This
means that the guanine base will detach itself from the DNA strand. However, the
more usual mode of action of a bifunctional alkylating agent is to cause cross-linking
between two separate strands of DNA. This renders the DNA unable to twist apart
and separate for replication which results in cell death (see scheme 1.4).
R = alkyl
R'=CH2CH~1
Scheme l.4:Cross Linking of two DNA Guanine Units
7
The mode of action of mechloroethamine 4 is as described in scheme 1.3.
Mechloroethamine 4 has a major problem, however. It is "too" reactive as it very
readily forms the aziridinium ion. It can only be administered intravenously and its
high reactivity causes irritation at the site of injection.U However, since its
introduction there has been considerable work done on the area of alkylating agents
and nitrogen mustards. Melphalan 6 and Chlorambucil 7 (see figure 1.3) are nitrogen
mustards in wide use today. They are not as reactive as mechloroethamine 4 because
of the aromatic ring adjacent to the nitrogen.P The aziridinium ion wiII therefore not
form so readily and this reduced activity allows time for wide distribution throughout
the body before they exert their effect.
Cl
~~
HOOC~N~
NH2 ClHOOC
6 7
Figure 1.3: Chlorambucil and Melphalan (L-PAM)
One of the most widely used alkylating agents to emerge IS the pro-drug
cyclophosphamide 8.13
o
II
( »<: YN-~"IOICI- "J2 HN0
8
Figure 1.4 Cyclophosphamide
Cyclophosphamide 8 was synthesised with the hope that it would be inactive in the
body until the ring structure was broken down by an enzyme more commonly found
in cancer cells than in normal cells therefore becoming active only in the cancer cell.
8
Although not converted in the cancer cells to its active form, cyclophosphamide is
converted to its active phosphoramide mustard 9 in the liver as shown in scheme 1.5.
In addition to the cytotoxic metabolites 9 and 10 there are a number of non-cytotoxic
metabolites which arise from enzymatic oxidation of the non-cytotoxic intermediates
4-hydroxycyclophosphamide 11 and aldophosphamide 12.
o
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Scheme 1.5: Generation of Phosphoramide Mustard from
Cyclophosphamide
Cyclophosphamide is superior to the other alkylating agents and is used in treatment
of lymphosarcoma, Hodgkin's disease, breast, ovarian and lung cancers.
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1.4.2 ANTIMETABOLITES
Antimetabolites resemble the structure of natural metabolites necessary for nucleic acid
synthesis required for cell division and therefore interfere with the normal utilisation.
The antimetabolite blocks the normal enzyme from doing its natural job. The three
classes of compounds under the category of antimetabolites are antifolates, antipurines
and antipyrimidines.
ANTIFOLATES
Following a report that folic acid concentrate inhibited sarcoma in mice Sidney Farber
investigated the effect of folic acid derivatives in leukaemic children. In 1947 he gave
16 children with leukaemia the drug aminopterin 13 and noted that temporary
remissions occurred in 10 out of the 16 children 14. The search for more powerful but
less toxic antifolates thus began. In 1949 a breakthrough occurred when an analogue
of aminopterin methotrexate 14was developed by Seegarl>.
13 R = H
14 R = Me
Figure 1.5: Aminopterin and Methotrexate
Methotrexate 14 is an analogue of the vitamin folic acid. Reduced folate is required
for the transfer of methyl groups in the biosynthesis of purines and in the conversion
of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP)
which are processes necessary for cell division (see scheme 1.6). The latter of these
10
reactions is dependent upon reduced folate being available. Methotrexate 14 is a
competitive inhibitor of dihydrofolate reductase, an enzyme essential for the
generation of the reduced folate. Without the reduced folate dTMP production is
inhibited and the cells cannot divide, resulting in cell death.
dUMP
o
HN~
O~N)
I
Deoxyribose
monophosphate
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dTMP
o
HN~CH3 ~.~DNA
I ,_.JJ synthesis
O-?--...N
I
Deoxyribose
monophosphate
Af,N10 - methylene
tetrahydrofolate..
Dihydrofolate
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tetrahydrofolate ,
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Scheme 1.6: Inhibition of Cell Division by Methotrexate
Currently methotrexate 14 is one of the best drugs of this class to be developed and is
still widely in use for the treatment of cancer of the uteris. After several treatments the
tumour is completely destroyed and the patient is restored to full health.
More recently Fernandez and co-workers 16 have developed a number of new
methotrexate analogues which have shown strong anticancer activity. The prototype
for these compounds is IAHQ 15 which, like methotrexate 14, has been shown to
compete with dihydrofolate reductase and is active against colon cancer.
1 1
Figure 1.6: lAHQ
ANTIPYRIMIDINES
Antipyrimidines were developed as potential anticancer compounds by Heidelberger
and co-workers 17. Previously it had been reported that abnormal cells in tumours
utilised an abnormally high quantity of uracil which is essential for nucleic acid
synthesis and cell division. Heidelberger postulated that if a compound were
structurally similar to that of uracil it may then compete with it and a potential
anticancer compound may consequently be found. This hypothesis led to the
discovery of 5-fluorouracil 16, a compound differing from uracil only by the fluorine
at position 5.
Figure 1.7 5-Fluorouracil
5-Fluorouracil 16 blocks the formation of thymidine nucJeotides from uracil
nucJeotides by inhibiting the enzyme thymidylate synthetase (see scheme 1.6).
Methylation is prevented because of the fluorine at position 5. 5-Fluorouracil 16 was
the first effective antipyrimidine to be found and is useful in the treatment of certain
forms of breast cancer and gastrointestinal cancer. Since the introduction of 5-
fluorouracil 16 other antipyrimidines have been developed for other cancers. For
12
example, cytosine arabinoside 17 is an antipyrimidine which was first used in patients
in the early 1960's and is still one of the main drugs used for antileukemic therapy
rodayl''.
OH
17 OH
Figure 1.8: Cytosine Arabinoside
ANTIPURINES
The development of antipurines as potential anticancer and antiviral compounds dates
back to the early 1940s to the work of George Hitchings and Gertrude Elion at the
Well come Research Laboratories.l? In 1944 Hitchings postulated that it might be
possible to prevent cell division by the inhibition of nucleic acid synthesis by a purine
analogue. Elion was given the task of synthesising hundreds of purine and
pyrimidine analogues. By 1951 they had synthesised and tested over one hundred
compounds and amongst the most active were 6-mercaptopurine 18 and 6-
thioguanine 19 which are the sulfur analogues of hypoxanthine 20 and guanine 21
respectively. Both were shown to be very active against rodent tumours and
leukaernia-",
R
HNJ)-N;~ ..JLN
N H
18 R = S
20 R=O
Figure 1.9: 6-Mercaptopurine and 6-Thioguanine
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Their mode of action is complicated but believed to be through incorporation of their
nucleotide metabolites into DNA. The cytotoxicity of 6-thioguanine 19 probably
results from its mistaken incorporation during DNA synthesis resulting in functionally
changed polynucleotides i.e. altered DNA. In contrast 6-mercaptopurine probably
affects a number of enzyme activities.
Clinical trials began involving children with leukaemia and it was observed that 6-
mercaptopurine caused the initial remission of cancer. 6-Thioguanine 19 was shown
to be more effective against rat tumours but was more toxic. Today, 6-
mercaptopurine 18 is used in combination with other drugs to cure almost 80% of
children with acute lymphocytic leukaemia and 6-thioguanine is used to treat acute
myelocytic leukaemia.
As well as anticancer drugs Hitchings and Elion also discovered several other
clinically useful drugs such as allopurinol for treatment of gout, acyclovir for
treatment of the herpes virus and azathiopurine, an immunosuppressive drug used in
kidney transplants. In 1988 Hitchings and Elion received the Nobel prize for their
contributions to the development of effective drugs for the treatment of cancer and
other diseases.
1.4.3 NON COVALENT DNA BINDING DRUGS21
The binding of drugs to DNA is complex involving interactions with sugars,
phosphates, bases and base stacks. The foremost type of physical interaction is
intercalation between the drug and the DNA double helix. Doxorubicin 22, an
anthracycline molecule linked to the sugar daunosamine is an example of such an
intercalator.
14
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Figure 1.10: Doxorubicin
To permit intercalation, the DNA double helix must stretch along the strand length to
allow insertion of the drug between, and parallel to, the stacked adjacent base pairs
without disturbing the overall stacking of the bases. The result of this is that the
backbone of the DNA becomes distorted leading to partial unwinding of the helix.
However, much of the DNA is packed in such a way as to be protected from this type
of drug. Doxorubicin 22 must therefore operate by other mechanisms to explain its
toxicity. The quinone ring may undergo metabolism to produce a semiquinone radical
which in turn reacts rapidly with oxygen to give the superoxide 02-.22 This
superoxide will then undergo several reactions which ultimately lead to cell death. In
hypoxic conditions i.e. where the cell is starved of oxygen doxorubicin 22 still leads
to cell death so the previous two mechanisms cannot be the only ones acting. A
mechanism involving the generation of free radicals can be used to explain this, but in
reality the exact mode of action of doxorubicin 22 is not fully understood.
Doxorubicin has a variety of clinical uses for many types of solid tumours and
leukaemia.
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Other intercalators include ellipticine 23 which is an alkaloid first isolated in 1959 by
Horning and co-workers= from the leaves of Ochrosia elliptica (Apocynaceae).
Ellipticine 23 and its analogue 9-methoxyellipticine 24 have been shown to possess
anticancer activity against experimental tumours and leukaemias.
R
23 R= H
24 R = OMe
Figure 1.11: Ellipticine and 9.Methoxyellipticine
1.2.4 INHIBITION OF CHROMATIN FUNCTION
Chromosomes are packed tightly in the nucleus of the cell and undergo many changes
with regard to intracellular positioning and conformation. There are several proteins
and enzymes in the cell which will control the way in which the DNA replicates and
agents have been developed which interfere with these processes. Two main classes
of such compounds are topoisomerase inhibitors and microtubule inhibitors.
TOPOISOMERASE INHIBITORS24
Prior to cell division DNA must unwind and untangle for processes such as
replication and transcription to occur. Topoisomerases are enzymes which selectively
relax and break parts of the DNA strand so that replication can occur. Topoisomerase
II interacts with the DNA strand to form a complex which is termed "non-cleavable"
as shown in scheme 1.7. The enzyme then cuts both strands giving a transient
cleavable complex. The DNA is then free to undergo the required conformational
16
change. The break then reseals and the topoisomerase dissociates from the DNA
double strand. The cleavable complex is however vulnerable to protein disruption or
denaturation as shown which results in permanently cleaved DNA.
TOPOISOMERASE II
.____1_L]
+
DOUBLE STRANDED DNA
FJI
L..- L____J
NON-CLEAVABLE COMPLEX
-
TRANSIENT CLEAVABLE
COMPLEX
Protein d;',"PI;~'
denaturation >n ~
Protein disruption or
denaturation
DOUBLE STRAND BREAK
Scheme 1.7: Inhibition of Topoisomerase 11 Enzyme
Drugs such as etoposide 25 stabilise the cleavable complex such that the chances of
double strand breakage are much higher. This destruction of the DNA therefore
results in cell death.
Figure 1.12: Etoposide
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MICROTUBULE INHIBITORS
Serendipity played a part in the discovery of the vinca alkaloids, the first microtubule
inhibitors to be found. In the late 1950's Noble and fellow workers-> examined the
claim that vinca alkaloids extracted from the periwinkle plant could produce
hypoglycaemia. Although the claims could not be substantiated, bone marrow
suppression was observed in experimental rats. Later Johnson and co-workers=
elaborated on this work by demonstrating that certain alkaloid fractions possessed
antileukaemic activity. Of the 4 alkaloids tested only two, vincristine 26 and
vinblastine 27, were used to treat cancer in humans.
26 R = CHO
27 R = CH3
Figure 1.13: Vincristine and Vinblastine
Vincristine 26 and vinblastine 27 are inhibitors of microtubule formation.
Microtubules are protein polymers that are responsible for various aspects of cellular
morphology and movement such as formation of the mitotic spindle which is
necessary for the separation of chromosomes during cell division. Their major
component is tubulin and they exist in a state of dynamic equilibrium with continuous
formation and degradation from cytoplasmic tubulin. Indeed, they can be thought of
18
as growing and shrinking polymers as shown in scheme 1.8.
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Scheme 1.8: Dynamic Equilibrium Between Microtubule Growing and
Shrinking Polymers
The tubulin released from a microtubule when it depolymerises would normally attach
itself to a growing polymer. The vinca alkaloids vinblastine 27 and vincristine 26
attach themselves to the tubulin rendering them useless for the growing microtubule.
The shrinking polymer will then release more tubulin which again will be bound to the
vinca alkaloid. Two shrinking polymers are thus formed with the result that there are
no effective microtubules in action. Note that although structurally similar vinblastine
27 and vincristine 26 display very different toxicities. Vinblastine 27 is used in
combination chemotherapy of testicular cancer whereas vincristine 26 is used for the
treatment of childhood leukaemia
Taxol® (paclitaxel) 28 is also a microtubule inhibitor and is one of the most
promising drugs for the treatment of breast or colon cancer. It is extracted from the
pacific yew but it takes one mature tree to provide enough Taxol® to treat one patient.
The tree is a slow growing evergreen and is becoming rare. A synthetic approach to
Taxol® from more readily available precursors is therefore desirable. Although total
synthesis of Taxol® has been successfully carried out, is not suitable for commercial
production due to low yields in multi-step syntheses.27,28,29
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Figure 1.14: Taxol®
Several companies are however investigating tissue cultures of the Pacific yew bark
cells to make Taxol® 28. Another approach to the problem is to use a tissue-culture
approach in plants which synthesise compounds which are structurally similar to
Taxol® 28. Pierre Potier-? found that 10-deacetylbaccatin III 29, a compound
structurally similar to Taxol® 28 could be isolated from Taxus baccata .
HO..··
o
HO OAe
OCOPh
29
Figure 1.15: IO-Deacetylbaccatin III
Semi synthesis of Taxol® 28 from this precursor can easily be achieved via several
simple steps as shown in scheme 1.9. 10-Deacetylbaccatin III 29 is first protected at
the carbon-7 position using triethylsilylation and acetylated at the carbon-I 0 position.
Acylation at carbon-13 by O-protected N-benzoyl phenylisoserine followed by
deprotection of both carbon-7 and carbon 2' affords Taxol® 28.
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Scheme 1.19: Synthesis of Taxol® from 10-Deacetylbaccatin III
The mode of action of Taxol® 28 is to promote the assembly of microtubules by
causing the stabilisation of the polymers. There will therefore be no free tubulin for
other microtubules to form and without the necessary microtubules the cells cannot
function properly resulting in cell death.
A compound which has recently been shown to possess the same inhibitory action on
cancer cells as Taxol® 28 is discodermolide 30. Discodermolide 30 was isolated
from Discodermia dissoluta, a sponge that grows at a depth of around 200 metres in
the Caribbean.' J Pre-clinical tests have shown that discodermolide 30 is at least as
potent as Taxol® 28 against breast cancer cells and eighty times as potent against
leukaemia cells. Since its discovery almost a decade ago there have been several
21
research groups looking at its synthesis and to date there are at least three methods
underway for total synthesis.32,33,34
0))0 ,,\\.'
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OH OH 30
Figure 1.16: Discodermolide
1.5 PRESENT DAY CANCER THERAPY
Surgery and radiotherapy can be used to eradicate small primary tumours but the main
problem with these treatments are that they are "local". This means that they are only
useful for the treatment of a tumour in one specific site and are therefore of no use as a
single therapy when the cancer has spread to sites distant from its origin.
Chemotherapy is a more wide reaching therapy and is therefore an acceptable
alternative for secondary tumours.
Clinical results have shown that when single drugs are administered to tumours they
do not give an optimum cure because of the resistance some tumours display to certain
drugs. Therefore if there is more than one drug present within the system then there
is a chance that the tumour will not show resistance to the second drug. Combination
chemotherapy involving the administration of several drugs at the same time or the
combination of chemotherapy with surgery and/or radiotherapy often provides the
best treatment. A summary of these treatments is given below.
22
1.5.1 COMBINATION CHEMOTHERAPy35
Combination chemotherapy involves the utilisation of several anticancer drugs in the
same treatment. In selecting drugs for use in this therapy there are several restrictions
which must be considered. Only drugs which have been shown to display excellent
anticancer activity and whose toxic effects either do not overlap or produce their side
effects at different times during or after treatment can be used. The drugs must also
have different modes of action and/or do not display cross-resistance. By using
combination chemotherapy patients with leukaemia will be free from the disease 5
years after treatment and many will go on to be completely cured.J''
1.5. 2 MULTIDISCIPLINARY CHEMOTHERAPY
Adjuvant chemotherapy involves the application of chemotherapy to tumours which
have previously been reduced in size or eradicated either by surgery, radiotherapy or
by a combination of both. An application of this therapy is to women who have stage
II breast cancer-? and whose primary tumour has successfully been eradicated.
Without the treatment these women have a 40% chance of dying due to residual cancer
cells still present. Adjuvant chemotherapy reduces this chance to 20%. However the
main drawback is that women who would normally be cured by the surgery and/or
radiotherapy alone risk the toxicities associated with the chemotherapy. Before this
therapy is used the risk: benefit considerations must be evaluated.
As well as applying chemotherapy after surgery there are advantages to applying it
before surgery.P' This method is commonly used for treating osteogenic sarcoma (a
bone cancer found in young women).39,40 Amputation achieves only a 20% cure rate
because in addition to the bone cancer there are small pockets of cancer cells in the
lungs that are too small to be detected when the amputation is carried out. However if
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chemotherapy is given before and after surgery the small pockets of cancer cells in the
lungs will be destroyed and the chances of survival will be vastly improved,
completely curing 70 - 80%.
1 .6 PROBLEMS WITH PRESENT DAY CHEMOTHERAPY
One of the main limiting factors with chemotherapy is that it is best used to treat small
tumours. Anticancer drugs can only penetrate and kill so much of a tumour in one
dose. Therefore in a large tumour only 99% of cancer cells may be eradicated
whereas in a small tumour all the cancer cells will be eradicated. The remaining
cancer cells in the large tumour although present in small quantities will quickly
multiply and replicate again producing a large tumour."!
Anticancer drugs also kill healthy dividing cells particularly those with a high rate of
proliferation such as hair follicles, gastrointestinal tract, bone marrow and
lymphocytes involved in the immune defence mechanism. It is their destruction
which causes the side effects commonly associated with chemotherapy such as hair
loss, nausea/vomiting and an increase in susceptibility to infection. This can cause
distress and embarrassment for the patient. In addition to the anticancer drugs, other
medication is often given to the patient for pain relief. However, this too can be
problamatic as the additional medication can interfere with the normal functioning of
the anticancer drug. For example if aspirin is given for pain relief it will inhibit the
normal excretion of methotrexate.t?
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1.6.1 THE THERAPEUTIC INDEX AND TUMOUR RESPONSE
Current anticancer drugs are said to have a low therapeutic index (TI).
TI = Dose producing toxicity in 50% of the population
Dose producing effectiveness in 50% of the population
This means that the doses which effect a good response in comparison to those which
give bad responses are only separated by a fine line - this is clearly seen in figure
1.17.43 It is not always possible, therefore, to increase the response by simply
increasing the dosage. To overcome this, combination chemotherapy can be
employed. Although this will bring about a reduction in tumour size it may also bring
about an increase in side effects for the patient mainly because the effect the drugs
have on one another is unknown.
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Figure 1.17: Effect of Drug Dosage on Cell Death
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1.6.2 TUMOUR RESISTANCE44
A major problem encountered when treating tumours is that they may show
resistance. This resistance can be divided into two types - intrinsic or acquired.
A tumour is instrinsically resistant if it does not initially respond to the the anticancer
drug. This could be due to the poor uptake of the drug by the cell or an inability of
the patient to convert the drug into its active form. The overall effect is that the
tumour does not receive the drug.
Acquired resistance results when there are many different types of cells arising from
mutations within a tumour. Present within a single tumour can be those cells which
do respond to treatment and those which simply do not respond. This means that a
tumour which has initially shown a good response may seem to develop resistance as
the proportion of non-resistant cells decreases.
It is however not fully understood why some cells display good responses to drugs
whilst others are non-responsive.
1.6.3 ABSORPTION, DISTRIBUTION AND EXCRETION45
The proportion of drug available for potential therapeutic effect is dependent on the
amount absorbed and delivered into circulation. This is usually called the
bioavailability of a drug and is dependent upon several factors. Physical
administration of the drug is important. If the drug is administered intravenously then
it is assumed that the drug has been absorbed completely. On the other hand if the
drug is administered by some other means such as oral or intramuscular then it may be
assumed that only partial absorption has taken place. This is because the drug has
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several "barriers" to penetrate before general circulation. The drug must first dissolve
and pass through the gastrointestinal mucosa in order to reach the intestinal capillaries.
From there the drug must be transported through the liver to allow metabolism
followed by general circulation. Bioavailability will decrease in each of these steps
and metabolism will often render many drugs inactive. The pathway of an anticancer
drug is shown in scheme 1.10.
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Scheme 1.10: Pathway of Anticancer Drug
Excretion of the drugs also poses a problem. Many have to be excreted via the kidney
in the urine. The problem is that many drugs such as methotrexate and cis-platin are
potentially toxic to the kidney. It may therefore be necessary to stimulate drug
excretion by maintaining an alkaline pH for methotrexate or by producing a rapid
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urinary flow of cis-platin, This type of excretion unfortunately cannot be tolerated in
patients who have problems with their renal function.
Existing anticancer drugs are therefore not effective enough and new targets and new
drugs must still be found.
1.7 RECENT DEVELOPMENTS IN THE SEARCH FOR NEW
ANTICANCER THERAPIES
The anticancer drugs previously described are concerned with inhibition of cell
replication by interfering with the DNA. There are however a number of new
approaches which look at tackling the problem of cancer from a different angle. This
section deals with a few of these approaches.
1.7.1 ANGIOGENESIS INHIBITORS46,47
Like any other growing tissue in the body, tumours require nourishment in the form
of nutrients and oxygen, as well as efficient elimination of waste material such as
carbon dioxide and lactic acid to survive. Tumours have therefore developed the
ability to release specific growth factors called angiogenic factors which induce blood
vessel formation. The formation and proliferation of these blood vessels is called
"angiogenesis". This, process however is not limited to tumours as angiogenesis
occurs naturally in the body when a wound heals.
Having recognised that tumour growth is angiogenesis-dependent, a new potential
cancer therapy has been proposed on the basis that if proliferation of blood vessels
could be halted then the cancer cells would die. A new class of compounds called
"angiostatic steroids" is emerging with tetrahydrocortisol as one of the most
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promising drugs in this area. Tetrahydrocortisol 31 is the breakdown product of
cortisone, a hormone responsible for regulating blood pressure and blood sugar
particularly when the body has experienced stress or an injury and has been shown to
inhibit capillary growth. When administered in combination with heparin, normally
used to prevent clotting, the inhibition is increased.
31
Figure 1.18: Tetrahydrocortisol
Angiostatic steroids have not yet been approved to treat cancer and along with many
other types of angiogenesis inhibitors are now being investigated for use.48,49
1.7.2 GENE THERAPY
Gene therapy is the replacement of genes such as tumour suppressor genes which
have become inactivated during malignant tumour development. The simplest strategy
to insert the gene is to infect the cancer cell with a virus carrying a normal copy of the
gene. It would be hoped that normal cells already carrying 2 copies of the gene would
tolerate additonal copies. Once the gene has been inserted the cancer cells should
revert back to their normal pattern of growth.
Although it is virtually impossible to deliver the missing gene to all the tumour cells
this does not pose a problem. Studies have shown that by replacing one tumour
suppressor gene in cells which have multiple genetic defects the tumour can be
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reversed and a normal growth pattern resumes. Gene therapy would be most suited to
those cancers which are genetically inherited and to those which are caused by genetic
defects. One gene which is being studied extensively for replacement gene therapy is
the pS3 gene. This encodes the protein pS3 which is involved in the control of DNA
replication in mutated cells. It is not expressed in normal undamaged cells but more
than half of human tumours have been found to react with antibody to pS3. After
mutation of the DNA p53 is activated halting DNA synthesis until the damaged DNA
has been repaired. However, if p53 is unable to switch off the replication, which
happens in mutated cells, then the cell will replicate in the uncontrolled and
undifferentiated manner associated with cancer cells. Recently there have been
successful trials in the US by Roth and co-workers at the M. D Anderson Cancer
Centre in Houston, Texas5o. They managed to replace defective pS3 genes with
normal copies in lung cancer patients using gene therapy and succeeded in either
shrinking tumours or halting their growth. However, all the patients subsequently
died from other tumours which had resulted from metastasis. This illustrates the
problem mentioned earlier of getting the normal copy of the pS3 gene either into all the
lesions or into the primary tumour before it has had a chance to spread.
1.7.3 BORON·NEUTRON CAPTURE THERAPy5 J
An alternative treatment for cancer, although not yet in use, is Boron Neutron Capture
Therapy (BNCT) involving the capture of a slow moving neutron by a JOBnucleus.
The main application of this treatment would be where tumours are inaccessible by
other methods.
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The IIB which is consequently formed undergoes nuclear fission to produce the
cytotoxins 4He2+ and 7Li2+ accompanied by 2.4 MeV of kinetic energy and weak
gamma radiation. These are short lived species which can travel only a small distance
to the surrounding cells. Thus, if the lOBcan be selectively placed in cancer cells then
the toxins produced will kill only the malignant cells whilst leaving the healthy cells
intact. This sequence of events is summarised in scheme 1.11.
"n + CELL NO REACTION
10B + CELL 10B • CELL (INTERACTION SPECIFIC
TO CANCER CELL)
10B • CELL + 1n------. (CELL DEATH)
Scheme 1.11 Cell Death Resulting from BNCT
The lOB is administered in the form of an enriched lOB compound although an
efficient mechanism of drug delivery has yet to be developed. Once administered a
beam of slow moving neutrons is then applied to the tumour resulting in cell death.
Currently B 12HIISH2- (BSH) 32 (injected intraveneously in the form of its sodium
salt) and 4-(dihydroxyboryl)phenylalanine (BPA) 33 are undergoing clinical trials
against primary melanoma lesions and brain tumours.
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Figure 1.19: BSH and BPA
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1.8 THE INTRACELLULAR SIGNAL TRANSDUCTION PATHWAY
In order to investigate new anticancer drugs one must first look at how the cell divides
and what triggers a cancer cell to divide in an uncontrollable and undifferentiated
fashion.
In healthy cells proto-oncogenes are genes which normally encode proteins that are
components of signalling pathways. The products of these genes fall into S main
categories as shown:52
1 Growth Factors: secreted by cells and stimulate cell growth eg platelet-
derived growth factor (pDGF).
2 Cell-Surface Receptors: receives and encodes growth factor.
3 Tyrosine Kinase: responsible for intracellular signalling and regulates
protein function.
4 GTP-binding proteins: involved in activation of several hormone and growth
factor mediated signalling pathways.
5 DNA-binding proteins: involved in regulation of gene expression in the nucleus
and in transcription.
The over expression of a proto-oncogene to give an oncogene can lead to the
overactivation of the signalling pathway and the cell will receive a signal for
unrestrained growth. If a drug could be found which would inhibit only the signal
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transduction pathway activated by an oncogene whilst leaving the other pathways
untouched then a route to reversing cancer will have been dicovered.
Cell division begins when a growth factor, a proto-oncogene as previously described,
binds to its specific cell receptor site on the cell membrane activating a cascade of
intracellular signalling reactions. These cascades involve small effector molecules
called second messengers and the overall result of this process is that the cell will
receive a signal to divide.
Receptor
Sites
~n~("v
Growth
Factor
Cell Membrane
Biological Cascade of
Second Messengers
.. Nucleus
CELL DIVISION
Scheme 1.12 Pathway leading to Cell Division
However in cancerous cells the process of cell division is over-exaggerated. This can
be due to several factors. Over production of the growth factor or mutation of the cell
receptor site in such a way that it accepts any growth factor are specific examples of
abnormal expression of proto-oncogenes. In both cases the signalling pathway will
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be over expressed and the cell will receive a signal to divide uncontrollably. Possible
targets for anticancer drugs can therefore be to prevent the overproduction of the
growth factor, blockage of the cell surface receptor site, blockage of components in
the signalling pathway or by direct inhibition of DNA replication in the nucleus.
As well as the over-expression of the oncogenes the inactivation of tumour suppressor
genes can also playa part in tumour growth. This was explained in more detail in
section 1.7.2 which dealt with gene therapy.
The area of anticancer drug therapy in which this project deals with is the inhibition of
the intracellular signal transduction pathway.
1.8.1 SIGNALLING PATHWAYS - WHICH ONE TO INHIBIT?
In cells there are many different signalling pathways involving secondary messengers
which initiate the various processes such as hair growth, cell division and other
regulatory functions which occur within the cell.s3 In cancerous cells it has been
observed that levels of one of the intracellular second messengers diacylglycerol have
been phenominally high.54 Presumably this is due to the over activation of the
signalling pathway leading to the formation of the diacylglycerol. Diacylglycerol has
been implicated in several cellular processes including regulation of cell growth.
differentiation and regulation of gene expression. In particular it activates protein
kinase C which initiates cell division.S> The role of diacylglycerol is therefore
essential. Without it cells cannot divide, whilst too much will cause over activation of
protein kinase C which results in overproliferation. In light of this evidence many
research groups have chosen to inhibit protein kinase C as a target for a potential
anticancer compound. This project deals with the inhibition of phospholipase D, a
key enzyme in the production of diacylglycerol. If the levels of diacylglycerol can be
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controlled, so too can protein kinase C activity and ultimately so too can cell division.
It is also hoped that inhibition of this signalling pathway would be selective enough to
leave all the other necessary pathways required for normal cell growth and function
intact.
1.8.2 SOURCES OF DIACYLGLYCEROL56
There are several routes to the production of diacyglycerol as shown in scheme 1.13.
Initially it was thought that one of the main sources of diacylglycerol was by the
phospholipase C catalysed breakdown of phosphatidyl inositol-4.5-bisphospate
(PIP2) to give inositol-l ,4,5-trisphospate (lP3) and diacylglycerol. IP3 is believed to
mobilise intracellular Ca2+ from the endoplasmic reticulum while diacylglycerol
increases the affinity that protein kinase C has for Ca2+. The result is an overall
increase in the activity of protein kinase C and the cell divides.
PLC
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DAG - Diacylglycerol
PIP2 - Phospatidylinositol-4,5-bisphosphate
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PAP - Phosphatidic acid phosphohydrolase
Scheme 1.13: Pathways Leading to Production of Diacylglycerol and
Protein Kinase C Activation
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The general belief now, however, is that the main source of diacylglycerol comes
from the breakdown of phosphatidyl choline found in the cell membrane. This
breakdown can occur via two different pathways as can be seen from scheme 1.13.
Phospholipase C catalysed breakdown involves a direct pathway to grve
diacylglycerol and choline. The phospholipase 0 catalysed breakdown goes via an
indirect pathway giving first phosphatidic acid which is broken down into
diacylglycerol by phosphatidic acid phosphohydrolase. This route is shown in more
detail in scheme 1.14.
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Phosphatidic Acid
PAP
PROTEIN KINASE C
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CH20C(O)R1
R2C02tH
OH
Diacylglycerol
Scheme 1.14 Direct Production of Diacylglycerol from Phosphatidyl
Choline
It is now widely believed that the indirect route to diacylglycerol involving
phospholipase 0 is the main route to the formation of diacylglycerol.l"
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1.8.3 INHIBITION OF PHOSPHOLIPASE D BY WORTMANNIN
AND RELATED COMPOUNDS
Reinhold and co-workers 57 carried out a series of experiments to deduce the mode of
activation of phospholipase D. Their experiments primarily involved the investigation
of a phospholipase D catalysed phosphatidylation reaction which converted ethanol to
phosphatidylethanol. The amount of phosphatidylethanol generated was then used as
a measure of the activation of phospholipase D. From their findings they concluded
that there were 3 separable but interacting mechanisms for phospholipase D activation.
In particular, one of these mechanisms was found to be inhibited by wortmann in.
In 1991 Bonser and co-workers= also demonstrated that wortmannin 34 and its
related compound demethoxyviridin 35 blocked both phospholipase C and
phospholipase D activation in the human neutrophil.
o
o
34 35
Figure 1.20: Wortmannin and Demethoxyviridin
In light of this evidence therefore it would seem appropriate that wortmannin 34,
demethoxyviridin 35 and their related compounds provide a starting point for the
synthesis of new anticancer drugs.
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CHAPTER 2
2.1 LEAD COMPOUNDS
Steroids belonging to the viridin series possess the common backbone 36 and share
the common feature of a furan ring fused between C-4 and C-6 of the steroidal
framework.
16
2
3
Figure 2.1: Common Backbone of the Viridin Steroidal Family
Many of these compounds possess selective antifungal activity and more recently they
have attracted interest in their ability to inhibit steps in the cell signalling process
making them attractive potential anticancer drugs.
2.2 VIRIDIN AND DERIVATIVES
Viridin 37 was first described in 1945 as an antifungal metabolite of Gliocladium
virens.r'
o
37
Figure 2.2: Viridin
38
Its structure was determined by oxidative degradation. When treated with hot aqueous
potassium permanganate viridin gave benzene-l ,2,3,4-tetracarboxylic acid6o,61 38
from the aromatic C ring. Milder oxidation with chromic acid gave the phthalide 39,
the structure of which was confirmed by synthesis. This degradation confirmed the
relationship of both the carbonyl at position 7 and of the methyl group at position 10.
The carbon skeleton of rings B, C and 0 and the position of the furan ring were
elucidated by the transformation of 4062,63 (which is the product of hydrogen
peroxide oxidation of viridin) into the methylcycJopentanaphtho[2,3-b]furan 41. Like
the phthalide the structure of this compound has also been confirmed by synthesise+
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Scheme 2.1: Structure Elucidation oj Viridin
39
Finally the overall structure was confirmed by IH nmr studies of viridin and its
derivatives= and by X-ray analysis'v. The absolute stereochemistry followed from
biosynthetic studies'".
Care must be taken when purifying viridin as it readily undergoes isomerisation at C-2
to give the epimer ~-viridin 42. To avoid this happening when isolating viridin 37 or
its derivatives acidic alumina must be used for purfication.
o
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Figure 2.3: {3-viridin
Viridiol 43 is a dihydroderivative of viridin 37 and studies by Jones and co-
workerssf have shown that it is formed irreversibly from the liquid culture of viridin
37 in the presence of C. virens, a viridin-producing fungus. Viridin 37 labelled with
14Cat the methoxy group was taken up by the mycelium of C. virens and reduced to
radiolabelled viridiol 43.
Viridiol 43 is ineffective as an antibiotic but is a potent phytotoxin.v? As the
reduction to viridiol 43 is independent of culture pH, carbon source and nitrogen
source this transformation is therefore seen to have potential herbicidal applications.
40
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Figure 2.4: Viridiol
Other viridin-producing fungi include Trichoderma viride where it is produced in the
surface culture of Raulin Thorn medium at 25°C_7o If, however, fermentation is
carried out at 32°C viridin 37 is produced in a much lower yield but is accompanied
by a less polar metabolite virone 44 which is not produced at all at 25"C. Its structure
was deduced by Blight and co-workers"! .
o
o
Figure 2.5: Virone
Demethoxyviridiol 45 and demethoxyviridin 35 have been isolated from
Nodulisporium hinnuleum. Both structures (see figure 2.6) were elucidated by X-ray
crystallography'? and extensive chemistry has been carried out on the latter derivative.
o
R
35 R=O
45 R = n-H, ~-OH
Figure 2.6: Demethoxyviridin and Demethoxyviridiol
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Like viridin 37, demethoxyviridin 35 is relatively unstable in alkaline conditions and
is handled in an acidic medium wherever possible. It readily gives its monoacetate 46
when treated with acetic anhydride and pyridine.T' Treatment with methanesulfonyl
chloride gives the monomethanesulfonate/J which undergoes facile elimination to
afford the a,~-unsaturated ketone 47 (see figure 2.8).
o o
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Figure 2.7 Derivatives of Demethoxyviridin
The lability to alkali shown by demethoxyviridin 37 and its derivatives may in part be
due to facile conjugate addition to the furan ring at C-20 under the influence of the
carbony Is at C-3 and C-7. 74 (see scheme 2.2)
1
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o
Scheme 2.2: Lability of Furan System to Base
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2.4 WORTMANNIN AND DERIVATIVES
Wortmannin 34 was first isolated from Penicillium wortmannii in 1946 by Brian and
co-workers v. The structure was elucidated both by chemical analysis." and by X-ray
crystallography 76.
o
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Figure 2.8: Wortmannin
Due to the sensitive nature of the furan system Haefliger and co-workers"? looked at
protecting the furan nucleus with secondary amines. This would allow manipulation
of the rest of the molecule (see scheme 2.3 for the protection).
MeO MeO,, """'-.
o
Et
o
HN(Etb.....-
H~-Et
Et
MeO" """'-.
Scheme 2.3: Protection of the Furan Nucleus
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The same group of workers isolated ll-desacetoxywortmannin 48 as a new
metabolite from the culture filtrate of Penicilliumfuniculosum Thorn."
o
48
Figure 2.9 l l-Desacetoxywortmannin
Although possessing weak antifungal activity) )-desacetoxywortmannin 48 is highly
active as an antiinflammatory agent. Owing to this interesting property, steps were
taken to further derivatise both wortmannin 34 and )) -desacetoxywortmannin 48
with the introducton of a corticoid side chain at position )7 and to transform the
acetoxy group at C-I ) into an alcohol. The antiinflammatory potency of the parent
compounds and their derivatives were then compared. When given to rhesus
monkeys, a single dose of 1 or 3 mg/kg caused weakness, decreased motility,
uncoordinated behaviour and anorexia. When given to rats, II-desacetoxy-
wortmannin 48 exhibited a dose-dependent inhibition of primary and secondary
arthritis by improving the grip function. However upon repeated application of the
compounds toxic side-effects were observed. Introduction of the corticoid side-chain
caused complete loss of activity.
Although these compounds were shown initially to have interesting and important
properties, their high toxicities prevented further development into useful drugs. The
chemistry then lay dormant for almost two decades but interest in these steroids
continued to grow. Interest grew particularly in their importance as inhibitors of
enzymes involved in the signalling pathways leading to cell division.
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Broka was the first to synthesise the furanocyclohexadienone lactone subunit 49 of
both wortmannin 34 and ll-desacetoxywortmannin 48,79 The subunit was tested
for biological activity to block fMet-Leu-Phe stimulated generation of superoxide by
neutrophils but was shown to be inactive under conditions where wortmannin 34 had
an ICso of 0.1 !J,M.
o
Figure 2.10: Furanocyclohexadienone unit of Wortmannin
In 1994 wortmannin 34 was reported to be a potent (4.2 nM) and selective inhibitor
of phosphatidylinositol-3' -kinase.s" This kinase has been identified as an important
enzyme in a number of signalling pathways leading to cell transformation.
Wortmannin 34 therefore became an attractive new compound for leads for new
anticancer compounds.
Researchers at Lilly in Indiana were interested in making synthetic modifications to
the furan portion of the molecule since the highly electrophilic C-20 position may be
responsible for much of its biological acrivity'' '. Studies on the configuration of the
double bond on ring opening with amines showed that secondary and primary amines
give the E- and Z-geometries respectively. This can possibly explain the marked
differences in activity (see scheme 2.4). The compound with Z-geometry displays
hydrogen bonding to the carbonyl at position 3 which will "lock" these molecules into
this position.
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Scheme 2.4 Primary and Secondary Amine Adducts of Wortmannin
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To explore further the chemistry of the furan and specifically the functionality at C-20,
wortmannin 34 was treated with diazomethane (see scheme 2.5).
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Scheme 2.S: Formation of 20-Methylwortmannin
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This gives the 20-methylwortmannin derivative 50 rather than the expected
cyclopropane or pyrazoline derivatives. Although the pyrazoline 51 was not detected
it is assumed that this is an intermediate which loses nitrogen to give the 20-
methylwortmannin 50. The addition of a methyl group the position 20 destroys the
PJ-3 kinase activity.
Unique ring expansions using trimethylsulfoxonium ylides were observed giving 52
and 53 and which product formed dependent on the number of equivalents of ylide
used. Results have shown that if two equivalents were used together then the
derivative 52 with the cyclopropane on the tetrahydropyran was made. However, if
wortmannin 34 was first treated with one equivalent of the ylide then a pyrone type
system was formed. Subsequent treatment of this with a second equivalent of the
ylide affords the tetrahydropyranl cyclopropane system. This is summarised in
scheme 2.6.
MeO <,AcO"-,
o
o
52t CH2S(O)Me,
Scheme 2.6: Unique Ring Expansions using Trimethylsulfoxonium
Ylides
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Although both products shown in scheme 2.6 displayed lower activity than
wortmannin 34 the cyclopropane adduct 52 (without the efficient C-20 Michael
acceptor site) showed the greatest loss of activity. Norman and co-workersf I
concluded that the C-20 position in the furan ring is an important site in the molecule
and that changes at that position have a dramatic consequence on the PI-3 kinase
inhibitory potency.
2.4 HALENAQUINONE AND RELATED COMPOUNDS
Halenaquinone 53, halenaquinol 54 and xestoquinone 55 were isolated as the major
components from the dichloromethane partition fraction of Xestospongia c. f
carbonaria. 82 Halenaquinone 53 and halenaquinol 54 are two of only four natural
marine products found to inhibit protein kinase C.
53 54
o
55
Figure 2.11 Halenaquinone, Halenaquinol and Xestoquinone
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Both halenaquinone 53 and halenaquinol 54 have been shown to be effective against
epidermal growth factor receptor protein tyrosine kinases. The potency of the
halenaquinol 54 is easily explained because it oxidises readily to halenaquinone 53.
As enhanced protein tyrosine kinase activity has been associated with proliferative
diseases such as cancer, the inhibition by this family of compounds shows potential
for the discovery of new chemotherapeutic agents. Due to the acti vity of
halenaquinone 53 and halenaquinol 54, other structurally similar compounds
including Xestoquinone 55 were tested for biological activity against protein kinase C
but all proved to be inactive. This supports the suggestion that the furan ring in
conjugation with the two carbonyl groups is essential for biological activity.
2.5 INTRODUCTION TO FURANS
Furans are volatile, fairly stable compounds with pleasant odours. The earliest furan
compound isolated was pyromucic acid 56, usually known as furoic or furan-2-
carboxylic acid which was obtained by Scheele in 1780 by the dry distillation of
mucic acid.83
Figure 2.12: Pyromucic Acid
Furan itself was first obtained in 1870 by treating barium furoate with soda lime.
Nowadays it is readily available and its commercial importance is mainly due to its
role as the precursor of the widely used solvent tetrahydrofuran. The arrangement of
atoms in furan was not established until 1877 when Baeyer treated furfural 57 with
acetic anhydride and sodium acetate followed by reduction and ring opening to give
pimelic acid 5S.83
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Scheme 2.7: Formation of Pimelic Acid
The furfural or furan-2-carbaldehyde used by Baeyer previously was first obtained in
1832 by the action of sulfuric acid and manganese dioxide on sugar. Incidentally the
name furfural is derived fromfuifur which is latin for bran. It was not however until
1920 that furfural became commercially available cheaply and in large quantities from
the acid catalysed ring-opening of xylose, obtained from pentosans which are
polysaccharides extracted from plants such as oat husks. As dehydrating agents such
as phosphorus pentoxide or zinc chloride do not bring about the formation of the
furan the transformation is not a simple dehydration. Similar treatment of erythritol
with dilute mineral acid fails to produce any furfural suggesting that the presence of a
~-hydroxyaldehyde is a necessary condition for the reaction.s+ The mechanism
shown is consistent with acid hydrolysis with the acid catalysing the overall loss of
three moles of water from the D-xylose.
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Scheme 2.8:Formation of Furfural through dehydration Di-Xylose by
Sulphuric Acid.
Other examples of the formation of furans from carbohydrates include the formation
of 5-hydroxymethylfurfural from the treatment of sucrose'i'' with oxalic acid at 125-
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2.6 NATURALLY OCCURRING FURANS AND COMPOUNDS OF
INTEREST
The aromatic furan ring system, although not found in higher animal metabolism
occurs widely in secondary plant metabolites especially in terpenoids such as peri Ilene
59 and the furocoumarin pimpenelin 60:86
Me
59
eco,
60
Figure 2.13: Perillene and Pimpenelin
It is common for plants to construct furans by modifying one end of a terpenoid chain
giving 3-monosubstituted furans although disubstituted furans have also been well
docurnented.s? Recent interest in marine natural products has shown several
terpenoids in which both ends of the system terminate in furan rings. An excellent
example of this is difurospinulosin 61.
61
Figure 2.14: Difurospinulosin
Interest is also growing in the pharmaceutical industry into the importance and use of
compounds containing furan rings. One of the most important furan containing
compounds is Zantac 62,which reduces gastric acid secretion and is important in the
treatment of ulcers.
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Figure 2.15: Zantac
There are a number of 5-nitrofurfural derivatives which are important
chemotherapeutic agents such as the bactericide 'Furacin' 63 being an example.sf
Figure 2.16 Furacin
Amongst furan compounds are several which are of great importance in fragrances
and flavours. Compounds like the 3-furanone derivative furaneol 64 are particularly
interesting because their odours depend on concentration. Indeed furaneol 64 can
seem to resemble pineapple, caramel or burnt toast. In low concentrations the odour
of furfuryl mercaptan 6S resembles that of roasted coffee which is only formed
during the roasting process of the coffee beans and is not present in the fresh beans.
64
Figure 2.17: Furaneol and Furfuryl Mercaptan
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2.7 SYNTHESIS OF FURANS86
There are several ways of synthesising furan compounds starting with non-
heterocyclic precursors, the most common involving ring closure with elimination of
water between the dienolic forms of 1,4-dicarbonyl compunds. Two of the most
common methods are the Paal-Knorr synthesis and the Feist-Benary synthesis.
2.7.1 THE PAAL-KNORR SYNTHESIS89
This synthesis involves the cyclodehydration of 1,4-dicarbonyl compounds 66. The
main limitation on the generality of this approach is the availability of an appropriate
I ,4-dicarbonyl compound. Once obtained, the cyclisation of such precursors, which
provide all of the carbon atoms and the oxygen atom necessary for the furan,
generally proceeds in high yield. Usually non-aqueous acid conditions are employed
to encourage the required loss of water. The process involves the oxygen of the enol
form of one of the carbonyl groups adding to the carbon of the other carbonyl group.
Elimination of water then completes the process. This sequence of events is shown in
scheme 2.9.
--
Scheme 2.9: The Paal-Knorr Synthesis
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2.7.2 THE FEIST-BENARY SYNTHESIS9o,91
The Feist-Benary synthesis involves the intermolecular pyridine catalysed aldol
condensation of an n-haloketone 67 with a 1,3-dicarbonyl 68 followed by ring
closure and elimination of water (scheme 2.10).
67 68
~ - H20
Scheme 2.10: The Feist-Benary Synthesis
The synthesis usually proceeds as shown but in a few instances the reaction stops
short of the final dehydrative step giving the 3-hydroxy-2,3-dihydro furan 69.
55
2.8 PHYSICAL PROPERTIES OF FURANS
Furan itself is a colourless liquid with a boiling point 31-32T with a chloroform-like
smell. It is only slightly soluble in water but is miscible with most organic solvents.
Microwave studies have shown it to be a planar molecule.v- Calculation of the
molecular parameters for a number of furan derivatives has found the following:
a the carbon - oxygen bonds in furan are shorter than those of reduced
derivatives such as THF
b the carbon - oxygen - carbon angle has contracted slightly in furan
The bond lengths and angles?' are shown in figure 2.18:
HO.431H1.361A4, \35 2
1.362A 0
1
CS-O-C2 = 106.6°
O-C2-C3 = 110.7°
C2-C3-C4 = 106.0°
Figure 2.18: Bond Lengths and Bond Angles of Furan
Comparing furan to benzene, the distance between carbon atoms 3 and 4 is slightly
longer than that of the aromatic carbon-carbon bond. Also the bond lengths between
carbons 2 and 3 and carbons 4 and 5 are very close to that of an olefin. These results
show that furan cannot be fully represented by classical formula A but it is best
considered as a resonance hybrid of structures A to E. The furan molecule is far from
a regular pentagon in shape, and the bond lengths suggest that structure A is the major
contributor to the resonance hybrid.v'
[) eu Oe CO d
0 0 0 0 0
G) G) G) G)
A B C D E
Figure 2.19: Resonance Structures of Furan
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Of the other resonance structures, Band C are expected to be the most important for
several reasons. The energy required to separate the charges is lower in these cases
than in other charged structures as the distance involved is less. Band C are also
completely conjugated and are more stable than 4 and 5 which are considered to be
cross-conjugated. However calculation of the rt-electron densities for furan gives the
result shown in figure 2.20 which is the reverse of what we might have expected from
the above argument. Electrophilic attack greatly favours substitution at positions 2
and 5 in agreement with resonance structures.
1.080
01.067o
1.705
Figure 2.20 Electron distribution on Furan
In order for the furan ring to behave as an aromatic structure it must have six 7t-
electrons in the ring. The oxygen atom must provide 2 electrons but since oxygen is
more electronegative than, say, nitrogen it will provide the 2 electrons less easily and
therefore furan is less aromatic than pyrrole. The physical data suggest therefore that
furan should behave as a diene ether.
2.9 CHEMICAL PROPERTIES OF FURANS
Furans undergo ring opening relatively easily under dilute acid conditions and this has
been compared to the hydrolysis of enol ethers.v' This hydrolysis however is not as
facile as that of enol ethers because the initial attack of the proton involves the
electrons of the oxygen atom. These electrons as previously discussed contribute to
the n-electrons required for the aromaticity. The withdrawal reduces the resonance
energy of the ring and converts the "aromatic" furan into the very much less stabilised
cation. Deuterium exchange experiments-" showed that cation 70 is formed 103
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times as rapidly as 71 but hydrolysis to succindialdehyde presumably takes place
through the latter.
UQe
70
,... [)
Qe
71
GH2- GH2
I I
GHQ GHO
......
Scheme 2.10: Hydrolysis of Furan to Succindialdehyde
The mildest conditions necessary to effect this hydrolysis are such that polymerisaton
of succindialdehyde occurs to a major extent.
Furan itself is not stable in the presence of air or oxygen and is usually stabilized by
the addition of small quantities of hydroquinone. Aerial oxidation usually takes place
by a 2,5-addition similar to addition to a 1,3 diene, leading to a peroxide 72 which
has been isolated and then through a free radical polymerisation to a resin.
Hydrogenation of the peroxide gives succindialdehyde 73.
[)
Q cat.
CH2- CH2
I I
GHQ CHQ
73
Scheme 2.11: 2,S-Addition by Aerial Oxidation leading to
Succindialdehyde
Furans also participate in a variety of cycloaddition reactions.?" In particular they
behave as 1,3-dienes in Diels-Alder type reactions. Its cycloaddition reaction with
maleic anhydride is outlined in scheme 2.12.97.
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Scheme 2.12: Cycioaddition of Furan with Maleic Anhydride
The exo adduct 74 is formed twice as fast as the less stable endo isomer. The endo
form changes to the exo form via disassociation then recombination.
Substitution of the hydrogen atoms of the furan ring can also take place readily with
substitutions usually taking place at positions 2 and 5. The substitutions can go by
two different mechanisms as shown in scheme 2.13.98,99 The first mechanism
involves 1,4- addition followed by elimination as shown in pathway A. Alternatively,
substitution can occur by electrophilic attack followed by proton loss as shown in the
pathway B which is analagous to substitutions in benzene.
R'J::'xR
H 0 H
[y:]
0-o R
~
Scheme 2.13: Substitution of Furan
As the intermediates from 1,4-addition are unstable they are often unable to be isolated
and subsequently can be mistaken for an electrophilic reaction. The nitration of furan
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gives a good example of where the two mechanisms operate under different reaction
conditions. With fuming nitric acid, acetic anhydride and pyridine 1,4- addition with
isolation of intermediate 75 as evidence of this pathway. However with nitronium
tetrafluoroborate where the BF4- counterion is non-nucleophilic, 2-nitrofuran IS
produced by the electrophilic mechanisml'v.
®
0
N02 [9<;02] AcO ACO~N02~ ~AC20
0 H 0 H
® 75
+
Pyridine
-HOAc
f[)_o N02
Scheme 2.14: Nitration of Furan
This project is concerned with the application of furan chemistry to the formation of
potential anticancer drugs based on the active component of wortmannin and related
compounds. In particular structures with the furan in conjugation with the two
carbonyl groups are examined.
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CHAPTER 3
This chapter describes the synthetic approaches to the ketofuran 76. This was chosen
as a target because it possesses the furan in conjugation with one carbonyl group
which would hopefully mimic the pharmacophore of the lead compounds -
wortmannin and demethoxyviridin. Two general approaches were taken. the first
involving the assembly of the furan nucleus on a cyclohexane ring base (sections 3.1
and 3.2) and the second starting with the furan ring intact and building the
cyclohexane ring onto it by applying a wide range of synthetic methodology (section
3.3 ).
76
Figure 3.1: Target Ketofuran
Synthetic approaches are also described to the diketofuran 77. In a similar fashion to
ketofuran 76 the diketofuran contains a furan ring in conjugation with two carbonyl
groups. Itwas expected that this would more accurately mimic the active component
of the lead compounds.
o
77
Figure 3.2: Target Diketofuran
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3.1 ATTEMPTED SYNTHESIS OF FURAN VIA DIOL
OXIDATION
The target furan in scheme 3.1 was chosen as it possesses the same carbon skeleton
as ketofuran 76. The synthesis involves a Diels-Alder reaction of dimethyl
acetylenedicarboxylate and 2,3-dimethyl-l ,3-butadiene followed by reduction of the
resulting dimethyl 4,5-dimethyl-l ,4-cyclohexadiene-l ,2-dicarboxy late 78.
Cyclisation followed by allylic oxidation would give a compound suitable for
biological testing against phospholipase D inhibition. Although there was literature
precedence for the feasibility of this scheme, problems were encountered which are
explained in the following text.
COOMe
II
yyCOOMe
~ COOMe
78COOMe
I LiAIH4
~ THF
)Ceo ..---------
80 79
,
o
)[co
Scheme 3.1: Synthesis via Diol Oxidation
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3.1.1 DIELS-ALDER BETWEEN 2,3-DIMETHYL-1,3-BUTADIENE
AND DIMETHYLACETYLENE DICARBOXYLA TE
The Diels-Alder (41t + 21t) cycloaddition between 2,3-dimethyl-l ,3-butadiene (the
diene) and dimethyl acetylenedicarboxylate (the dienophile) gave dimethyl 4,5-
dimethyl-I ,4-cyclohexadiene-l ,2-dicarboxylate in 55% yield. The reaction proceeds
well for a number of reasons. Both the diene and the dienophile possess the
necessary characteristics required for a successful Diels-Alder reaction. The diene has
electron donating methyl groups which increase the energy of the HOMO 1t-orbital
and the dienophile has methyl ester withdrawing groups which lower the energy of
the LUMO n-orbital.l'" The energy gap between the HOMO and LUMO orbitals is
therefore decreased leading to an overall faster reaction. The effect of the substituents
is shown diagramatically in scheme 3.2
ENERGY n
LUMO
HOMO
DIENE DIENOPHILE
COOMe H
II II
COOMe H
+++ +
Figure 3.2: Electronic Substituent effects on orbital energies
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Water is a good solvent for Diels-Alder reactions involving substances with non-polar
regions.U'- This is due to the "hydrophobic effect" where a polar solvent, in this
case water, pushes two non-polar reactants close together thus accelerating the
reaction.
However, the diene can exist in either a cisoid or a transoid state. If the methyl
groups were replaced by larger groups then the transoid state would be favoured and
since Diels-Alder reactions prefer the cisoid state the reaction would proceed less
efficiently. In this case, however, the cisoid and transoid states are present in almost
equal amounts. The reaction therefore proceeds quickly as the transoid equilibriates to
the cisoid when the latter is consumed (see scheme 3.3)
.c x
CISOIO TRANSOIO
Scheme 3.3: Equilibrium Between Cisoid and Transoid States of 1,4-
Dimethylbutadiene
The structure identification of dimethyl 4,5-dimethyl-1 ,4-cyclohexadiene-1 ,2-
dicarboxylate 78 in figure 3.4 was confirmed by IHand 13C nmr.
Figure 3.4: Dimethyl 4,5-dimethyl-1 ,4-cyclohexadiene-l ,2-
dicarboxylate
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IH Nmr indicated the presence of the methoxy groups at 03.76, the methyl groups at
01.7 and the methylenes at position 4 at 02.29. The I3C nmr spectrum showed peaks
at 133.3, 34.05 and 121.47 corresponding to C-3, 4 and 5 respectively of the
cyclohexadiene. The signal corresponding to C-3 is shifted significantly downfield
because it is in conjugation with the carbonyl of the ester.
3.1. 2 REDUCTION OF THE DI-ESTER TO 1,2-BIS(HYDROXY-
METHYL)-4,5-DIMETHYL-l,4-CYCLOHEXADIENE (79)
The diol 79 was obtained by reduction with lithium aluminium hydride in a poor yield
(18%). The IH nmr spectrum showed three peaks at 04.22, 03.8 and 02.74
corresponding to the carbon adjacent to the alcohol, and to the methylene and methyl
groups respectively. The I3C nmr spectrum showed the absence of the ester groups.
This together with mass spectral data helped to confirm the structure 79. However,
due to the low yield from this method other ways of reducing dimethyl 4,5-dimethyl-
1,4-cycJohexadiene-l ,2-dicarboxylate 78 were looked at.
Reduction of the ester 78 was attempted using sodium borohydride.Iv' This proved
unsuccessful and although starting material was consumed and several products were
observed, none were isolated. Consultation with the literature revealed that esters can
be reduced by sodium borohydride in the presence of iodinc'?+, This method
generates borane in situ:
THF
The sodium borohydride was used in excess and the iodine added slowly to it. No
identifiable products were obtained from this reaction.
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3.1.3 CYCLISATION OF 1,2-DIHYDROXYMETHYL-4,5-
DIMETHYL-I,4-CYCLOHEXADIENE TO FURAN 80
I ,2-Dihydoxymethyl-4,5-dimethyl-1 ,4-cyclohexadiene 79 was treated with
pyridinium chlorochromate in dichloromethane and gave no cyc1ised product 80 (see
scheme 3.1). This was disappointing because Nishiyama and co-workers+v- had
reported the effective transformation of (Z)-2-butene-1 A-diols to substituted furans
by this method (see scheme 3.4).
U(0HI
OH
PCC Leo
Scheme 3.4: Pyridinium chlorochromate cyclisation of
(Z)-2-Butene-} ,4-diol
The pyridinium chlorochromate oxidises only one of the alcohol groups to give the
intermediate 81 which cyc1ises to give the hemiacetal and dehydrates to give the
furan.
R2 R3R,XR4
OH 0
81
(PyH)+(Cr03CI)
•
!
Scheme 3.5: Transformation of (Z)-2-Butene-l,4-Diol to Furan via
Pyridinium Chlorochromate.
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This is similar to the Paal-Knorr intermediate (see section 2.7.1). The intermediate
from pyridinium chlorochromate involves one carbonyl and one alcohol and a 1,4-
elimination whereas the Paal-Knorr intermediate involves two carbonyls and a 1.2-
elimination of water.
Since the pyridinium chlorochromate route of cyclisation was not successful. attempts
were made using manganese dioxide as the oxidant. An early paper by Butina and
co-workers 106 showed that oxidation of the analogous diol 82 initially gave the
monoaldehyde 83 which then cyclised to the 5-membered lactol 84. Butina found,
however, that rather than eliminating water to give the furan, the lactol underwent a
second oxidation to the lactone 85.
82
OH
oCoOCOH_-I"~OH
84
85
Scheme 3.6: Oxidation to Lactone
However, Nishiyama reported that cyclisation of diol 86 to the corresponding furan
can be achieved using manganese dioxide.
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86
Scheme 3.7: Oxidation of (Z)-2-Butene-I,4-diol via Manganese
Dioxide
Despite using 10 equivalents of manganese freshly prepared dioxide from manganous
sulfate and potassium permanganate, diol 79 failed to cyclise to give the desired
furan. The scheme was therefore abandoned.
3.2 SYNTHESIS VIA ALLYLIC SULPHIDES
An alternative route to fused furans was set out by Hiroi and Satolv? and is outlined
in scheme 3.7.
Furan annulation occurred via the aluminium chloride catalysed acylation of allylic
phenyl sulfide 87 followed by refluxing with sulfuric acid and benzene. Finally
reductive desulfurisation with Raney Nickel removed the unwanted a-phenylthio
group from the furan to give the desired furan 88. We therefore proceeded to follow
Hiroi and Sato's work in detail below.
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THF
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THF
HC5SPh
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H2S04 PhS
Benzene
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95
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Scheme 3.8: Furan Annelation via Allylic Sulphides
69
3.2.1 THIOANISOLE ADDITION TO CYCLOHEXANONE
Cyc1ohexanone was treated with the anion generated by n-butyl lithium and
thioanisole at OCC to give the cyclohexanol 89. Hiroi and Sato used
diazabicyclo[2.2.2]octane (DAB CO) in their system. In our hands, however good
yields (81%) and fast reactions occurred both with and without the addition of
DABCO.
Figure 3.5: Diazabicyclo[2.2.2Joctane
DABCO is a strong electron donor possessing two lone pairs and therefore co-
ordinates strongly to the lithium. In THF n-butyl lithium exists in both trimeric and
dimeric forms so this co-ordination helps to break up these clusters thus accelerating
the reaction.
The 1H nmr spectrum of cyclohexanol 89 showed a broad singlet at B 1.98
corresponding to the hydroxyl group. In addition to the peaks at B7.07 for the phenyl
and the multiple at B1.3 for the cyclohexane ring there was a singlet at B2.89
integrating for 2 protons which corresponds to the CH2 group adjacent to the sulfur.
This data together with the notable absence of the carbonyl stretch and the appearance
of the hydroxyl at 3400 crrr l confirmed that the expected product 89 had been
formed.
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3.2.2 DEHYDRATION OF 1-(PHENYLTHIOMETHYL)-
CYCLOHEXANOL
Dehydration was effected using Dean and Stark conditions with toluene and p-
toluenesulfonic acid. During the dehydration there can be seen to be two possible
routes for water elimination, giving the double bond either endo or exo to the
cyclohexane ring. Hiroi reported that only I-(phenylthiomethyl)cyclohexene 90 was
formed whereas we also managed to isolate phenylthiomethylidenecyclohexane 91,
the exo isomer, as a minor product.
6
5
2
3
9 108--011
I
4
91
EXO
90
ENDO
Scheme 3.8: Equilibrium Between Major and Minor Isomers
This regioselectively occurs because under acidic conditions the endo 90 and the exo
91 isomers will be in equilibrium, with the more thermodynamically stable endo-
isomer being predominanttv''. The two nmr spectra of these compounds are quite
different from one another as shown in table 3.1.
ENDO EXO
H 90 91
oppm oppm
2 5.51 2.5
3,4,5,6 1.1 2.5
7 3.46 5.78
9,10,11 7.12 7.2
Tables.l : Nmr Constants for the Exo and Endo Isomers
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The most notable change is H-7 and H-2 arising from the different exo and endo
positions of the double bond. The olefinic proton in each case is found further
downfield at approximately <>5.5. This can be attributed to the anisotropy of the
double bond.
3.2.3 SILYLATION OF l-(PHENYLTHIO(TRIMETHYLSILYL)-
METHYL)CYCLOHEXENE
Treatment of the mixture of l-(phenylthiomethyl)cyclohexene 90 and its isomer 91
with lithium diisopropylamide (LDA) and trimethylsilyl chloride afforded 1-
(phenylthio(trimethylsilyl)methyl)cyclohexene 87 in 380/0 yield. Separation of the
endo and exo isomers was not essential as when treated with LDA both isomers
generate the same allylic anion as shown in scheme 3.9.
SPh SPh
Scheme 3.9: Common AUylic Anion Through Resonance
The nmr for the silylated compound 87 (see scheme 3.8) is similar to the endo
compound with a large singlet at 80.15 corresponding to the TMS group. Addition of
the TMS group does not cause a significant change in the chemical shift of the
neighbouring proton.
3.2.4 ALUMINIUM CHLORIDE CATALYSED ACYLATION
Several attempts at acylation of l-(phenylthio(trimethylsilyl)methyl)cydohexene 87 to
give 2-propanoyl-l-phenylthiomethylenecyclohexane 95 were made. The mechanism
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of the desired reaction involves the formation of adduct 92 between the propanoyl
chloride and the aluminium chloride. The double bond of the cyclohex-I-ene ring
attacks the adduct at the carbonyl to form the stabilised ~-silyl cation 93. Overall loss
of trimethylsilylchloride gives 94 and aqueous work up would then give 2-propanoyl-
l-phenylthiomethylene cycJohexane 9S
SPh e
00..A1C13
I
(CH3bSi
..
93
!
(CH3bSi Sp~e
O,AICI3 erI...
87
94
95
Scheme 3.10: Proposed Acylation to give 2-Propanoyl-l-
Phenylmethylene cyclohexane
In all cases despite careful drying of reagents the desired compound 9S was not
isolated. Instead the procedure produced only the the exocyclic olefin 91 (scheme
3.11 ):
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(CH3bSi
87 91
Scheme 3.11:Transformation to Exocyclic Olefin
Attempts using titanium tetrachloride as an alternative Lewis acid were made but
again the exocyclic olefin was obtained. If this method of furan annulation had been
successful the route would have been repeated using the protected form of cyclohexa-
1,3-dione which would have given the target 96. This transformation is shown in
scheme 3.12:
o 0Q
OEt
------------
Scheme 3.12: Proposed Furan Annulation via Allylic Sulphide Route
using Cyclohexa-1,3-dione
3.3 ATTEMPTED SYNTHESIS OF FURAN (76)V1A AN
INTRAMOLECULAR GRIGNARD - METHOD ONE
Given the difficulties encountered in assembling the furan ring it was decided to start
with an intact furan nucleus and build on the cyclohexane portion. This approach
involves the cyclisation via an intramolecular Grignard. Ideally an intermediate of
general structure 97 is desired in order to allow ring closure.
74
Br
Meo,J;hco.J.Ae L 0 KO
~ ~
.. ..
0 0
98 97 76
where L = good leaving group
Scheme 3.13: Proposed Synthesis to Target Furan via Intramolecular
Grignard
The first attempt considered was to mono hydrolyse selectively dimethyl furan-3.4-
dicarboxylate 98. Once obtained the acid could then be selectively reduced to the
alcohol 99. Attack with vinylmagnesium bromide at the ester and the conversion of
the hydroxyl group into a better leaving group would give the desired intermediate
100. Hydrobromination followed by the intramolecular Grignard would give the
desired furan 76.
°iio
76
1 Hydrobromination
~C02Me
HO l!._ ~
o
99
~ ~MgBr
1 Hydrolysis
2 Reduction
2 Grignard L
o
100
Scheme 3.14: Proposed Synthesis to Target Furan 76 via Mono-
hydrolysis of Di-ester
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3.3.1 SELECTIVE HYDROLYSIS OF ESTER FUNCTION
Initial attempts to differentiate between the two methyl groups were made by forming
the cyclic anhydride 101. The first attempt used the mild base lithium hydroxide in
methanol. The main assumption of this mechanism is that under basic conditions the
shown more clearly in scheme 3.15:
anhydride 101 will predominate and not the unwanted his-acid product 102. This is
e
H02CbCOO 01JO 0I ~ ------o ~e I ~HO 0
104 101
1~
102 105
Scheme 3.15: Proposed Selective Mono-hydrolysis via Lithium
Hydroxide
The hydroxide anion is a better leaving group than the methoxide anion and therefore
there will be a drive to form intermediate 103 rather than 104. Acidic work up
would then give the desired product 105. This method however proved to be
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unsuccessful and a second attempt to form the anhydride using concentrated sulfuric
acid was tried. Again product 105 was not formed.
A final attempt using trimethylsilyl iodide was tried and was found to be successful
(see scheme 3.16).
Me02C'r,-{C02Me
~ ")o
98
e
I
... + Mel
106
+
Scheme 3.16: Selective Mono-Hydrolysis via Trim ethyls ily I iodide
Trimethylsilyl iodide was made in situ by refluxing trimethylsilyl chloride and sodium
iodide in acetonitrile. Addition of the dimethyl furan-3,4-dicarboxylate 98 gave the
silyl ester 106 via the intermediate iodide salt. The main driving force for this is the
formation of the strong silicon-oxygen bond. Hydrolysis of the silyl ester 106 with
aqueous work up afforded the product which was isolated as the sodium salt by
extraction into sodium bicarbonate. Acidification of the aqueous layer gave the
product 105. The molecular ion of 170.0205 corresponding to C7HSOS combined
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with IHand 13C nmr spectra showing an unsymmetrical furan confirmed the structure
of the product.
3.3.2 ATTEMPTED SELECTIVE REDUCTION OF ACID GROUP
IN PRESENCE OF ESTER
Carboxylic acids can be reduced to the corresponding alcohol by a variety of methods
including metal hydrides such as lithium aluminium hydride. lOY The problem with
these reducing agents is they will reduce the ester function as well as the acid.
Reports by Yoon and fellow workers 110 indicated that it was possible to reduce acids
in the presence of other functional groups including esters using a borane.THF
complex in mild conditions. The acid 105 was therefore treated with BH3.THF to
attempt to form the trialkoxyboroxine intermediate as shown in scheme 3.17. On
hydrolysis this should have given the alcohol and boric acid.
THF
3RCOOH + 3BH3 3(RCH20BO) + 3H2
~ TRIMERISATION
OCH2RI
O/B,O
I I
RCH20/B'0/BOCH2R
...
HYDROLYSIS
Scheme 3.17: Reduction of Acid with BH3. TH F
However this reaction was not successful and alcohol 99 was not isolated.
As an attempt to reduce the acid group with sodium borohydride also failed, other
methods were looked at. Kim and co-workers!"! indicated that it was possible to
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reduce acid chlorides in the presence of other functional groups such as acid
anhydrides, acids and esters. Reduction of the acid in the form of its acid chloride
using two different forms of zinc-modified cyanoborohydride prepared by two
different methods was attempted.
First the acid chloride was prepared by refluxing the acid in THF and a large excess of
thionyl chloride for 4 hours. The zinc-modified cyanoborohydride was prepared
using a 2: 1 mixture of sodium cyanoborohydride and zinc choride in THF. A white
precipitate was formed which according to Kim did not contain much of the reducing
power. The reducing agent was soluble in THF so the supernatant solution was
transferred from the reaction flask into the acid chloride. The resulting solution was
stirred for 48 hours after which time no reaction had occurred.
A second attempt at preparing the zinc-modified cyanoborohydride was made. This
time diethyl ether was used as the reaction medium. The reagent was prepared in the
same way as previous attempt and a white slurry was again observed. This time
according to Kim this slurry should contain 90% of the reducing power and very little
contained in the diethyl ether. At first Kim believed that the slurry formed was sodium
chloride but when the reagent was prepared in methanol no slurry was obtained.
From this Kim drew the conclusion that the zinc-modified cyanoborohydride was the
white slurry and that this reagent was made up of a mixture of Na[ZnCI(BH3CN)2J,
Na2[ZnCI2(BH3CNh], Na[Zn(BH3CN)3] and Zn(BH3CN)2 rather than pure
Zn(BH3CNh as the reducing species.
In light of this the acid chloride prepared was syringed into the flask containing the
slurry of zinc-modified cyanoborohydride in diethyl ether. Unfortuntely again no
reaction was observed and so this reaction was abandoned.
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3.4 ATTEMPTED SYNTHESIS OF FURAN (76) VIA AN
INTRAMOLECULAR GRIGNARD- METHOD 2
An alternative synthesis to structure 76, and the similar compound 107, follows the
methodology shown in scheme 3.18. Since only one of the ester groups was
selectively hydrolysed as described in section 3.3.1 it was thought that dimethyl
furan-3,4-dicarboxylate could be selectively attacked at only one ester group by
vinylmagnesium bromide to give the intermediate 108. Hydrobromination of 108
followed by an intramolecular Grignard reaction would give 107. Alternatively
conversion of the ester moiety to a good leaving group would allow a Grignard
cyclisation similar to that in scheme 3.14 to give 76.
-:;::::::-...MgBr..
o
Me02C, ~0-
o
108!Hy~rObromination
Grignard... Me~C
Br
109
Scheme 3.18: Alternative Synthesis to Ketofuran 76 via an
Intramolecular Grignard
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3.4.1 GRIGNARD ATTACK USING VINYLMAGNESIUM BROMIDE
A solution of dimethyl furan-3,4-dicarboxylate in THF was treated with vinyl-
magnesium bromide and as expected the desired mono-ester 108 was isolated as a
yellow oil. Structure identification by IH nmr showed clearly the signals due to the
vinyl protons at 05.16 and 06.06 (showing the expected coupling pattern). The 13C
nmr spectrum showed the presence of two distinct carbonyls with peaks at 0165.5
and 0178.1 for the ester and the ketone repectively. Signals due to olefinic carbons at
0114.8 and 0129.3 were also observed. Even when the furan was treated with an
excess of Grignard reagent still there was attack at only one ester site. This can be
explained by the relative electron-withdrawing properties of the ester and ketone
functions.
Figure 3.7: Comparison of Ester and Enone
The ketone fragment in product 108 is less electron withdrawing than the
corresponding ester in starting material 98. The ester group in the product is
therefore less vulnerable to nucleophilic attack.
3.4.2 ATTEMPTED HYDROBROMINATIONS
Hydroboration followed by bromination should provide an excellent route to the anti-
Markovnikov hydrobromination of the double bond. The first hydroborating agent to
be considered was borane (used as a IM solution in THF).112 An excess of this
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reagent was added to the ketone 108. The reaction was then wrapped in aluminium
foil to exclude light and the bromine added. Tic indicated that many products had
been formed as well as a considerable amount of baseline material. The mechanism
involves free-radical bromination as shown in scheme 3.19 and does not involve the
simple rupture of the carbon-boron bond by bromine.
R~
•
(RCH2CH2hBCHCH2R + HBr
•
(RCH2CH2hBCHCH2R + Br2
R =
o 0
Meo~/
o
Scheme 3.19: Mechanism of Anti-Markovnikov Hydrobromination
As this reaction proved to be unsuccessful the same reaction was repeated using
dicyclohexylborane as the hydroborating species.l U Dicyclohexylborane is normally
used in systems where there are more than one double bond present. Because of its
•
large steric bulk dicyclohexylborane will selectively hydroborate the less sterically
hindered double bond. However, in our case we simply wanted to hydroborate the
only double bond present in the molecule. Two different methods were used for
dicyclohexylborane. The first involved addition of the alkene solution to the
preformed dicycohexylborane solution. After allowing to stir for 2 hours light was
excluded and a solution of bromine was added and stirred for a further 1 hour at O'C
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before being quenched with water. Tic indicated that no product had been formed.
This method was repeated but light was not excluded and the reaction worked up
using sodium methoxide in methanol. Again no product was formed.
As the brominations using molecular bromine were proving troublesome a different
brominating species was used. Bromine chloride was generated in situ from the
reaction between chloramine- T and sodium bromide.'!" The first stage of the reaction
involves the reaction between chloramine- T and water to generate hypochlorous acid
as shown in scheme 3.20.
1 TsNCI H2O TsNHCI + HOe+
2 2TsNHCI TsNCI2 + TsNH2
3 TsNCI2 + H2O TsNHCI + HOCI
4 TsNHCI + H2O TsNH2 + HOCI
HOe e5 TsNH2 + TsNH + H2O
o
HC-o-~ 5-3 II
- 0
= Ts
Scheme 3.20: Generation of Hypochlorous Acid via Chloramine- T
As can be seen hypochlorous acid is generated in steps 3 and 4. This is an excellent
source of positive chlorine which will react with sodium bromide to give bromine
chloride as shown below:
NaBr + HOCI --- ....~ NaOH + BrCI
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Hydrochloric acid was added to neutralise the excess sodium hydroxide generated.
However, this method failed to produce the desired brominated product 109.
As the brominations via hydroboration were not proceeding as expected attention was
turned to different methods of anti-Markovnikov hydrobromination.
Hydroalumination involving lithium aluminium hydride was looked aLlis The
overall reaction equation is shown in scheme 3.21:
+ 4RCH=CH2
~ nci,
LiAI(CH2CH2R)4 + 8CuBr2 ___. 4RCH2CH2Br + 8CuBr + LiBr + A1Br3
Scheme 3.21: Reduction of Alkene via Hydroalumination
No mechanistic investigation has been carried out but it has been assumed that the
reaction proceeds by two separate steps:
formation of an alkyl radical either by direct electron transfer
oxidation of a carbon-aluminium bond by the copper(U)halide or
via homolytic decomposition of the alkyl copper intermediate
produced by the reaction of the alkylaluminium with
copper(ll)halide.
2 alkyl radical then reacts with a second equivalent of the copper
(II) halide by a ligand transfer process.
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When we tried to hydrobrominate 108 using this method it failed to give us our
desired hydrobrominated compound 109. Due to the unsuccessful nature of this
reaction scheme it was subsequently abandoned.
3.5 ATTEMPTED SYNTHESIS OF KETOFURAN (76) VIA AN
INTRAMOLECULAR GRIGNARD - METHOD THREE
3.4. An outline of this is shown in scheme 3.22.
The methodology for this route follows that of the vinyl route as described in section
== MgBr
•
o=g=o
o
107
Scheme 3.22: Route to Target Furan via Acetylene
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3.5.1 GRIGNARD ATTACK USING ETHYNYLMAGNESIUM
CHLORIDE
Dimethyl furan-3,4-dicarboxylate 98 was treated with ethynyl magnesium chloride
giving the mono-ketone 110. Despite using several equivalents of ethynyl
magnesium chloride the reaction did not go to completion and a mixture of the product
110 and starting material 98 was isolated. The IH nmr spectrum showed a singlet
for the ethynyl proton at 31.7 and peaks at 37.2 and 37.6 for the two furan protons.
In addtion to these, there were also peaks corresponding to the starting material.
Several attempts were made to purify the mixture by column chromatography but all
gave inadequate separations and therfore futher characterisation was not attempted It
was therefore decided to carry the mixture through to the bromination stage in the
hope that the brominated product would be sufficiently more polar than the starting
material allowing satisfactory separation, purification and characterisation.
3.5.2 ATTEMPTED BROMINATIONS OF ACETYLENIC KETONE
Early literature has shown that terminal acetylenes can be brominated usmg
hypobromite solutions.Uv-U? The sodium hypobromite solution was prepared by
adding bromine to an aqueous solution of sodium hydroxide. The acetylene 110 was
then added to the hypobromite solution and the hypobromite ion should have
abstracted a proton to leave the sodium salt of the acetylene. The anion of the
acetylene should then have attacked the bromine of the hypobromous acid to give the
brominated acetylene 111 and sodium hydroxide. This is shown in scheme 3.23.
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R H NaOBr ~ R
_8
HOBr+ +
+
R Br + NaOH
Scheme 3.23: Bromination of Acetylene via Sodium Hypobromite
However this reaction proved to be unsuccessful in our system.
Attention was therefore turned towards the possibility of brominating the acetylene via
the lithium acetly lide which had previously been well documented. I I H Deprotonation
of our acetylene was carried out in THF at -78°C using n-butyl lithium. Treatment of
this lithium acetylide with molecular bromine as the bromination agent would have
been expected to give the desired bromoacetylene 111. However, careful addition of
the bromine at -20°C with the exclusion of light did not give the desired product.
Instead a complex mixture of products were formed which could not be isolated.
This attempt using lithium acetyl ide was repeated using N-bromosuccinimide (NBS)
as the source of bromine. NBS releases bromine steadily but still no desired
brominated product was formed.
3.6 ATTEMPTED SYNTHESIS OF FURAN (112)
This section describes the attempted synthesis of target molecule 112 which is
structurally similar to the target diketofuran 77. Esterification of 4,5,6,7-tetrahydro-
4-oxobenzo[b ]furan-3-carboxylic acid will protect the acid during the attack by
vinyl magnesium bromide on the ketone. This also provides a better leaving group for
the anticipated intramolecular Grignard later in the synthesis (see scheme 3.24).
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MeOH
C02Me')---( Dehydration...
I Hydrogenation
2 Hydrobromination
3 Intramolecular Grignard
o
112
Scheme 3.24: Synthesis to Target Furan via Dehydration
3.6.1 ESTERIFICATION AND GRIGNARD ATTACK
Esterification of 4,5,6,7-tetrahydro-4-oxobenzo[b]furan-3-carboxylic acid was
successfully achieved using a catalytic amount of concentrated sulfuric acid in
methanol. Identification of the methyl ester 113 was by primarily by nmr and mass
spectroscopy. The most notable feature in IH nmr spectrum was the singlet at 83.78
corresponding to the methyl ester. The l3e nmr spectrum showed the presence of
two carbonyls with peaks at 8161.4 and 8192.0 corresponding to the ester and ketone
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respectively. These data together with accurate mass and elemental analysis
confirmed the structure of the ester.
Grignard attack with vinylmagnesium bromide successfully gave 114. The attack
was exclusively at the ketone and not at the ester group as expected since ketones are,
in general, more reactive towards nucleophiles than esters. The structure of the
alcohol was confirmed by both infra-red and nmr spectroscopy. Infra-red showed the
presence of only one carbonyl with a signal at 1714 crn! corresponding to the ester.
Each of the olefinic protons was observed as a doublet of doublets occurring at 84.7,
05.07 and 06.08.
3.6.2 ATTEMPTED DEHYDRATION OF TERTIARY ALCOHOL
The alcohol was first treated with thionyl chloride in the presence of pyridine in an
attempt to effect the dehydration. This method is known to be effective for
dehydrating tertiary alcohols. Schwartz and Madaml !" demonstrated its use in
dehydrating the hindered alcohol 115 to give cyclohexene 116 as shown in scheme
3.25.
115 116
Scheme 3.25: Dehydration of Hindered Alcohol via SOCl2 and
Pyridine
The mechanism for this dehydration is fairly simple with the thionyl chloride-pyridine
complex reacting with the alcohol to form an alkyl chlorosulfate 117 (scheme 3.26).
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Removal of the proton B- to the alcohol by pyridine leading to the elimination of
sulfur dioxide and the chloride ion gives the desired olefin. Unfortunately, however,
this was not effective for our system.
Scheme 3.26: Chlorination of alcohol via SOCl2 and Pyridine
Traditional methods of dehydration were also tried including acid catalysis using para-
toluene sulfonic acid and concentrated sulfuric acid, but these all proved to be
ineffective despite literature precedence I 20. Boron trifluoride was then tried as
Hua 121 had previously used this to dehydrate the alcohol 118 to give (+) pentalenene
119.
118 119
Scheme 3.27: Synthesis of (+)Pentaienene via Dehydration using
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As boron trifluoride is a Lewis acid it accepts electrons and readily forms a complex
120 which will readily eliminate to form the olefinic product 121.
e
BF3
01
~~O" COOMe
I~
o
120
121
Scheme 3.28: Mechanism of Dehydration via BF3.0Et2
However all attempts using this reagent was proved to be unsuccessful and starting
material was recovered in all cases.
Copper (II) sulfate adsorbed onto silica gel was tried as a final attempt at dehydration.
Although it is widely known that anhydrous Copper (II) sulfate can be used to
dehydrate alcohols under fairly drastic conditions, 122,123 a paper by Nishiguchi and
co-workers 124 demonstrated that dehydration of alcohols can occur under mild
conditions through a silica-supported copper(II)sulfate catalyst. An example of the
use of this is shown in scheme 3.29.
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TOLUENE
oo
REFLUX! 60 MINS
HO
Scheme 3.29: Example of Dehydration via Silica Supported Copper(lJ)
Catalyst.
A solution of copper sulfate in water was pre-adsorbed onto silica by removal of the
water in vacuo. Activation of the catalyst was achieved by heating in an oven at
150°C for 2 hours. This catalyst was then added to a solution of the alcohol in
cyclohexane and stirred for 1 hour. Tlc unfortunately indicated the presence of
baseline material. Using potassium hydrogen sulfate gave a product which was
possibly the desired alkene 121 but this could not be identified as it readily
decomposed on standing. This backed the growing suspicion that this compound was
highly unstable and subject to polymerisation. This route was therefore abandoned.
3.7 ALTERNATIVE SYNTHESIS TO TARGET FURAN(112)
The final attempt in this series was based on similar methodology as outlined in
section 3.6. Attempts at protecting the carbonyl were therefore made in the hope that
if this were successful then the Grignard vinyl magnesium bromide could selectively
attack only the methyl ester. This would then allow bromination followed by an
intramolecular Grignard to give the target 112 as seen in scheme 3.30.
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2 Hydrobromination
3 Grignard
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5 Hydrogenation
o
1\
~COOH
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125
1 Esterification
, 2 ~MgBr
1\ 0Clore,
o
Scheme 3.30: Ketal Protection in Attempted Synthesis to Furan 112
Attempts at protecting the ketone carbonyl were first made using trimethylsilyl
chloride, ethylene glycol and methanol.t-> As can be seen in the mechanism (scheme
3.31) the ketone carbonyl should first attack the silicon with expulsion of a chloride
ion to form the intermediate 122. This intermediate has a strong silicon-oxygen bond
with a stabilised carbocation ~ to the silicon. Methanol then attacks the oxonium ion
to give 123 which undergoes proton transfer followed by a second methanol attack to
give the dimethyl ketal 124. Transacetalation with ethylene glycol would give the
desired protected ketone 125. However only starting material was recovered.
Changing to neat ethylene glycol or an ethylene glycolldichloromethane mixture
showed no improvement and starting material was still recovered.
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Scheme 3.31: Ketal Protection via TMSCI and Ethylene Glycol
Due to the unsuccesful nature of the trimethylsilylchloride and ethylene glycol system
a different approach was tried using triethyl orthoformate+?". In this case the ketone
was treated with the triethyl orthoformate and should have given the diethyl ketal 126
and ethyl formate as shown in scheme 3.32. Again transacetalation with ethylene
glycol should have given the desired protected ketone but in all attempts using this
method only starting material was recovered.
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Scheme 3.32: Ketal Protection via Trimethytorthoformate and Ethylene
Glycol
A final attempt using ethylene glycol and oxalic acid was tried but again no product
was formed. Since the formation of the acetal was proving to be troublesome this
scheme was abandoned.
3.8 CONCLUSION
Athough several attempts were made to make the target furans (such as 76) all were
unsuccessful. Attention was therefore turned to making a simpler compound but with
the active component of the lead compounds still intact. This strategy is examined in
chapter 4.
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CHAPTER 4
As attempts to make the 3,4-disubstituted furans as described in chapter 3 were
unsuccessful we decided to investigate routes to making the 3,5-disubstituted furans
with the backbone shown in figure 4.1.
o
Figure 4.1: Target 3,S-Disubstituted Furan
These compounds which contain the pharmacophore of the lead natural products
could then undergo biological testing.
4.1 SYNTHESIS OF 3,5-DISUBSTITUTED FURANS VIA
FRIEDEL-CRAFTS ACYLATION
A simple approach to forming 3,5-disubstituted furans is to start with the
commercially available 3-furoic acid 127. Esterification followed by Friedel-Crafts
acylation would provide access to compounds with the desired 3,5-dicarbonyl
arrangement 128 as shown in scheme 4.1.
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127
Esterification..
jFriedel CraftsAcylation
o
R1, R2= alkyl or aryl
o 128
Scheme 4.1: Esterification and Friedel-Crafts Acylation Leading to
Target 3,5-Disubstituted furan
4.1.1 ESTERIFICATION OF 3-FUROIC ACID
METHYL 3-FUROATE
Two methods to make methyl 3-furoate 130 were used. The traditional way of
forming esters using methanol and concentrated sulfuric acid gave the desired methyl
ester but in a poor 38% yield. An unusual approach utilising the mild conditions set
out by Brook and Chanl-? involving the generation of a silyl ester intermediate
proved to be more successful. Thus, chlorotrimethylsilane reacted with the 3-furoic
acid to give the silyl ester 129 and hydrochloric acid. Displacement of the silanol
group with methanol then afforded methyl 3-furoate 130. The 57% yield obtained
was higher than that obtained with the traditional method. Methyl 3-furoate was
isolated as a colourless oil which exhibited the expected sharp singlet in the IH nmr
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spectrum at 8 3.74 for the methyl ester and a carbonyl peak at 1728 crrr ' in the infra-
red spectrum.
!OHoo
TMSCI
odO™S
o
129
TMS-O-TMS + Hel +
1~MeOH/H+
odOMe
o
130
Scheme 4.2: Esterification via Silyl Ester
ISOPROPYL 3-FUROATE
Formation of isopropyl 3-furoate was first attempted via the silyl ester. Exactly the
same conditions as for the preparation of methyl 3-furoate were used but when the
resulting mixture was analysed by tIc no ester was present. The more traditional,
harsher conditions of concentrated sulfuric acid in isopropanol were therefore resorted
to. Isopropyl 3-furoate 131 was successfully obtained as a colourless oil in 60%
yield by this method. 1H nmr showed the distinctive septet at 8 5.07 for the single
proton and a doublet at 81.20 for the terminal methyl groups of the isopropyl group.
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Figure 4.2: Isopropyl 3-furoate
PHENYL 3-FUROATE
Phenyl 3-furoate 132 was formed using two different coupling agents, the first being
dicyclohexylcarbodiimidet-f (Dee) which gave the product but in a very poor 38%
yield. However when diisopropyJcarbodiimide (Ole)was used a much better yield of
68% was acheived. Phenyl 3-furoate 132 was isolated as white crystals with a low
melting point of 38°C. Usually, when isolated, it was at first in the form of a
colourless oil which gradually formed white crystals on standing.
4.3: Phenyl-3-furoate
An advantage of using Ole over Dee is that with the Dee method the insoluble
dicyclohexylurea is formed but using Ole the more soluble diisopropylurea is
formed. The mechanism for the coupling using DIe is shown in scheme 4.2.
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Scheme 4.2: Mechanism of Diisopropylcarbodiimide Esterification.
4.1.2 FRIEDEL-CRAFTS ACYLATIONS ON 3-FUROATE ESTERS
Having formed the desired 3-furoate esters a Friedel-Crafts acylation would put in
place a carbonyl group at position 5 giving the desired target compounds 128. This
type of reaction has been documented extensively for the acetylation of furan at O'C
with acetic anhydride and boron trifluoride etherate.l-? The mechanism is shown in
scheme 4.3.
100
+ (MeCOhO - MeCOO, ~ e+ .....C=O-BF3M~)
'0
~BF3
Me
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Scheme 4.3: General Mechanism for Friedel-Crafts Acetylation
This reaction system was applied to the furoate esters but heat was required to effect
the transformation. Although acetic anhydride was used to give the 5-acetyl ester
derivatives, acid chlorides were used to put in other groups. The acid chlorides used
were isobutyryl chloride and cyclohexylcarbonyl chloride. Table 4.1 shows the range
of Friedel-Crafts derivatives made with their yields and conditions used.
o
o
tol
RI R2 TIMEHR TEMPT YIELD%
133 Me Me O. ] 50 46
134 IPr Me 0.] 50 32
135 Ph Me 0.1 50 65
136 Me iPr 0.5 50 21
137 IPr IPr ] 90 63
138 Ph IPr 1.5 60 52
139 Me C6HII ] 100 60
140 IPr C6HII 2 90 32
Table 4.1: Reaction Conditions and Yields for 3,5 Disubstituted
Furans
IH nmr spectra in each case showed the disappearance of one of the furan signals and
a change in the coupling pattern and coupling constants. Table 4.2 shows these
changes for methyl 3-furoate and its respective Friedel-Crafts derivatives.
o
4JOR1SJ[)2
R2 0
RI R2 2-H 4-H Coupling pattern and
constants (Hz)
130 Me H 8.02 6.74 dd 14,5 1.8814.20.68
lz 5 1.5
133 Me COMe 8.13 7.46 d 1420.64
136 Me COIPr 8.06 7.39 d 14 20.59
139 Me COC6H}} 7.99 7.32 Unresolved
Table 4.2: Coupling Constants and Shift Patterns for H-4 and H-2 for
Methyl ester and its Friedel Craft Derivatives
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As can be seen there is a downfield shift for proton 4 caused by the effect of the
carbonyl at position 5 pulling away electron density from H-4. It is consequently
deshielded and shifted downfield. Additionally two carbonyl absorptions were
observed at around 1650 crrr l and 1720 crrr l in the infra-red spectrum corresponding
to the acid and ester respectively. In a normal unsubstituted furan, the coupling
constants are h,3 1.8, hA 3.4, h,5 1.5 and hA 0.9. Comparison of these coupling
constants and those of methyl 3-furoate with those in table 4.2 led us to the
conclusion that the derivatives were substituted at the 5 position.
These data with the IH nmr, 13Cnmr and accurate mass spectra helped to confirm the
identity of the various Friedel-Crafts derivatives.
4.2 SYNTHESIS OF 3,5·DISUBSTITUTED THIOPHENES VIA
FRIEDEL· CRAFTS ACYLATION
As the synthesis of the 3,5-disubstituted furan derivatives was successful the
thiophene analogues were also synthesised. Once made they could then undergo
biological testing to establish whether the sulfur in place of the oxygen would have
any significant effect on biological activity.
4.2.1 SYNTHESIS OF THIOPHENE ESTERS
The methyl, isopropyl and phenyl esters of thiophene-3-carboxylic acid were
successfully prepared using the procedures described for the esterification for 3-furoic
acid. Thus, methyl 3-thiophene carboxylate 141a was prepared in 60% yield using
chlorotrimethylsilane and methanol, isopropyl 3-thiophenecarboxylate 141b was
prepared in 63% yield with isopropanol and a catalytic quantity of concentrated
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sulfuric acid and finally phenyl 3-thiophenecarboxylate 141b was prepared in 60%
yield using diisopropylcarbodiimide and phenol in THF.
141a R = Me
141b R = iPr
141c R = Ph
Figure 4.4: General Structures for Thlophene-S-carboxylate Esters
Table 4.3 shows the IH nmr details for the methyl ester for both furan and thiophene
methyl esters.
H Methyl 3-thiophenecarboxylate Methyl 3-furoate
141a 130
2 8.00 dd 12 4 1.08 and 12 5 3.02 8.02 dd 12 4 0.73 and 12 5 1.48
4 7.42 dd 142 1.01 1455.05 6.74 dd 14 20.68 and 14 5 1.88
5 7.19 dd 15 23.02 and 15 45.05 7.43 dd 15 4 1.72and 15 2 1.52
7 3.75 s 3.79 s
Table 4.3: Comparison of JH nmr values for Methyl 3-thiophene
carboxylate with Methyl 3-furoate
The biggest difference in the spectra is the chemical shift for H-4. H-4 of methyl 3-
thiophene carboxylate is shifted considerably more downfield than its H-4 in the furan
analogue. This can be attributed to the relative aromaticities of the furan and the
thiophene. Since the sulfur is more electropositive than oxygen it will give up its
electrons more readily and will therefore contribute to the rt-aromatic sextet more
readily. Thiophene is therefore more aromatic than furan and so due to the increased
anisotropy effect its protons are deshielded and are consequently shifted more
downfield (ie higher 8). However, oxygen will inductively pull electrons away from
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protons in positions 2 and 5 causing them to appear at similar shifts to those in
thiophene.
4.2.2 SYNTHESIS OF THIOPHENE FRIEDEL-CRAFTS
DERIV ATIVES
The methyl, isopropyl and phenyl 3-thiophene carboxylate esters were treated with
acetic anhydride and isobutyryl chloride in the presence of BF3.0Et2 to give the
respective disubstituted Friedel-Crafts derivatives. Table 4.4 shows these derivatives
with the reaction conditions and yields.
o
RI R2 TIME (HR) TEMP °C YIELD%
142 Me Me 0.1 50 79
143 iPr Me 2.0 70 38
144 Ph Me 1.5 50 55
145 Me IPr 4.0 50 57
146 iPr IPr 2.0 90 51
147 Ph IPr 1.5 90 20
Table 4.4: Reaction Conditions for Acylation of 3-
Thiophenecarboxylate Esters
Structure identification was carried out by infra-red, IH nmr and 13C nmr
spectroscopy. Infra-red first helped to identify the presence of two carbony I peaks for
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each of the derivatives at 1660 and 1720 cm! . The IH nmr spectra also showed that
there were peaks present at approximately (58.0 and (58.4 corresponding to two
thiophene protons. The coupling constants of 1.2 Hz between these thiophene signals
helped to identify which isomer had been isolated. In a normal unsubstituted
thiophene the coupling constants are h,3 4.8 Jz» 1.0 h,5 2.8 and 13,4 3.5 Hz, If,
therefore, substitution had occurred at the 2 position then we would have expected to
see a coupling constant of around 4.8 Hz. The coupling constant we obtained was
1.2 Hz confirming that substitution had occurred at the 5 position.
4.3 SYNTHESIS OF 3,S-DISUBSTITUTED FURANS VIA
FORMYLA TION
Formylation would provide an excellent starting point for a variety of 3,5
disubstituted furans which would have the two carbonyl groups in the correct
positions as the target molecule. It was envisaged that these formyl derivatives could
then undergo nucleophilic attack from a variety of nucleophilic reagents such as
Grignard reagents to give the corresponding alcohol. Oxidation of this would give the
desired 3,5-disubstituted compounds. This is summarised in scheme 4.4.
106
oJ'OH
o
Esterification..
o
j POCI3DMF
o
H
OH o
j Oxidation
o
o
Scheme 4.4: Generation of 3,S-Disubstituted Furans via Formylation
and Nucleophilic attack.
In the scheme, the Grignard reagent vinylmagnesium bromide was used. The
secondary alcohol when oxidised would provide access to an allylic ketone which
mimics the active component and the a,~-unsaturation in wortmannin giving highly-
desirable compounds for biological testing.
to7
4.3.1 VILSMEIER-HAACK FORMYLATION
In order to introduce a formyl group at position 5 a Vilsmeier-Haack reactionl30,131
was carried out using dimethylformamide and phosphorus oxychloride to form the
electrophile 148 (see scheme 4.5). Electrons from the lone pair of the dimethylamine
feed in to the carbon-nitrogen bond encouraging the attack by the carbonyl oxygen on
the electropositive phosphorus atom. Expulsion of a chloride ion gives intermediate
149. Chloride attack then gives 148 as the electrophile.
~n ~ f6e
CI-~-CI CI-P-O~ 0'-
Cl • cI0FNMe2
I HU
o 149:Jl
H eMe2 !
Cl~e
H NMe2
148
Scheme 4.5: Generation of Electrophile for Vtlsmeier-Haack
Formylation
In our system an accurate J: J molar ratio of dimethylformamide and phosphorus
oxychloride was required to make the yellow solid of the Vilsmeier salt. If a J: I
molar ratio was not used then the solid did not form and on reacting the resulting
yellow oil with the appropriate furoate ester no formylation was observed. However
when the yellow Vilsmeier salt was efficiently formed and reacted with the appropriate
furan the desired 5-formyl-3-furoate ester was obtained. The mechanism involves the
initial attack from the furan on the electrophile. Deprotonation by the chloride ion
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results in formation of intermediate 150 which will hydrolyse to give the desired
aldehyde upon aqueous work up.
o
RO~~~
(J H(JMe2
er
-Hel
o o
RO RO
H
o
151 R=Me
152 R=ipr
153 R=Ph
Scheme 4.6: Electrophilic attack to give 5-Formyl-3-Furoate Ester
Nmr of the 5-formyl-3-furoate esters (lSI, 152, 153) clearly indicated the presence
of two compounds for substitution at the 2- and 5- positions. At this stage they could
not be separated by column chromatography on silica. The ratios of the respective
isomers were obtained from the nmr spectra and then confirmed by the isolation of the
allylic alcohol derivatives (see table 4.5). The ratios are, however, not directly
comparable with each other because of the different reaction conditions used in each
case.
Attack was found to be preferentially at position 5 as expected. The intermediate 154
derived from substitution at position 5 has greater delocalisation of the positive charge
than the intermediate formed on substitution at position 4. The electron withdrawing
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ester groups also disfavour attack at position 2 as this would result in a positive
charge at the 3 position. Steric hindrance also plays a part in the selectivity since
substitution at position 2 would form the intermediate 155 in which there would be a
significant steric interaction.
o
~Me2 CI
G
H
155
Figure 4.5: Adduct from Electrophilic Attack at Position 2
4.3.2 GRIGNARD ATTACK BY VINYLMAGNESIUM BROMIDE
ON 5- AND 2-FORMYL-3-FUROATE ESTERS
Mixtures of the 2- and 5-formyl-3-furoate esters were treated with the Grignard
reagent vinylmagnesium bromide to give the respective allylic alcohols. Purification
by column chromatography successfully separated the two isomers at this stage.
o o
7
OMe
OH OH Hb
159 R = Me
160R=ipr
161 R=Ph
156 R = Me
157R=ipr
158 R = Ph
110
Table 4.5 shows the yields of the various isomers isolated.
R 5- isomer 2- isomer RATIO
Me 53 5 10:1
IPr 41 8 5: 1
Ph 46 - -
Table 4.5: Relative Yields of 2- and 5- Isomers
The results shown in table 4.5 are surprising as we would have expected the
proportion of 2- substitution to decrease with increasing steric bulk of the ester.
Although the tic of the allylic phenyl ester did show the presence of two species, only
the 5- substituted isomer could be successfully isolated.
There are marked differences observed in the IH nmr spectrum for the two allylic
alcohols. The most notable difference is the change in the shift and coupling patterns
of the furan signals. Table 4.5 shows these differences for methy I 5-( l-hydroxy-2-
propenyl)-3-furoate and methyl 2-(1-hydroxy-2-propenyl)-3-furoate. The other
allylic alcohols isolated showed similar coupling patterns. The assignment of the
substitution pattern was done by comparing the coupling constants for the allylic
alcohols with that of unsubstituted furan as described previously in 4.1.2.
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Methyl 5-( I hydroxy-2- Methyl 2-( I hydroxy-2-
propenyl)-3-furoate 156 propenyl)-3-furoate 159
H 0 Coupling pattern 0 Coupling pattern
2 7.83 d, 12 40.84 NOT APPLICABLE
4 6.45 d, 1420.84 7.22 d,i451.94
5 NOT APPLICABLE 6.59 d.154 1.93
7 3.72 s 3.72 s
8 5.05 br d, i8 I) 5.82 4.74 br d, i8 I) 5.31
9 5.95 ddd, i9,8 5.81, 19,IOb 6.01 ddd, i9.8 5.63, iI), IOa
16.15,19 lOa 10.33 10.32, iy lOb 15.9,
lOa, 5.35 unresolved 5.35 unresolved
lOb
Table 4.6: Comparison of J H nmr spectra for Allylic Alcohols
4.3.3 OXIDATION TO ALLYLIC KETONES
SWERN OXIDATION
The first attempt to oxidise the allylic alcohols to their respective ketones used Swern
conditions.I= Oxalyl chloride was treated with dimethylsulfoxide in dichloromethane
at very low temperatures. The procedure recommends -60°C but for practical
reasons we chose -78 °C using an acetone/dry ice bath. This low temperature is
important as this initial reaction to form intermediate 162 is highly exothermic and can
be explosive. This intermediate breaks down releasing carhon dioxide and carhon
monoxide giving the salt 163. Upon reaction of the alcohol to he oxidised with the
salt 163 an alkoxysulfonium salt 164 is formedl33,134 which hreaks down on
treatment with triethylamine to give the ketone and dimethylsulfide. The latter reaction
has been well documented.135,136
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Scheme 4.7: Mechanism of Swern Oxidation
Our system failed to produce the ketone and the starting alcohol was recovered. There
are several reasons why the alcohol may not have been oxidised including of course
failure of the initial alkoxysulfonium salt to form. Steric hindrance of the alcohol and
the mechanism of the breakdown of the alkoxysulfonium salt by the triethylamine may
give another possible explanation. As shown in scheme 4.8 there are two possible
breakdown pathways of the salt 164. Path A shows proton abstraction by the CH2-
to give the desired ketone and dimethylsulfide. However path B provides an
alternative pathway regenerating the alcohol. Rather than deprotonating the methyl
group triethylamine in this case has attacked the electropositive sulfur. Proton
elimination and sulfur-oxygen bond fission then generates the alkoxide which in turn
regenerates the alcohol.
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PATHWAY A PATHWAY B
!
j
+
Scheme 4.8 Two Possible Pathways for Swern Oxidation
The size of the R groups is important in determining which pathway is followed. As
bulk and steric hindrance are increased the sulfur becomes less accessible for
nucleophilic attack from the triethylamine and pathway A will be favoured. Small R
groups on the other hand will favour pathway B. Comparing our substrate 165 to
other substrates (166, 167) which have undergone successful oxidation under
114
Swern conditions it can be seen that ours is less sterically hindered than the others
which could explain the observed lack of oxidation.
o
OR
OH 165 166 *OH167
Figure 4.6: Comparison of Allylic Alcohol with known Substrates for
Swern Oxidation
MANGANESE DIOXIDE
Since the Swern oxidation was proving to be difficult, manganese dioxide was
considered as an alternative oxidant. It is a heterogeneous oxidative reagent similar to
oxidants such as copper oxide, silver oxide and manganese (Ill) acetate I.n. Its
potential as an oxidant was first documented by Goodwin, Ball and Mortonl " for its
use in the oxidation of vitamin AI into retinal.
6 days/25°C
80%
Scheme 4.9: Oxidation of Vitamin A J to Retinal
Since then it has been used extensively in the selective oxidation of a,~-unsaturated
alcohols, saturated alcohols, phenols, hydrazines, hydrocarbons and others. There
are commercial sources of active maganese dioxide with Backson and Winthrop
Laboratories in New York and E. Merck in Darmstadt in Germany as the main
suppliers but we decided to make our own, following the procedure laid out by
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Mancera, Rosenkranz and Sondheimerl-". The reagent was precipitated from a warm
solution of manganese sulfate and potassium permanganate. The pH of the solution is
important in defining how active the precipitated manganese dioxide is. The
procedure we followed gave "active" manganese dioxide from an acidic medium.
Preparation of the reagent by the method of Attenburrow, Cameron and Chapman 140
gives active manganese dioxide from alkaline conditions whilst that prepared by the
original Ball, Goodwin and Morton procedure gives manganese dioxide from neutral
conditions and is reportedlyl+' less active than the other two. Once prepared. the
manganese dioxide was dried in the oven at 11DoCfor 24 hours in order to activate it.
It was in fact stored in the oven until it was required. Pratt and Van de Castlet+?
showed that heating at 125°C for a longer time gives a more active material.
There are several forms of manganese dioxide and their various reactivities were
compared by Vereschagin and co-workersl+' who concluded that the order of
reactivity for the oxidation of benzyl alcohol was:
'V-Mn02 > active Mn02 > (X-Mn02
Additionally they concluded that the oxidisng power of active manganese dioxide was
dependent upon the content of 'V-manganese dioxide.
The structure of active manganse dioxide was determined by various physical
methods including thermogravimetric analysis (TGA) which showed that there were
three distinct areas of weight loss as shown:
TEMPERATURE
20 - 200 T
200 - 500 °C
500 - 525°C
ELIMINATION OF
non bonded water molecules
bonded water molecules i.e. hydroxy ligands
labile oxygen ligands
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On the basis of the above information as well as ESR studies it was proposed that the
structure of active manganese dioxide 168 was as shown in figure 4.7.
Figure 4.7: Proposed structure of Manganese Dioxide
The mechanism of oxidation by manganese dioxide is unclear. Based on the
observation that the rate of oxidation of various benzyl alcohols by manganese dioxide
is relatively independent of the nature of benzyl substituents, Pratt and co-
workersI44,145,146 proposed a free radical mechanism. Later, in 1967, Hall and
Story 147 re-interpreted these results in terms of a formally ionic mechanism with the
positive charge on the oxygen 169 and not the benzylic carbon as expected.
Both the free radical and the ionic mechanisms begin with the adsorption of the
alcohol onto the manganese dioxide via an allylic or aromatic 1t-bond or via
manganese ions and alcohol oxygen co-ordinationt+" to give the co-ordination
complex 170. In the free radical mechanism a hydrogen atom is then transferred
which gives the stablilised radical which undergoes intramolecular electron transfer to
give the products. In the ionic mechanism the co-ordinated complex loses the
manganese fragment to form the transition state 169 which loses a proton to give the
oxidised product.
)) 7
FREE RADICAL
R-CH2OH IONIC
PATHWAY 1~MnO, PATHWAY
R-CH2OH/Mn02
"adsorption"
• Ill/OH
1~IV.O- RCH2O-Mn:OHRCHO-Mn
'OH "co-ordination"
"radical formation" 170
II OH (±) "OH
/ RCHi) + Mn'aGRCHO/Mn,
OH 169
"adsorption"
\ /
Scheme 4.10: Two possible pathways for Manganese Dioxide
Oxidation
There was considerable literature precedence for the successful oxidation of our
compounds. Brooks and Draffanl+? showed the oxidation of an alcohol next to a
furan 171 which gave the cis fused keto alcohol 172
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""OH 24hl R.T.
171 172
Scheme 4.11: Oxidation of Sesquiterpenoid Furanopentasol 171 by
Manganese Dioxide
Similarly, oxidation of allylic alcohols has been well documentedI5o,151. Scheme
4.12 shows the transformation of the both aromatic and allylic alcohol cis-l-phenyl-2-
buten-l-ol 173 to the corresponding cis ketone 174.152
Ph
I
H3C CH-OH
>=<H H
173
Mn02
acetone / 6 h ..
Ph
IH3C>=!=O
H H
174
Scheme 4.12: Oxidation of Allylic Alcohol cis-l-Phenyl-2-buten-
1-01.
In view of the literature precedence we treated our alcohols with 10 equivalents of
manganese dioxide in light petroleum (40:60). Purification afforded the methyl,
isopropyl and phenyl 5-(2-propenoyl)-3-furoates. Table 4.7 shows a comparison of
the IH nmr shift values of the propenoyl fragment showing that there is little change
irrespective of which ester is present.
o
OR R = Me, ipr, Ph
o
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H1 2 4 5a 5b
175 Me 8.06 7.46 6.96 5.85 6.48
176 iPr 8.08 7.47 6.9 5.86 6.51
177 Ph 8.28 7.60 6.98 5.91 6.55
Table 4.7: Comparison of IH nmr data for ketones
Large changes were oberved when comparing the IH shifts for 5-(2-propenoyl)-3-
furoates with their corresponding alcohols. The changes shown in table 4.8 are for
methyl 5-(2-propenoyl)-3-furoate and its corresponding alcohol but the shift pattern is
typical for both the isopropyl and phenyl esters.
OH 0
156 175
H 1 2 3 4 5a I 5b
156 7.83 6.45 5.05 5.95 5.35
175 8.06 7.46 N/A 6.96 5.85 J 6.48
Table 4.8: Comparison of 1H Nmr Values of Allylic Alcohol 156 with
Enone 175
The changes in the IH nmr spectrum between the allylic aIcohol156 and the allylic
ketone 175 can be attributed to the change in electron delocalisation between the two
molecules. The ketone is electron withdrawing and deshields the protons in the
double bond and in the furan causing a downfield shift (i e higher () values).
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4.4 SYNTHESIS OF 3,5-DISUBSTITUTED THIOPHENES VIA
FORMYLATION
The synthesis of 3,5-disubstituted thiophenes following parallel methodology to the
synthesis of 3,5-disubstituted furans described in section 4.3 is detailed below.
4.4.1 FORMYLATION OF METHYL 3-THIOPHENECARBOXYLATE
Methyl 3-thiophene carboxylate was added to the yellow Vilsmeier salt formed from
phosphorus oxychloride and dimethylformamide. The reaction mixture was warmed
to 100 QCand held at this temperature for one hour. Tic indicated that two products
had been formed - methyI5-formyl-3-thiophenecarboxylate 178 and methyl 2-formyl
3-thiophenecarboxylate 179. Unlike the two formyl isomers of methyl 3-furoate
these thiophene isomers were separated and isolated at this stage in a ratio of 4: I
respectively by column chromatography. Table 4.9 shows the comparison between
the nmr spectra of the two different isomers.
o o
4~7~ ~ OCH3
5 8 H
S
179 0
H
o 178
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H Methyl-5-fonnyl-3- Methyl-2-fonnyl-3-
thiophenecarboxylate thiophenecarbox ylate
178 179
2 8.36 d 12,4 1.29 NOT APPLICABLE
4 8.08 d 142 1.29 7.57 br. s
5 NOT APPLICABLE 7.59 br. s
7 3.87 s 3.90 s
8 9.85 dd 18,4 1.34 10.53 s
and 18 22.59
Table 4.9: Comparison of 1H nmr Values Methyl 5-Formyl-3-
thiophenecarboxylate with Methyl 2-Formyl-3-thiophenecarboxylate
The protons at position 4 are markedly different due to this proton in the 5-formyl
isomer being in conjugation with the aldehyde. Electron withdrawal by the aldehyde
causes H-4 to be deshielded and so it appears more downfield. This does not occur in
the 2- isomer. H-2 is more downfield in methyl 5-formyl-3-thiophenecarboxylate
than H-5 in methyl 2-fonnyl-3-thiophenecarboxylate due to it being in conjugation
with the carbonyl of the ester. H-5 however has moved slightly downfield from
07.19 in the starting ester to B7.59 in the 2- isomer because it is slightly deshielded by
the formyl group. The carbonyls in the IR spectra are found at similar frequencies for
the two isomers at 1670 and 1720 crrr '. This, although confirming the introduction
of the formyl group does not help distinguish the two isomers.
122
4.4.2 GRIGNARD ATTACK ON FORMYL ESTER
Addition of vinylmagnesium bromide to a solution of methyl 5-formyl-3-
thiophenecarboxylate in THF gave methyl 5-( l-hydroxy-2-propeny 1)-3-
thiophenecarboxylate 180 in 57% yield.
9
OH
180
Figure 4.8: Methyl 5-(l-Hydroxy-2-propenoyl)-3-
thiophenecarboxylate
The IH nmr spectrum of the allylic alcohol 180 shows clearly the doublet of doublet
of doublets at 86.01 for proton 9. Infra-red detected the presence of only one
carbony I at 1720 crrr ' corresponding to the ester.
4.4.3 OXIDATION OF METHYL 5-(1-HYDROXY-2-PROPENYL)-
3- THIOPHENECARBOXYLATE
Methyl 5-( l-hydroxy-2-propenyl)-3-thiophenecarboxylate was stirred at room
temperature with 10 equivalents of freshly prepared manganese dioxide to give methyl
5-(2-propenoyl)-3-thiophenecarboxylate 181 in 60% yield
o
181
Figure 4.9: Methyl 5-(2-propenoyl)-3-thiophenecarboxylate
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The IH nmr spectrum showed clearly the doublet of doublets for H-I Oa at 85.87 and
for H-lOb at 86.46. H-9 is found more downfield at 87.02 due to the deshielding
effect of the carbonyl. Infra-red helped confirm the structure by showing the presence
of two carbonyls - 1660 cm-! for the allylic ketone and 1720 cm' for the ester.
4.5 ALTERNATIVE SYNTHESIS TO KETONE t 75
Although the route to formation of methyl 5-(2-propenoyl)-3-furoate 175 was
successful it is lengthy and involved. Therefore, a different approach was taken using
the methodology behind the successful Friedel-Crafts reactions in section 4.1. In
light of this attempts were made to couple methyl 3-furoate with acryloyl chloride in
the presence of boron trifluoride etherate as the Lewis acid. All attempts were
unsuccessful and baseline material was isolated.
odOMe
o
~CI
o
X •
o
OMe
o 175
Scheme 4.13: Alternative Pathway to Methyl 5-(2-propenoyl)-3-
furoate via Friedel-Crafts Acylation
4.6 FORMATION OF DIELS-ALDER ADDUCTS
Once the allylic ketone was formed it seemed appropriate to make Diels-Alder adducts
as this would provide more derivatives for biological testing with greater steric bulk at
the 5-position of the molecule. Methyl 5-(2-propenoyl)-3-furoate was refluxed with
2,3-dimethyl- I,3-butadiene, 2,3-dimethoxy- I,3-butadiene and cyclohexa-I ,3-diene in
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dichloromethane solution. Successful reactions were obtained under these conditions
with the first two forming adducts 182 and 183.
o
R
OMe
R
o
182 R = Me
183 R = OMe
Figure 4.10: Cycloadducts from Diets-Alder Reactions
On treatment with cycIohexa-1 ,3-diene no reaction was observed and starting material
was recovered. This was surprising because cyclohexa-l ,3-diene is locked into the
cisoid conformation which implies that this should be a fast reaction. The adduct 184
was successfully made, however, when the Lewis acid aluminium chloride was
added.
o o oOMe OMe
I
~/O185
CI3AJ
Ios~
CI3A(
OMe
o
184 + AICI3
Scheme 4.14: Formation of Lewis Acid Accelerated Diets-Alder
Adduct
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Yates and EatonJ53 in the early 1960's first reported accelerated Diels-Alder [4+21
cycloadditions of maleic anhydride, dimethylfumarate and p-benzoquinone to
anthracene. Since then there have been many other Lewis acid accelerated Diels-Alder
reactions reported.J54,J55 The aluminium co-ordinates to the oxygen of the ketone
forming complex 185. Electrons therefore are pulled away from the allylic double
bond (as seen in scheme 4.14). The effect of the electron withdrawing property is to
decrease in the energy difference between the HOMO and LUMO orbitals of the diene
and dienophile resulting in a faster reaction. (see Figure 3.3 in Chapter 3)
4.7 ALTERNATIVE SYNTHESIS TO DIELS·ALDER ADDUCT
An alternative convergent synthesis to the Diels-Alder adduct 182 would be the
Friedel-Crafts reaction between the furoate ester and the appropriate acid chloride (see
scheme 4.15).
o
:dCI
186 0[fOMe
o
BF30E~
o
OMe
o
182
Scheme 4.15: Convergent Synthesis of Diets-Alder Adduct
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Acryloyl chloride was refluxed with 2,3-dimethybutadiene to form the desired acid
chloride 186 via a Diels-Alder reaction as shown in scheme 4.14. The
dichloromethane solvent was then removed in vacuo to leave the acid chloride as a
colourless oil. Methyl 3-furoate and boron trifluoride etherate were then added and
the resulting mixture refluxed. The IH nmr spectrum of the isolated material was
consistent with the product isolated from the Diels-Alder reaction between methyl 5-
(2-propenoyl)-furoate and 2,3-dimethylbutadiene. However, the yield was low
(23%) but in comparison to the overall yield via formylation (4.8% - based on methyl
3-furoate) this is obviously preferable. The conditions would be further optimised if
this method were to be used again.
Attempts to form the isopropyl ester adduct following this method proved to be
unsuccessful. However it is envisaged that transesterification of the methyl ester
prepared above would give access to other desired compounds.
4.8 BIOLOGICAL TESTING
Several of the compounds made (133 - 140) have been sent away for testing of their
ability to inhibit phospholipase D. We are still waiting on the results of this biological
testing.
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CHAPTER 5
5.1 ISOLATION AND DERIVATISATION OF WORTMANNIN
Wortmannin 34 was isolated from the freeze dried culture of Talaromyces wortmanii
which was incubated on Raulin and Thorn still culture. Since wortrnannin 34 has
been shown to exhibit phospholipase D inhibition it therefore seemed appropriate to
derivatise it in order to test the biological activity. Functionalisation centred around
the carbonyl at position 17 since it had been previously been shown that derivatisation
of the furan or of the two carbonyls in conjugation with it destroyed any biological
activity it possessed.
H
~ }-OAC~
~
~OH/W
o
OMe
OMe
OAe
CH20 Cl /
HN(CH3)2.H/
o
34
OH
Figure 5.1: Functionalisation at C-17 of Wortmannin
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The main chemistry centred around work by Haefliger and co-workers 77 who
derivatised wortmannin as shown in scheme 5.1. As the compounds they prepared
were not tested for phospholipase D inhibition they provided a suitable starting point.
5.1.1 SYNTHESIS OF WORTMAN-17~-OL
Wortmannin was reduced to wortman-IZjl-ol 187by using the BH3.THF complex as
shown in scheme 5.2.
MeO'-..._ACO" -,
OH
o
187
Scheme 5.2: Reduction of Wortmannin to Wortmannin-17{3-01
There are 4 carbonyls in wortmannin 34 and therefore 4 possible sites for reduction.
The carbonyl at C-3 and the acetyl ester were not reduced because the former is a
lactone and the latter an ester neither of which are easily reduced by borane. The
carbony I at C-7 is a,~ unsaturated and once again such systems are not reduced by
borane. The ketone carbonyl at C-17 was found to be reduced. These general
observations can be explained by the relative nucleophilic nature of the various
carbonyls. Borane is an electrophile (i.e. a Lewis Acid) 156,157 and will therefore
attack the oxygen and not the carbon of the carbonyl functional group unlike hydride
reagents such as lithium aluminium hydride. The selectivity is consequently different
and the most nucleophilic carbonyl will be reduced preferentially. In this case it is the
ketone carbonyl since in both the ester and the lactone the nucleophilicity is reduced
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by the oxygen neighbouring the carbonyl. Likewise for the a,~-unsaturated ketone
resonance delocalisation reduces the nucleophilicity.
When the ketone is reduced the alcohol forms selectively on the same face as the
neighbouring methyl group as the incoming BH3.THF complex will prefer to attack
the side of the ring with the smallest group - in this case the side opposite the methyl.
Hydrogen delivery will therefore be on the a face and the alcohol will be on the ~
face.
5.1.2 SYNTHESIS OF WORTMANNIN ENOL ACETATE
Wortmannin 34 was treated with isopropenyl acetate and catalytic para-
toluenesulfonic acid to give the expected wortmannin enol acetate 188 in 58°kJ yield.
This transformation is seen in scheme 5.3.
o
}OAC
OAc
Meo~ AcO" -,
o
o
188
Scheme 5.3: Transformation to Wortmannin Enol Acetate
The mechanism involves firstly protonation of the isopropenyl acetate which is then
attacked by the oxygen of the carbonyl displacing isopropenol. The isopropenol is in
equilibrium with the more stable acetone and it is the formation of this which is the
driving force for the reaction. Like the previous reduction formation of this derivative
on the C-17 carbonyl is dependent upon the nucleophilicity of the oxygen. Following
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the same arguments as previously C-17 has the most nucleophilic oxygen and will
therefore react preferentially over the other carbonyl groups.
5.1.3 SYNTHESIS OF 16-METHYLIDENEWORTMANNIN
Formation of 16-methylidenewortmannin 189 was done using the Mannich reaction.
Usual Mannich conditionst-f involve condensation of formaldehyde with ammonium
chloride and a compound containing an active hydrogen. The system used to generate
16-methylidenewortmannin 189 used dimethylamine hydrochloride, the salt of the
secondary amine. The use of primary or secondary amines or even amides have been
well documented.U? The dimethylamine reacts with the formaldehyde to gi ve
Me2NCH20H 190 which then reacts with the enol form of the ketone giving 191.
which is called the Mannich Base.
The Mannich reaction can either be base or acid catalysed and kinetic studies have led
to proposals for the mechanism. Scheme 5.4 shows the proposed mechanism for the
acid catalysed reaction.Iw
This Mannich base can have several different fates dependent upon whether the amine
is primary, secondary or tertiary. In the case of shown tertiary amine no further
condensation with either the aldehyde or the ketone takes place. The amino group is J3
to the carbonyl and so dimethylamine is easily eliminated providing an easy route to
the a,J3-unsaturated ketone.
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Scheme 5.4: Mechanism of Mannich Reaction
5.1.4 ATTEMPTED KETAL FORMATION AND ATTEMPTED
HYDROGENATION OF 16-METHYLIDENEWORTMANNIN
An attempt was made to form the ketal at carbonyl-17 by reacting wortmannin 34
with methanol in the presence of acid. A white precipitate was observed which was in
agreement with literature but when isolated this proved to be starting material. This
was repeated on several occcasions but no ketal was isolated.
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An attempt was also made to hydrogenate l6-methylidenewortmannin 189 using
hydrogen and a palladium/carbon catalyst. This was unsuccessful and resulted in
baseline material being formed.
S .2 ISOLA TION OF DEMETHOXYVIRIDIN AND
DERIV ATISATION
Demethoxyviridin 3S was isolated from Nodulisporium hinnuleum grown on Rhaulin
and Thorn culture medium.
o
35
Figure 5.1: Demethoxyviridin
Demethoxyviridin 35 was treated with methanesulfonyl chloride in the presence of
pyridine to give first the methanesulfonate ester 192 which undergoes further
elimination to give the a.,~-unsaturated derivative PLD-7 47. This compound has
since been sent for biological testing and we are awaiting results.
133
192
47
M~~_C®r=\
O~
OH
o
o
o
Scheme 5.5: Formation 0/ PLD-7
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CHAPTER 6
6.1 GENERAL NOTES
Melting points were measured on a Gallenkamp melting point apparatus and are
uncorrected. Nuclear magnetic resonance spectra were recorded with a Perkin Elmer
R32 spectrophotometer operating at 90 MHz (OH) or a Bruker AM200 or WP200-SY
spectrophotometer operating at 200 MHz (OH) and 50 MHz (Oc). Tetramethylsilane
(TMS) was used as an internal standard in deuterated solvents. The numbering
schemes used are to aid identification in the 1H and DC spectra. Infra red (Ik )
spectra were obtained on either a Perkin Elmer 983 spectrophotometer or a Philips PU
9800 FTIR spectrophotometer. Elemental analyses were performed using a Carlo-
Erba 1106 elemental analyser. Mass spectra (MS) were recorded on AEI MS 12 or
MS902 spectrometers. Only major peaks are quoted.
Thin layer chromatography (TLC) was carried out on glass backed silica plates of
0.25 mm thickness. Compounds were visualised using UV light and by staining with
vanillin solution with heat development. Column chromatography was carried out on
silica gel, 70-230 mesh with solvent systems described.
All solvents were purified by standard techniques as described in Perrin and
Armarego.!"'
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6.2 SYNTHESIS OF TARGET FURAN VIA DIOL OXIDATION
DIMETHYL 4,5-DIMETHYL-I,4-CYCLOHEXADIENE-l,2-
DICARBOXYLATE (78)
II
4 2 1
HO 6DcoOMe
2 .. 5 1 13
60oC/24h COOMe
78
COOMe
COOMe
Dimethyl acetylenedicarboxylate (6 g: 42 mmol) and 2.3-dimethyl-1 ,3-butadienc
(4.14 g: 50.4 mmol) were added dropwise to water (40 ml). The resulting solution
was stirred for 24 h at 60T and on cooling to room temperature a white precipitate
formed which was filtered, dried and recrystallised from methanol yielding dimethyl
4,5-dimethyl-I,4-eyelohexadiene-I,2-diearboxylate 78 (5.14 g. 54.6%); m.p. 69-
70°C IR Vmax 1720 and 1658 crrr ': OH (200 MHz: CDCI~) 1.71 (6H. s, H-6). 2.29
(4H, s, H-4) and 3.76 (6H, s, H-I); OC (50 MHz): 17.90 (C-6), 34.05 (C-4), 52.12
(C-I), 121.47 (C-5), 133.30 (C-3) and 168.5 (C-2). mlz 224 (M+, 2.6), 193 (M+-
OMe,14.7) and 177 (100.%) (Found M+, 224.1058: C 64.86 and H 6.41%.
C 12H1604 requires M, 224.1048; e 64.86 and H 6.30%)
REDUCTION OF DIMETHYL 4,5-DIMETHYL-l,4-CYCLO-
HEXADIENE-I,2-DICARBOXYLATE (79)
THF
6rr41I I OHOH
79
xxCOOMeI COOMe
78
METHOD I: VIA LITHIUM ALUMINIUM HYDRIDE
To a flame dried flask under nitrogen was charged lithium aluminium hydride (167mg:
4.41 mmol) at G'C followed by THF (10 ml). Whilst the temperature was
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maintained at O°C the ester (500 mg: 2.2] mmol).was slowly added dropwise and
the resulting solution stirred for Lf h. The reaction was quenched with a solution of
sodium sulfate decahydrate. Hydrochloric acid (l M) was slowly added until the
solution hecame acidic (pH 3). The solution was extracted with ethyl acetate (3 x
30ml) and the organic extracts combined, washed with sodium bicarbonate (3 x
25ml), brine (3 x 25 ml) and dried over magnesium sulfate. The solvent was
removed under reduced pressure to give the residual oil as the crude product.
Purification via column chromatography eluting with hexane: ethyl acetate (I: I )
afforded ] ,2-dihydroxymethyl-4,5-dimethyl-] ,4-cyclohexadiene 79 (676 mg:
4 mmol: 18%) m.p. 70°C; 8H (CDCb: 200 MHz): 2.74 (6H, s, H-6), 3.8 (2H, s, H-
4) and 4.22 (4H, s, H-2). 8c (CDCI3: 50 MHz):]7.38 (C-6), 34.5 (C-4), 61.3 (C-2),
121.0 (C-5) and 129.9 (C-3). m/z: 168 (M+, 1.7), 150 (15.3) and 121 (32%)
(Found M, 168.1159 CwH 1602 requires 168.] 150).
METHOD 2: USING SODIUM BOROHYDRIDE
To a stirring solution of dimethyl 4,5-dimethyl-] A-cyclohexadiene-l ,2-dicarboxylate
(200 mg: 0.89 mmol) in methanol (I 5 ml) was added sodium borohydride
(130 mg: 3.57 mmol). After the initial effervescence the resulting solution was
stirred for 3 h. TIc eluted with hexane: ethyl acetate (2:]) indicated that no reaction
had occurred. A further portion of sodium borohydride (130 mg: 3.57 mmol) was
added and the resulting solution stirred overnight. Tic indicated again the presence of
starting material only.
METHOD 2: USING IN SITU FORMATION OF BORANE
Sodium borohydride (240 mg: 6.63 mmol) was aded to a dry flask in a nitrogen
atmsphere followed by THF (15 ml). The solution was cooled to O°C and iodine
(560 mg: 2.2 mmol) was slowly added. dimethyl] A-cyclohexadiene-4,5-dimethyl-
] ,2-dicarboxylate (500 mg: 2.2 mrnol) in THF (5 ml) was added and the mixture
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brought to reflux for 0.5 h. Tic indicated the presence of only starting material and
low running baseline material.
ATTEMPTED CYCLISATION TO FURAN (80)
79
-----.xf---~.. XX>
80
YfOH
~OH
METHOD 1: USING PYRIDINIUM CHLOROCHROMATE
Pyridinium chlorochromate (380 mg: 1.78 mmol) was added portionwise to a
solution of 1,2-dihydroxymethyl-4,5-dimethyl-1 ,4-cyclohexadiene (200 mg:
1.19 mmol) in CH2Ch (25 ml) and stirred at room temperature for 0.5 h. The
resulting solution was then extracted with diethyl ether (3 x 25 ml) and the organics
washed with sodium bicarbonate (2 x 20 ml), brine (2 x 20 ml) and dried over
magnesium sulfate. The solvent was removed under reduced pressure and tic
indicated that there was a mixture of products.
METHOD 2: USING MANGANESE DIOXIDE
Manganese dioxide was first prepared as follows: a solution of manganous sulfate
(7.16 g: 47 mmol) in water (400 ml) was warmed to 90°C and potassium
permanganate (6 g: 37 mmol) in water (20 ml) was slowly added. Brown solid
manganese dioxide precipitated immediately and the resulting slurry was heated at
90°C for I h. The solution was then filtered to give manganese dioxide which was
washed with hot water (200 ml), methanol (200 ml) and diethyl ether (200 ml).
Drying overnight afforded active manganese dioxide (6.09 g : 90.4%).
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To a stirred solution of the diol 79 (200 mg: 1.19 mmol) in CH2CI2 (25 rnl) was
added 10 equivalents of manganese dioxide (10.2 g: 11.9 mmol). The resulting
slurry was stirred at room temperature for 24 h. TIc indicated the presence of only
starting material.
6.3 SYNTHESISVIA ALLYLIC SULPHIDES
l-(PHENYLTHIOMETHYL)-l-CYCLOHEXANOL (89)
CH3SPh
DABCO ..
n-BuLi
THF 4 89
A dry 3 neck flask in a nitrogen atmosphere was charged with
diazabicyclo[2.2.2]octane (2.24 g: 20 mmol), THF (20 rnl). thioanisole (2.34 ml:
2.48 g: 20 mmol) and cooled to O'C. n-Butyllithium (12.7 ml: I.SM. 20 mrnol )
was slowly added and the resulting solution stirred for 1.5 h Cyclohexanone
(2.1 ml: 1.86 g: 20 mmol) was added and the mixture stirred for I h at O°C then I h
at room temperature. The reaction was quenched with ammonium chloride solution
and the solution extracted with ethyl acetate (3 x 30 ml). The combined organic
extracts were washed with sodium bicarbonate (3 x 30 ml), brine (3 x 30 ml) and
dried over magnesium sulfate. The solvent was removed under reduced pressure to
give the crude product as a yellow oil. Purification using column chromatography
eluting with light petroleum/ethyl acetate (10: I ) afforded 1-
(phenylthiomethyl)cyclohexanol 89 as a yellow oil (3.59 g: 16.2 mmol: 81%): IR
(neat) v max; 1580 and 3400 crrr l; OH (200 MHz; CDCl3); 1.1- 1.5 (I OH, m, H-
2,3 and 4),1.98 (IH, br s, OH), 2.89 (2H, s, H-5) and 7.07 (5H, m, H-7,8 and 9).
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Dc (50 MHz) 22.04 (C-4), 25.57 (C-3), 33.74 (C-2), 47.71 (C-5), 71.22 (C-I),
126.07 (C-9), 128.89 (C-7) and 129.47 (C-8) and 137.2 (C-6). m/: 222(M+, 7.7),
124 (100) and 99 (22.5%).
l-(PHENYL THIOMETHYL)CYCLOHEXENE (90)
pTsOH
TOLUENE..
9 10 9 10
REFLUX
12 H
6 ~2 + 6 2
5 3 5 3
4 4
90 9189
A solution of l-(phenylthiomethyl)-l-cyclohexanol (1.54 g: 6.9 mmol) in 10 Illi
toluene and a catalytic amount of para-toluene sulfonic acid was allowed to reflux
under Dean and Stark conditions for 12 h. The solution was cooled and was extracted
with ether (3 x 20 ml). The combined organic extracts were washed with sodium
bicarbonate (3 x 20 ml), brine (3 x 20 ml) and dried over magnesium sulfate. The
solvent was removed in vacuo giving the crude product. Purification by column
chromatography eluting with cyclohexane) afforded the two isomers 1-
(phenylthiomethyl)cyclohexene 90 (566 mg: 2.77 mmol: 40%) and phenylthio-
methylidenecyclohexane 91 (119 mg:0.58 mmol: 8%) as yellow oils in a ratio of
5:1:
Data for I-(phenylthiomethyl)cyclohexene 90: IR (CDCh solution); 1580 and
1660 crrr l. oH (200 MHz; CDCI3); 1.1-1.2 (IOH, m, H-3,4,5 and 6),3.46 (2H,
s, H-7); 5.51 OH, m, H-2) and 7.12-7.47 (5H, rn, H-9,JO and II). OC (50 MHz);
22.69(C-4),25.25 (C-5), 27.21 (C-3) 29.69 (C-6), 42.3 (C-7), 125.59(C-II),
126.00 (C-9), 128.58 (C-IO), 130.06 (C-2), 133.00 (C-I) 136.85 (C-8). m/: 204
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(M+, 42.6), 110(39.7) and 95 (100%) (Found M, 204.0977 CnH 16S requlrcs
204.0972)
Data for phenylthiomethylidenecyclohexane 91: OH (200 MHz: COCl); 1-2.5 (IOH,
m, H-2-6), 5.78 (IH, s, H-7) and 7.02-7.23 (5H. m, H-9, 10 and II). Oc(50 MHz
) 26.44 (C-4), 28.37 (C-3), 30.41 (C-2),125.42 (C-7), 127.68 (C-9), 128.82 (C-
10),129.06 (C-I), 137.68 (C-8) and 148.26 (C-7). mlz 204 (M+, 95.1),147
(17.5),141 (10.5) and 129 (20.3%) (Found M+, 204.0976 C13Hl6S requires M,
204.0972)
1-(PHENYLTHIO(TRIMETHYLSILYL)METHYL)-
CYCLOHEXENE (87)
cA
S~11
TMSCI •
3LOA
THF
4
8790
To a solution of I-(phenylthiomethyl)cyclohexene (1.35 g: 66.2 mmol) in 10 ml
THF held at -78°C was added dropwise LOA (6.61 ml: 100 mmol). The resulting
solution was stirred for 2 h maintaining the temperature at -78°C. A solution of
trimethylsilylchloride (1.26 ml: 1.08 g: 100 mmol) was then slowly added and the
mixture stirred at -78°C for 4 h. The reaction was quenched with a saturated solution
of ammonium chloride and extracted with ether. The organic extracts were washed
with 10% aqueous hydrochloric acid (2 x 20 ml), sodium bicarbonate (3 x 20 ml),
brine (3 x 20 ml) and dried over magnesium sulfate. The ether was then removed
under reduced pressure to give the crude product as the residue. Purification via
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column chromatography eluting with petroleum ether afforded 1-
(phenylthio(trimethylsilyl)methyl)cyclohexene 87 as a yellow oil (69X mg:
2.52 mmol: 38%); IR (neat) vrnaxl590 and 1650 crrr l. OH (200 MHz: CDCI3): 0.15
(9H, s, TMS), 1.4 - 2.1 (8H, m, H-3,4,5 and 6), 3.14 (I H, s, H-7), 5.45 (I H, m,
H-2) and 7.03 - 7.30 (5H, m, H-9,10 and II) Oc (50 MHz): -1.86 (TMS), 22.57.
23.08,26.44,29.72,123.05 (C-ll), 125.05 (C-9), 127.47 (C-IO), 129.04 (C-2),
138.46 (C-8) and 148.22 (C-I) m/z: 276 (M+, 9.3), 199 (7.9), 167 (6.3) and 109
(35%) (Found M+, 276.1369 C16H24SSi requires M, 276.1598)
ATTEMPTED PREPARATION OF 2-PROPANOYL-I-PHENYLTHIO-
METHYLENE)CYCLOHEXANE (95)
87 91
A dry flask held in a nitrogen atmosphere was cooled to -78°C and aluminium
chloride (72 mg : 0.54 mmol) and CH2CI2 (10 ml) were added. A solution of
propionyl chloride (0.05 ml: 0.54 mmol) in CH2CI2 (4 ml) was then slowly added
followed by 1- (phenylthio(trimethylsilyl)methyl)cyclohexene 87 (10 mg:
0.36 mmol) and the resulting solution was stirred for 6 h with the temperature
maintained at -78°C. The reaction was quenched with ammonium chloride (4 ml: IM
solution) and warmed to room temperature. The reaction was diluted with diethyl
ether (10 ml) and washed with brine (2 x 20 ml), sodium bicrbonate (2 x 20 ml)
and dried over magnesium sulfate. Tic indicated that a product had been made and
nmr was consistent with phenylthiomethylidenecyclohexane.
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6.4 ATTEMPTED SYNTHESIS OF FURAN (76) VIA AN
INTRAMOLECULAR GRIGNARD - METHOD ONE
4-CARBOMETHOXY -3-FUROIC ACID (lOS)
o 0
H3CO~OCH3
o
98
o 0
HOWO~H3
5 0 2
1
105
ATTEMPT 1: USING LITHIUM HYDROXIDE
A stirring solution of dimethyl 3,4-furan dicarboxylate (200 mg: 1.08 mrnol) in
methanol (9 ml) and water (3 ml) was cooled to DoCand lithium hydroxide (228 rng:
5.4 mmol) slowly added. The resulting solution was stirred for 24 h. Water (10 rnl)
was then added and the solution brought to pH 5 with IM HC!. The solution was
extracted with ethyl acetate (3 x 10 ml) but tic of this extract indicated the presence of
starting material only.
ATTEMPT 2: USING CYCLIC ANHYDRIDE WITH ACID CATALYST
Dimethyl 3,4-furan dicarboxylate 98 (115 mg: 0.62 mmol) was dissolved in THF
(10 ml) and a catalytic amount of cone. sulfuric acid added. The resulting solution
was then refluxed for 4 h. Tic indicated starting material only.
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ATTEMPT 3 USING IN SITU SIL YL ESTER FORMATION
To a flame dried flask, flushed with nitrogen, was charged dimethyl 3,4-furan
dicarboxylate 98 (500 mg: 2.7 mmol), acetonitrile (10 ml) and sodium iodide
(1.22 g: 8.14 mmol). To this stirring solution was added dropwise a solution of
trimethylsilylchloride (1.027 ml: 0.88 g: 8.09 mmol) in acetonitrile (25 ml) and the
resulting solution refluxed for 4 h. The solution was cooled and water (50 ml) added
to hydrolyse the silyl ester. The solution was extracted with diethyl ether (3 x 20 ml).
The organic extracts were combined and washed with sodium thiosulfate and sodium
bicarbonate (3 x 20 ml). The sodium bicarbonate washings were cooled to OT and
acidified with 1M HCI. The resulting aqueous solution was then extracted with ethyl
acetate (3 x 20 ml) and the combined organic extracts washed with brine (3 x 20 ml).
The solvent was removed in vacuo and purification via column chromatogaphy,
eluting with light petroleum! ethyl acetate (1: 1) afforded 3-carbomethoxy-4-furoic acid
105 (218 mg: 1.28 mmol: 47%) OH (200 MHz: COCl]): 3.93 (3H, s, H-7), 8.07
(IH, d,h.s 1.78 Hz, H-2), 8.17 (tH, d, JS.2 1.77 Hz H-5) Oc (50 MHz): 53.57 (C-
7),114.99 (C-4), 116.66 (C-3), 150.72 (C-5), 152.54 (C-2), 161.14 (C-6) and
167.09 (C-8); m/z: 170 (M+, 15.5), 139 (95.5) and III (3.5%) (Found M+,
170.0205, C7H60S requires 170.0.215).
ATTEMPTED SELECTIVE REDUCTION OF ACID GROUP IN
PRESENCE OF ESTER
x •
o
HO~OCH3
o
METHOD 1: USING BORANE REDUCTION
To a flame dried flask flushed with nitrogen was added THF ( 10 ml) followed by the
acid 105 (272 mg: 1.6 mmol) and the flask was cooled to -20°C. Borane-THF
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adduct (1.6 ml: 1.0 M solution in THF: 1.6 mmol) was slowly added and the
solution allowed to warm slowly to room temperature. The resulting solution was
stirred overnight but tic indicated the presence of starting material only.
METHOD 2: USING REDUCTION OF IN SITU ACID CHLORIDE
(IN THF)
Preparation of Acid Chloride: To a flask containing THF (20 ml) was added the acid
105 (147 mg: 0.86 mmol) followed by thionyl chloride (1.88 ml: 3.0 g:
2.58 mmol) and the solution refluxed for 4 h.
Preparation of zinc modified sodium cyanoborohydride solution: A flame dried flask
held in a nitrogen atmosphere was charged with sodium cyanoborohydride ( 108 mg:
1.7 mmol), zinc chloride (118 mg: 0.86 mmol) and THF (20 rnl). The resulting
mixture was stirred at room temperature for 3 h.
The THF solution of the zinc modified sodium cyanoborohydride, which contains
most of the reducing power was syringed out of the flask and slowly added to the acid
chloride. The solution was then stirred for 48 h at room temperature. Methanol
(5 ml) was then added followed by potassium iodate (20 ml: 0.1 M). Tic of the
solution indicated that only starting material was present.
METHOD 3:USING REDUCTION OF IN SITU ACID CHLORIDE
(IN DIETHYL ETHER)
Preparation of Acid Chloride: To a flask containing the acid 105 (150 mg: 0.8 mmol)
was charged diethyl ether (to ml) followed by thionyl chloride (0.12 ml: 1.99 mg:
1.68 mmol) and the resulting solution stirred for I h then brought to reflux for 3 h.
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Preparation of zinc modified sodium cyanoborohydride: A flame dried flask held in a
nitrogen atmosphere was charged with sodium cyanoborohydride (92 mg: 1.46
mrnol), zinc chloride (200 mg: 1.5 mmol) and diethyl ether (20 rnl). Thr resulting
slurry was stirred for I h.
The acid chloride was then syringed into the flask containing the zinc modified
sodium cyanoborohydride and the resulting solution stirred for 24 h. Methanol (5 ml)
was then added followed by potassium iodate (20 ml: 0.1 M). Tic of the resulting
solution indicated that only starting material was present.
6.5 ATTEMPTED SYNTHESIS OF FURAN (76) VIA AN
INTRAMOLECULAR GRIGNARD - METHOD TWO
METHYL 4-(2-PROPENOYL)-3-FUROATE
o 0
CH30~OCH3
o THF
~MgBr
•
98
To a solution of dimethyl 3,4-furan dicarboxylate 98 (5 g: 27.15 mmol) in THF
(30 ml) was added vinylmagnesium bromide (30 ml: 1.0 M solution in THF:
35 mmol) dropwise. The resulting solution was stirred at room temperature for 12 h
before being quenched with water and the solution extracted with ethyl acetate (3 x
25 ml). The organic extracts were combined, washed with sodium bicarbonate (3 x
25 ml), brine (3 x 25 ml) and dried over magnesium sulfate. The solvent was
removed under reduced pressure to leave the crude product as an oil. Purification via
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column chromatography eluting with light petroleum/ethyl acetate (5: I ) afforded
methyl-4(2-propenoyl)-3-furoate 108 as a yellow oil (1.8 g: 10 mmol: 37%)
8H(200 MHz; CDCI3) 3.85 (3H, s, H- 7), 5.16 (I H, dd,J lOa,1Oh 1.18 Hz, J lOa,9
10.43,Hz H-lOa), 5.24 (tH, m, H-IOb), 6.06 (tH, dd,J9,IOa 11.70 Hz, J9,IOh 16.08
Hz, H-9), 7.27 (tH, d,h,s 1.7 Hz H-2 ),8.03 (IH, d,JS,2 1.72 Hz H-5); 8c(50
MHz) 52.29 (C-7), 114.78 (C-IO), 117.16 (C-4), 116.2 (C-3), 129.36 (C-9),
141.61 (C-2), 150.62 (C-5), 165.52 (C-6) and 178.1 (C-8). m/z: 180 (M+, 100),
153 (M+-C2H3, 32) and 121 (M+-COOMe, 44%) (Found M+, 180.1614; C9H~04
requires M, 180.1617).
ATTEMPTED HYDROBROMINA TION OF METHYL 4-(2-
PROPENOYL)-3-FUROATE
o 0MOCHa x.
o Br
108 109
METHOD 1: USING HYDROBORATION WITH BORANE
A solution of the alkene 108 (179 mg: 0.99 mmol) in THF (5 ml) was added to a
dry flask held in a nitrogen atmosphere followed by THF (15 ml). The flask was
cooled to O°C and BH3.THF (3.0 ml: 1.0 M solution in THF; 3.0 mmol) was added
dropwise. The resulting solution was stirred for I h and the temperature was
maintained at O°C. Light was then excluded from the reaction by wrapping the
reaction vessel in aluminium foil and a solution of Br2 (0.15 ml ; 467 mg:
0.46 mmol) in THF (2 ml) was added. The resulting solution was stirred at room
temperature for 2 h before being quenched with water and the solution extracted with
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ethyl acetate (2 x 20 ml). TIc of the extract indicated that only starting material was
present.
METHOD 2: USING HYDROBORATION WITH DICYCLOHEXYL-
BORANE AND EXCLUSION OF LIGHT
To a dry flask at O°C in a nitrogen atmosphere was added cyclohexene (0.3 ml:
243 mg: 2.8 mmol), THF (5 ml), borane- THF adduct (1.44 ml: 1.0 M solution in
THF; 1.44 mmol) and the solution stirred for 1.5 h. A solution of the alkene 108
(200 mg: 1.11 mmol) in THF (5 ml) was added and the resulting solution stirred for
2 h. The flask was shielded from light and water (10 ml) followed by bromine
(0.1 ml: 311 mg: 1.95 mmol) was added and the resulting solution was stirred at
O°C for 1 h before being quenched with water and the solution extracted with ethyl
acetate (2 x 20 ml). Tic of the extract indicated that no product had been formed and
the starting material remained.
METHOD 3: USING HYDROBORATION WITH DICYCLOHEXYL-
BORANE
To a dry flask flushed with nitrogen and and cooled to O°C was added cyclohexene
(0.3 mmol: 243 mg: 2.8 ml), THF (5 ml) and borane-THF (1.44 ml: 1.0 M
solution in THF: 1.44mmol). The resulting solution was then stirred for 1 h. The
alkene 108 (200mg: 1.11 mmol) was then slowly added and the resulting solution
was stirred for 0.75 h. Without sheilding from light and without quenching the
borane a solution of bromine (0.1 ml: 312 mg: 1.95 mrnol) in THF (2 ml) was
slowly added followed by a solution of sodium methoxide in methanol. The resulting
solution was alowed to stir for 12 h at room temperature. Tic indicated that no
product had been formed.
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METHOD 4: USING IN SITU FORMATION OF BrCI
To a dry flask flushed with nitrogen and cooled to Qoe was charged the alkene t 08
(200mg; 1.11 mmol), THF (to ml), borane.THF adduct (1.66 ml: 1.0M solution in
THF; 1.66 mmol) and the reaction stirred for 2h. Sodium bromide (171 mg: 1.66
mmol) in water (to ml) was added and the reaction cooled to Doe and sheilded from
light. Chloramine-T (758 mg: 3.7 mmol) was dissolved in a mixture of THF (7.5 ml)
and water 0.5 ml) and then added to the solution. The mixture was then treated with
a 10% Hel solution saturated with sodium chloride (10 ml) and the resulting solution
was stirred for 15 minutes. The resulting solution was quenched with ammonium
chloride. Tic indicated the presence of only starting material.
METHOD 5:USING HYDROALUMINATION WITH LITHIUM
ALUMINIUM HYDRIDE
To a dry flask flushed with nitrogen was added the alkene 108 (200 mg:
1.11 mmol), THF (10 rnl), lithium aluminium hydride (0.3 ml: 1.0 M solution in
THF; 0.3 mmol), and a catalytic amount of titanium tetrachloride and the resulting
solution stirred for 3 h. The solution was cooled to -78T and copper (II) bromide
(0.59 g: 2.6 mmol) added before stirring the solution overnight and allowing to
warm gradually to room temperature. The reaction was quenched with water and the
solution was extracted with diethyl ether. Hydrochloric acid (1M) was added in order
to solubilise the green precipitate which had formed. The combined extracts were
then washed with sodium bicarbonate and brine and dried over magnesium sulfate.
The solvent was reduced in vacuo. TIc indicated a mixture of products which could
not be separated.
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6.6 ATTEMPTED SYNTHESIS OF FURAN (76) VIA AN
INTRAMOLECULAR GRIGNARD - METHOD THREE
GRIGNARD ATTACK USING ETHYNYLMAGNESIUM BROMIDE
o 0
H3CO~OCH3
o
o== MgBr
98
1
110
To a flame dried flask held in a nitrogen atmosphere was added the dimethyl 3,4-furan
dicarboxylate 98 (200 mg: 1 mmol) followed by CH2CI2 and the solution cooled to
O°C. Ethynylmagnesium bromide (2.6 ml: 1.5 M solution in THF: 1.73 mmol) was
added to the stirring solution before stirring for for 6 h. The solution was diluted with
water (50 ml) and then extracted with diethyl ether (3 x 25 ml). The combined
organic extracts were washed with sodium bicarbonate (3 x 20 ml), brine (3 x
20 ml), dried over magnesium sulfate and the organics removed in vacuo.
Purification via column chromatography eluting with light petroleum/ ethyl acetate
(5: I) afforded a mixture of starting material 98 and product 110, which could not be
separated further by this method. OH (CDCI3: 90 MHz): 1.7 (IH, s, H-IO), 3.5 (3H,
s, H-7), 7.4 (1H, s, H-2) and 7.6 (1H, s, H-5)
ATTEMPTED BROMINATIONS
OCH3 x Br
150
METHOD 1: USING HYPOBROMITE SOLUTION
Sodium hydroxide (5 g) was dissolved in ice (20 g), and to the resulting slurry
bromine (3.2 ml: 9.98 g: 62 mmol) was added. The alkyne 11 0 (150 mg:
0.78 mmol)was added to the hypobromite solution formed and the mixture stirred
overnight. A saturated solution of ammonium chloride (20 ml) was then added and
the solution extracted with diethyl ether (2 x 15 ml). The combined organic extracts
were washed with water (2 x 10 ml) and dried over magnesium sulfate. TIc of the
resulting organics indicated that no product had been formed. Starting material was
reclaimed.
METHOD 2 : USING n-BUTYL LITHIUM I BROMINE
A solution of the alkyne 110 (161 mg: 0.9 mmol) in THF (10 ml) was cooled to
-78°C and shielded from light. n-Butyl lithium (0.85 ml: 1.6 M solution in THF;
1.3 mmol) was slowly added and the reaction vessel temperature raised to -20"C. A
solution of bromine (0.1 ml: 312 mg: 1.95 mmol) in THF (5 ml) was added. The
solution was then warmed to room temperature and stirred for 24 h before quenching
with a saturated solution of ammonium chloride (J 0 ml). Tic indicated a complex
mixture of unisolable products.
METHOD 3: USING n-BUTYL LITHIUM I N-BROMOSUCCINIMIDE
A solution of the alkyne 110 (134 mg: 0.7 mmol) in THF (10 ml) was cooled to
-70°C and n-butyl lithium (0.8 ml: 1.6 M solution in THF; 1.3 mmol) added. N-
bromosuccinimide (224 mg: 1.26 mmol) was added and the resulting solution stirred
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at ODC for 1 h. TIc indicated no product so the reaction was warmed to room
temperature and stirred overnight. Tic indicated no reaction.
6.7 ATTEMPTED SYNTHESIS TO FURAN (112)
METHYL 4,5,6,7- TETRAHYDRO-4-0XO-BENZO[b ]FURAN -3-
CARBOXYLATE
MeOH
OH
A solution of 4,5,6,7-tetrahydro-4-oxo-benzo[b ]furan-3-carboxylic acid (190 mg:
] .05 rnrnol) in methanol (15 ml) and a catalytic amount of sulfuric acid was refluxed
for] 2 h. The mixture was then cooled, water was added and the solution was
extracted with ethyl acetate (3 x 20 ml), washed with sodium bicarbonate (3 x
20 ml), brine (3 x 20 ml), dried over magnesium sulfate and the solvent removed
under reduced pressure. Purification using column chromatography afforded 113 as
a yellow powder (89.3 mg: 0.46 mmol: 47%) m.p. 103°C: BH(200 MHz: COCI3):
2.11 (2H, m, H-7), 2.48 (2H, m, H-6), 2.84 (2H, m, H-8), 3.78 (3H, s, H-ll) and
7.81 (1H, s, H-2); Be (50 MHz ): 22.06 (C-7), 23.5 (C-6), 38.59 (C-8), 51.92 (C-
] 1), 1]5.96 (C-4), 117.61 (C-3), 147.95 (C-2), 161.30 (C-IO), 168.42 (C-5) and
192.04 (C-9). m/t: M+, 194 (37.3), 166 (100) and 108 (42.8%) (Found M+,
]94.0586; C 61.72 and H 5. ]4%, CIOH 1004 requires M, 194.0579: C 61.85 and
5.15%)
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GRIGNARD ATTACK ON ESTER 113
o Ha
11
MgBr Hb..
THF
12
OMe
13
OMe
113 6 1
114
To a solution of ester 113 (1.93 g: 9.99 mmol) in THF 20 ml in a flame dried flask
held in a nitrogen atmosphere and cooled to O'Cwas added vinylmagnesium bromide
(11.5 ml: 1.0 M in THF: 11.5 mmol) and the resulting solution stirred for 12 h. The
reaction was then quenched with a saturated solution of ammonium chloride and the
solution extracted with ethyl acetate (3 x 25 ml). The combined extracts were washed
with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml), dried over magnesium
sulfate and the solvent removed in vacuo to give the crude product as the residual oil.
Purification using column chromatography eluting light petroleum; ethyl acetate (4: I)
afforded the desired compound 114 as a yellow powder; 1.23 g (5.54 mmol: 55%)
m.p. 66T IR Vmax (nujol mull): 3128 and 1714 cnr+, DH (200 MHz; CDCI}): 1.6-
1.9 (6H, m, H-6,7 and 8), 3.83 (3H, s, H-13), 4.7 (IH, dd,Jllb,lla 1.22 Hz
,Jllb,IO 17.23 Hz, H-Ilb), 5.07 (lH, dd,Jlla,llb 1.22 Hz, Jlla,lO 10.45 Hz, H-
Ila), 6.08 (lH, dd,JIO,llb 10.44 Hz, JIQ,lla 17.26 Hz, H-IO) and 7.87 (IH, s, H-
ID); se (50 MHz): 19.59 (C-7), 22.77 (C-6), 36.07 (C-8), 52.03 (C-I3), 71.93 (C-
9), 113.99 (C-ll), 117.19 (C-4), 120.66 (C-3), 143.92 (C-IO), 147.54 (C-2),
153.91 (C-5) and 165.49 (C-12). m/z: 222 (M+, 18.9), 191 (M+-OMe, 6.9) and
163.9(M+-COOMe, 100%) (Found M, 222.0893, C12H1404 requires 222.0892)
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6.6 ATTEMPTED DEHYDRATION OF TERTIARY ALCOHOL (114)
OMe x • OMe
114 121
METHOD 1: USING SOCh / PYRIDINE
To a flame dried flask held in a nitrogen atmosphere were charged the alcohol 114
(100 mg: 0.45 mmol), pyridine (l ml) and thionyl chloride (2 ml). The resulting
solution was stirred for 1 h before being poured into an ice-water mixture.(20 g) The
solution was then extracted with ethyl acetate (2 x 15 ml). Tlc indicated that only
baseline material was present and the reaction was abandoned.
METHOD 2: USING p-TsOH / BENZENE
A catalytic amount of para-toluenesulfonic acid was added to a solution of the alcohol
114 (100 mg: 0.45 mmol) in benzene (25 ml) and the resulting solution was
refluxed under Dean and Stark conditions. The solution turned black and tic indicated
that mainly baseline material was present. The reaction was abandoned.
METHOD 3: USING BF3.0Et2
To a solution of the alcohol 114 (100 mg: 0.45 mmol) in CH2CI2 (20 ml) was
added slowly dropwise BF~.OEt2 (0.06 ml: 71.4 mg: 0.50 mmol), The solution
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turned a deep purple colour and tIc indicated that all the starting material had been
converted to baseline. The reaction was abandoned.
METHOD 4: USING CUS04 SUPPORTED CATALYST
The catalyst was first prepared by adding silica (1 g) to a solution of copper sulfate
(390 mg: 2.45 mmol) in water (10 ml). The water was removed under reduced
pressure and the resulting powder was heated at I50aC for 2 h. The catalyst (0.56 g)
was then added to a solution of the aIcohol114 (lOOmg: 0.45 mmol) in cycJohexane
(l 0 ml) and stirred for 1 h. TIc indicated that there were several unisolable products
present.
METHOD 5: USING KHS04
To a flame dried flask held in a nitrogen atmosphere was added the alcohol 114
(100 mg: 0.45 mmol), THF (10 ml) and a catalytic amount of KHS04. The
resulting solution was allowed to reflux for 3 h. Tic indicated that there was a less
polar product and this was attempted to be isolated by column chromatoraphy eluting
with light petroleum: ethyl acetate but decomposition occurred and product was never
recovered.
6.8 ALTERNATIVE SYNTHESIS TO TARGET FURAN (112) VIA
PROTECTED KETOFURAN (125)
xOH
METHOD 1: USING ETHYLENE GLYCOL AND TMSCI
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Ethylene glycol (4 ml: 4.45 g: 72 mrnol), methanol (10 ml), ketone (120 mg:
0.61 mmol) and trimethylsilyl chloride (153 mg: 0.18 ml: 1.4 mmol) were stirred at
room temperature for 50 hours. The reaction was monitored by tic but after this time
only starting material was present.
METHOD 2: USING ETHYLENE GLYCOL AND TMSCI
(CONCENTRATED)
A solution of ketone (120 mg: 0.6 mmol), ethylene glycol (10m)) and trimethylsilyl
chloride (0.334ml: 285 mg: 2.64 mmol) was stirred at room temperature for 24 h.
Tic revealed that no product had been formed.
METHOD 3:USING ETHYLENE GLYCOL AND TRIETHYL-
ORTHOFORMA TE
Ethylene glycol (5 ml: 5.56 g: 89 mmol), triethyl orthoformate (0.1 ml), ketone
(120 mg: 0.61 mmol) and a catalytic amount of p-TsOH was stirred for 24 h. TIc
analysis indicated that no product had been formed.
METHOD 4: USING ETHYLENE GLYCOL AND OXALIC ACID
A solution of ethylene glycol (5 ml), oxalic acid (lOOmg: 0.7 mmol) and ketone
(120 mg: 0.61 mmol) in CH3CN (I5ml) was allowed to stand at room temperature
for I h before cold water (10 ml) was poured onto the mixture. The organics were
extracted with diethyl ether. Tic analysis of this revealed that no product had been
formed.
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6.9 SYNTHESIS OF 3,5 DISUBSTITUTED FURANS VIA FRIEDEL-
CRAFTS ACYLATION
ESTERIFICATION OF FUROIC ACID
METHYL 3-FUROA TE (130)
orJ'OH
o
127
TMSCI.. onf06H,
5 0 2
1
130
MeOH
RT24 h
Chlorotrimethylsilane (4.97 ml: 4.25 g: 39.16 mmol) was added dropwise to a
stirred solution of 3-furoic acid (2 g: 17.8 mmol) in dry methanol (20 ml) in a
nitrogen atmosphere. The resulting solution was stirred at room temperature for 24 h.
Water (25 ml) was added and the solution extracted with ethyl acetate (3 x 35 ml).
The combined extracts were then washed with sodium bicarbonate (3 x 30 ml), brine
(3 x 25 ml), dried over magnesium sulfate and the solvent removed in vacuo to give
the crude product. Purification via column chromatography eluting with light
petroleum/ethyl acetate (4: 1) afforded methyl 3-furoate 130 as a colourless oil (1.3 g:
10 mmol: 57%). IR vrnax(CHCl3 soln) 1728,3024 and 3156 cm+: OH(200MHz:
CDCI3) 3.79 (3H, s, H-7) 6.74 (IH, dd, J4,2 0.68 Hz, J4,5 1.88 Hz, H-4), 7.43
(lH, dd, J5.4 1.72 and J5.2 1.52 Hz, H-5) and 8.02 (IH, dd, h.4 0.73 Hz, h.5
1.48Hz, H-2);OcC50 MHz) 51.2 (C-7), 109.5 (C-4), 119.0 (C-3), 143.5 (C-5),
147.5 (C-2) and 161.3 (C-6r; m/: 126 (M+, 45.7) and 95 (M+-OMeIOO%) (Found
M 126.0317: C6H603 requires 126.0316)
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ISOPROPYL 3·FUROATE (131)
orS'0H
o127
4--JO,(
~ - ~~~-
5 0 2
1
131
P~OH
RT 18 h
To a stirred solution of 3-furoic acid 127 (10 g, 89 mmol) in isopropanol (75 ml)
was added dropwise a catalytic amount of concentrated sulfuric acid. The resulting
mixture was then stirred at room temperature for 18 h. Water (100 ml) was added
and the solution extracted with ethyl acetate (3 x 25 ml). The organic layers were
combined, washed with sodium bicarbonate (3 x 25 ml), brine (3 x 25 ml) and dried
over magnesium sulfate. The solvent was then removed under reduced pressure and
the residual oil purified by column chromatography with light petroleum: ethyl acetate
(4:1) as the eluent to yield isopropyl 3-furoate 131 (S.25 g: 53 mmol: 60%), IR
vrnax(film) 1722 cm! ). OH(200MHz; film) 1.20 (6H, d, 18.7 6.27, H-8) ), 5.07
(IH, septet, Jt» 6.6 Hz, H-7), 6.62 (lH, dd, 14,5 1.87 Hz, J4,20.72 Hz, H-4), 7.30
(lH, dd, 15,4 1.72 Hz 15,2 1.44 Hz, H-5), 7.89 (lH, dd, 12,4 0.7 Hz, 12,5 1.48 Hz,
H-2); 8c(50 MHz; CDCI3) 21.64 (C-8), 67.57 (C-7), 109.66 (C-4) 119.84 (C-3),
143.41 (C-5), 147.31 (C-2), 162.40 (C-6); m/z: 154 (M+· 10.1), 112 (33.2) and 95
(100.0%) (Found M+, 154.0624 CgH 1003 requires M 154.0629).
PHENYL 3·FUROA TE (132)
or{OH
o
127
DIG
9
J;(f
4~ . ~3,,- 0
502
1
132
PhOH
RT 12 h
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To a stirring solution of furoic acid 127 (1 g: 8.9 mmol) and phenol (1.25 g:
13.35 mmol) held in a nitrogen atmosphere was added diisopropylcarbodiimide
(2.09 ml: 1.68 g: 13.3 mmol) dropwise. The resulting solution was stirred at room
temperature for 12 h before being quenched with water (50 ml) and the solution
extracted with ethyl acetate (3 x 25 mI). The combined organic extracts were washed
with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml) and dried over magnesium
sulfate. The solvent was removed under reduced pressure to give the crude product
as a residual oil. Purification by column chromatography eluting with light
petroleum/ethyl acetate (10: 1) afforded phenyl 3-furoate 132 as white crystals ( 1.13
g: 6.01 mmol: 68%) m.p. 36-38°C IR Vmax (CHCh solution): 1739,3013,3029
and 3154 cmI. ()H (200 MHz): 6.88 (1H, d, 14,5 1.21 Hz, H-4), 6.97 - 7.50 (6H,
m, H-5,8,9 and 10) and 8.20 (1H, d, h,4 0.63 Hz, H-2); Be (50 MHz): 110.03 (C-
4),118.84 (C-3), 121.67 CC-8), 125.90 (C-IO), 129.46 (C-9), 144.04 (C-5), 148.65
(C-2), 150.41 (C-7) and 161.38 (C-6). m/z: 188 (M+, 21.6) and 95 (M+-OPh,
100%) (Found M+, 188.0474 CIIHg03 requires 188.0473).
GENERAL PROCEDURE FOR FRIEDEL·CRAFTS REACTIONS
A solution of the appropriate ester and either acetic anhydride or the appropriate acid
chloride (2 ml) was heated to the desired temperature before BF3.0Et2 was added
dropwise. The reaction was monitored by tic and quenched with water when
complete. The solution was extracted with ethyl acetate (3 x 25 ml) and the combined
organic extracts washed with sodium bicarbonate, brine and dried over magnesium
sulfate. The solvent was reduced in vacuo to leave the crude product as a black
residual oil. Purification procedures are described followed by the data for each
compound.
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METHYL 5·ACETYL·3·FUROATE (133)
o
u:5'OCH3
o
130
The general procedure was followed using methyl 3-furoate (200 mg; 1.58 mmol),
acetic anhydride (2 ml), and BF3.0Et2 (0.48 ml: 0.57 g: 4.08 mmol). The
temperature of the reaction was 50°C and the time taken for completion was 5
minutes. Purification by column chromatography eluting with light petroluml ethyl
acetate (4:1) afforded methyI5-acetyl-3-furoate 133 (122 mg: 5.8 mmol: 46%) IR
vrnax(KBr disc); 1721 and 1673.9 crrr l;OH(200 MHz: CDCI3) 2.50 ( 3H, s, H-9),
3.90 (3H, s, H-7), 7.46 OH, d, J4,2 0.63 Hz, H-4) and 8.13 (IH, d, 12,40.64 Hz,
H-2); Oc(50MHz); 26.101 (C-9), 52.032 (C-7), 114.41 (C-4), 116.305 (C-3),
150.197 (C-2), 153.214 (C-5), 162.397 (C-6) and 186.52 (C-8). m/z168 (M+,
48.0), 153 (lOO), 121 (25.3) and 95 (29.8%); (Found M+ 168.0414; C 57.29 H
4.72%; C8H804 requires M+, 168.0421 C 57.14, H 4.76%)
ISOPROPYL 5-ACETYL-3-FUROA TE (134)
The general procedure was followed using isopropyl 3-furoate 131 (260 mg:
1.68 mmol), acetic anhydride and BF3.0Et2 (0.2 m): 238 rng: 1.7 rnmol), The
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temperature was 50°C and the time for completion was 5 minutes. Purification by
column chromatography eluting with light petroleum/ethyl acetate (5: I) afforded
isopropyl 5-acetyl-3-furoate 134 as a yellow solid; 105 mg (0.535 mmol: 32%); IR
Vmax (CHCI3 solution); 3147, 3030, 3011, 1719.4 and 1683.2 crrr+; bH(200 MHz:
CDCI3):1.34 (6H, d, J8,7 6.24 Hz, H-8), 2.5 (3H, s, H-l0), 5.17 (IH, septet, 17.8
6.25 Hz, H-7), 7.46 (lH, d, J4,2 0.62 Hz, H-4) and 8.1 (IH, d, Jz:« 0.62 Hz, H-2)
Be (50 MHz): 21.87 (C-8), 36.96 (C-lO), 68.72 (C-7), 116.56 (C-4), 128.94 (C-3),
150.09 (C-2), 153.2 (C-5) 152.9 (C-6) 186.5 (C-9). m/z: 196 (M+, 25.5), 180
(23.5),153 (37.3), 139 (100) and 124 (29.8%); (Found M+, 196.0723: CIOH 1204
requires 196.0735.
PHENYL 5·ACETYL·3·FUROATE (135)
132
9
o :0'7 10
~I07
12lr'o1
o 135
The general procedure was followed using phenyl 3-furoate 132 (320 mg:
1.7 mmol), acetic anhydride (3 ml) and BF3.0Et2 (0.4 ml: 0.476 g: 3.4 mmol).
The temperature was 50°C and the time taken for completion was 5 minutes.
Purification via column chromatography eluting with light petroleum/ ethyl acetate
(5: I) afforded phenyl 5-acetyl-3-furoate 135 as a yellow solid (255 mg: 1.1 mrnol:
65%); IR vrnax(KBr disc): 1678, 1738, 3067 and 3134 crrr l. BH (200 MHz;
CDC)3): 2.53 (3H, s, H-12), 7.16-7.54 ( 5H, m, H-8,9 and 10),7.58 (IH, d. 14.2
0.68 Hz, H-4) and 8.29 OH, d, 12,4 0.70 Hz, H-2) Be (50 MHz): 26.11 (C-12),
116.34 (C-4), 121.43 (C-8), 126.19 (C-IO), 129.54 (C-9), 150.89 (C-2), 151.32
161
(C-7)153.2(C-7),160.1 (C-6) and 190.8 (C-II) m/z: 230 (M+, 24.7) and 137 (100%)
(Found 230.0577 CI3HI004 requires 230.0579)
METHYL 5·ISOBUTYRYL·3·FUROATE (136)
or?OCH,
o
130
o
10 o! 74 3 6 OCH3
~ ~ 2
'0
o 1
136
The general procedure was followed using methyl 3-furoate 130 (300 mg:
2.38 mmol), isobutyryl chloride (3 ml), BF3.0Et2 (0.5 ml: 0.595 g: 4.25 mmol).
The temperature for the reaction was 50°C and the solution was stirred for 0.5 h.
Purification via column chromatography eluting with light petroleum/ ethyl acetate
(10: I) afforded methyl 5-isobutyryl-3-furoate 136 (98 mg: 0.5 mmol: 21%); m.p.
48-50°C IRvrnax (CH2CI2 solution): 1682,1729,3062 and 3144 cm". bH
(200MHz; CDCI3): 1.14 (6H, d, JIO,9 6.86 Hz, H- 10),3.26 (1H, septet, J9.IO 6.94
Hz, H-9), 3.78 (IH, s, H-7), 7.39 (IH, d, J4,2 0.59 Hz, H-4), 8.06 (IH, d, hA
0.59 Hz, H-2) be (50 MHz): 18.71 (C-IO), 36.25 (C-9), 51.77 (C-7), 109.01 (C-
3), 115.98 (C-4), 149.96(C-2), I52.36(C-5), 162.25(C-6) 190.42 (C-8) m/z: 196
(M+, 21.6), 165 (M+-OCH3, 9.7), 153 (M+-C3H7. 100%) (Found 196.0714
Cl oH 1204 requires 196.0735).
162
ISOPROPYL 5·ISOBUTYRYL·3·FUROATE (137)
o~rfO
o
131
The general procedure was followed using isopropyl 3-furoate 131 (300 mg:
1.9 mrnol), isobutyryl chloride and BF3.0Et2 (0.46 ml: 0.54 g: 3.89 mmol). The
temperature was 90°C and the time for completion was Ih. Purification by column
chromatography eluting with light petroleum/ethyl acetate (5: I) afforded isopropyl 5-
isobutyryl-3-furoate 137 as a yellow solid (277 mg: 1.32 mmol: 63%); IR Vmux
(CH2CI2 soln); 1682,1706 and 3062 em-I; 8H (200 MHz; CDCI3 ); 1.19 (6H, d.
110,117.02 Hz, H-IO), 1.34 (6H, d, 111,10 6.24 Hz, H-II), 3.32 (IH, septet,
17,8.6.3 Hz, H-7), 5.16 (6H, septet, ig,7 6.26 Hz, H-8), 7.49 (IH, d. i4.2 0.7 Hz,
H-4) and 8.13 OH, d, h,4 0.66 Hz, H-2); 8c(50MHz); 18.61 (C-II), 21.71 (C-8),
36.29 (C-IO), 68.62 (C-7), 116.30(C-4),120.2 (C-3) 149.98(C-5), 152.7 (C-2),
161.59 (C-6), and 193.41 (C-9); m/: 224 (M+, 9.7),181 (27.6) and 139 (37.1%);
(Found M+, 209.0834 : CIIHI604 requires 209.0813)
PHENYL 5·ISOPROPYL·3·FUROATE (138)
9
o :0'9' 10
13 o! ~I3 6 0 7liFZo~2
1
o 138
163
The general procedure was followed using phenyl 3-furoate 132 (90 mg:
0.46 mmol), isobutyryl chloride and BF3.0Et2 (0.1 ml: 119 mg: 0.85 mmol). The
temperature was 60°C and the time taken for completion was 1.5 h. Purification via
column chromatography eluting with light petroleum/ ethy I acetate ( 10: I ) afforded
phenyl 5-isopropyl 3-furoate 138 as a yellow oil (64 mg: 0.248 mmol: 52%;); m.p.
94°C; IR vmax(CH2Cl2 solution): 1705, 1744,2979 and 3063 crrr l:DH(200 MHz;
CDCI3): 1.22 (6H, d, JI3.12 6.83 Hz. H-13), 2.64 ('H, septet, JI2.U 6.88 Hz, H-
12), 7.07-7.21 (6H, m, H-8, 9 and 10), 7.53 (' H, s, H-4) and S.2' (' H, d, Jz.«
0.39 Hz, H-2); Be (50 MHz): 18.662 (C-J3), 33.755 (C-12), 116.22 (C-4), 120.60
(C-3), 121.44 (C-S), 126.15 (C-I 0), 129.50 (C-9), '50.09 (C-2), 152 (C-5), 160.32
(C-6) and 183.63 (C-II); m/z: 258 (M+, 14.0), 165 (M+-OPh, 100) and 137 (M+-
COOPh, 1.3%): Found 258.0877 CISHI404 requires 258.0892.
METHYL 5·CYCLOHEXYLCARBONYL·3·FUROATE (139)
od'0CH3
o
o
Cl 0
11 7
• ~ ~ 3
BF30Et2 9" 2oo 1
The general procedure was followed USIng methyl 3-furoate 130 (350 mg:
2.77 mmol), cyclohexylcarbonyl chloride (3 ml) and BF3.0Et2 (0.66 ml: 0.785 g:
5.61 mmol). The temperature for the reaction was 100°C and the time taken for
completion was I h. Purification via column chromatography eluting with light
petroleum/ ethyl acetate (10: I) afforded methyl 5-cyc1ohexylcarbonyl-3-furoatc 139
(387 mg: 1.64 mmol: 60%) IR Vmax (CHCI3 solution) 3145, 3027, 3013, 1702 and
1728 crrr '. BH(200 MHz: CDCI3) 1.51 (IIH, m, H-9,10,11 and 12),3.71 (3H, s,
H-7), 7.32 (1H, s, H-4) and 7.99 (I H, s, H-2); Be (50 MHz); 24.62 (C-12), 25.55
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(C-II), 28.56 (C-IO), 46.22 (C-9), 51.72 (C-7), 115.86 (C-4), 120.79 (C-3),
149.95 (C-2), 152.49 (C-5), 162.26 (C-8) and 182.1 (C-6). mil 236 (M+, 24.6),
206(1.7), 181(50.9) and 168 (96.4%); (Found M+ 236.1042; C13H1604 requires
M+, 236.1047).
ISOPROPYL 5-CYCLOHEXYL-3-FUROA TE (140)
o~d'o
o 131
o
~CI 12 0 .l,
-B-F3-.0-E-t2 .....~13(J11 9 ~o
~O o 1
140
The general procedure was followed using isopropyl 3-furoate 131 (200 mg:
1.58 mmol), cyclohexylcarbonyl chloride (3 ml) and BF3.0Et2 (0.28 ml: 333 mg:
2.25 mmol). The temperature was 90°C and the time for completion was 2 h.
Purification via column chromatography eluting with light Petroleum/ ethyl acetate
(10: I) afforded isopropyl 5-cyclohexyl-3-furoate 140 (134 mg: 0.5 mmol: 32%) ;
IR Vmax (CHCI3 soln.): 3146,2984, 1720 and 1678 cm+: 8H (200 MHz; CDCI3):
1.14-1.97 (l3H, m, H-8,1O,11,12 and 13 ), 5.16 (IH, septet, 17,'1. 5.77 Hz, H-7),
7.38 OH, s, H-4) and 8.03 (lH, s, H-2). OC (50 MHz): 20.67 (C-8), 21.79 (C-B),
25.57 (C-l3), 25.65 (C-12) (C-28.8 (C-II), 46.39 (C-IO), 68.57 (C-7), 116.17 (C-
4), 121.70 (C-3), 149.87 (C-2), 152.3 (C-5), 161.5 (C-6) and 192.62 (C-9). mil:
264 (M+, 2.6), 221 (M+-C3H7, 3.4) and 205 (M+-OC3H7, 5.0%) (Found M+,
264.1354 C 15H2004 requires M, 264.1361).
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6.10 SYNTHESIS OF 3,5·DISUBSTITUTED THIOPHENES VIA
FRIEDEL· CRAFTS ACYLATION
ESTERIFICATION OF THIOPHENE·3·CARBOXYLIC ACID
METHYL 3·THIOPHENECARBOXYLATE (141a)
oc(OH
S
TMSCI.. odo6H35 S 2
1
141a
MeOH
RT24 h
Chlorotrimethylsilane (5.9 ml: 5.05 g: 46.4 mmol) was added dropwise to a flask
containing thiophene-3-earboxylic acid (3 g ; 23.4 mmol) in methanol (10 rnl). The
resulting solution was stirred at room temperature before being quenched with water
(50 ml) and the solution extacted with ethyl acetate (3 x 20 mI). The comhined
organic extracts were washed with brine (3 x 20 ml) and sodium hicarbonatc (3 x
20 ml) and before drying over magnesium sulfate. The solvent was removed under
reduced pressure giving the crude product as the residual oil. Purification via column
chromatography eluting with light petroleum/ethyl acetate (5: I) afforded methyl-3-
thiophenecarboxylate 141a as a colourless oil 2.2 g (15 mmol: 60%); IR Ymax
(CHCh): 1717,3020 and 3117 crrr l , BH(200 MHz; CDCh): 3.75 (IH. s, H-7L. .
7.19 (lH, dd,15,2 3.02 Hz, 15,4 5.05 Hz, H-5), 7.42 (IH, dd, 14.2 1.01 Hz. 14.5
5.05 Hz, H-4) and 8.00 (1H, dd, hA 1.08, Ji» 3.02 Hz. H-2). Bd50 MHz): 51.58
(C-7), 125.94 (C-5), 127.75 (C-4), 132.54 (C-2), 133.42 (C-3) and 162.99 (C-6).
mlz 142 (41.7) and 111 (M+-OMe. 100%) (Found 142.0081 C6H602S requires
142.0088).
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ISOPROPYL 3-THIOPHENECARBOXYLATE (14th)
o
eJ'OH
S
A catalytic amount of concentrated sulfuric acid was added to a stirring solution of
thiophene-3-carboxylic acid (5 g: 39 mmol ) in isopropanol (50 ml). The resulting
solution was stirred for 12 h at room temperature. The solution was then poured into
water (50 ml) and extracted with ethyl acetate (3 x 20 ml). The combined organic
extracts were washed with sodium bicarbonate (3 x 25 rnl), brine (3 x 20 ml) and
dried over magnesium sulfate. The solvent was removed in vacuo giving the ester as
the residual oil. Purification via column chromatography eluting with light petroleum!
ethyl acetate (5: 1) afforded isopropyl-3-thiophenecarboxylate t4t b as a colourless oil
(4.2 g: 24 mmol: 63%); DH (200 MHz; CDCI3); 1.34 (6H, d, h.7 6.27 Hz, H-8),
5.20 (1H, septet, 17.8 6.27 Hz, H-7), 7.28 (I H, dd, }5,2 3.03 Hz }SA 5.03 Hz, H-
5),7.51 (lH, dd, J4,2 1.14 Hz, J4,5 5.05 Hz, H-4) and 8.08 (IH. dd, Ji.« 1.16 Hz,
}z,5 3.05 Hz, H-2). DC (50 MHz); 21.88 (C-8), 67.96 (C-7), 125.75 (C-5), 127.87
(C-4), 132.25 (C-2), 134.37 (C-3) and 162.25 (C-6) m/: 170 (M+, 17.1), 12g
(36.4) and 111 (100%) (Found M+, 170.0406 CIIH702S requires 170.0401).
PHENYL-3-THIOPHENECARBOXYLATE (l41c)
DIC
9.J;010
~_~ ;j0- 0
5 S 2
1
141c
PhOH
RT 12 h
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Diisopropylcarbodiimide (2.09 ml: 1.68 g: 13.3 mmol) was added dropwise to a
solution of thiophene-3-carboxylic acid (1.00 g: 8.9 mmol) and phenol (1.25 g:
13.3 mmol) in THF (20 ml). The resulting solution was stirred overnight at room
temperature. Water (50 ml) was added and the solution extracted with ethyl acetate (3
x 25 ml). The combined organic extracts were combined and washed with sodium
bicarbonate (3 x 20 ml), brine (3 x 20 ml) and dried over magnesium sulfate. The
ethyl acetate was then removed in vacuo to leave the crude ester as a white solid.
Purification by column chromatography eluting light petroleum/ethyl acetate ( 10: I)
afforded phenyl-3-thiophenecarboxylate 141c as a white solid (1.02 g: 4.9 mmol:
60%); m.p. 63-65°C; IR vmax(CHCI3); 3117, 3028, 3013 and 1733 crrr l. 8H (200
MHz; CDCI3); 7.16-7.4 (6H, m, H-Ph and H-5), 7.64 (IH, dd, J4,2 1.18 Hz, J4,)
5.08 Hz, H-4) and 8.29 (1H, dd, J2,5 1.2 Hz, 12,4 3.06 Hz, H-2). 8c (50 MHz):
121.21 (C-8), 125.89 (C-4), 126.4 (C-lO), 128.21 (C-5), 129.48 (C-9), 132.1 (C-
3), 134.03 (C-2), 150.66 (C-7) and 161.05 (C-6); m/: 204 (M+, 11.1) and III (M+-
OPh, 100%) (Found M+, 204.0244 CIIHg02S requires 204.0245).
SYNTHESIS OF THIOPHENE FRIEDEL·CRAFTS DERIVATIVES
METHYL 5·ACETYL·3·THIOPHENECARBOXYLATE (142)
orS'0CH3
S
141a
The general procedure for Friedel-Crafts reactions was followed using methyl 3-
thiophenecarboxylate 141a (200 mg: 1.4 mmol), acetic anhydride, BF).OEt2
(0.08 ml: 95 mg: 0.7 mmol). The temperature for the reaction was 50T and the
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time taken for reaction to go to completion was 5 minutes. Purification by column
chromatography eluting with light petroleum/ ethyl acetate 5: I) afforded methyl 5-
acetyl-3-thiophenecarboxylate 142 (204 mg: 1.11 mmol: 79%) IR vrnax(CHCh
solution); 1671, 1720,3009 and 3026 crrr l. BH (200 MHz: CDCl3): 2.57 (3H, s, H-
9),3.88 (3H, s, H-7), 8.04 (IH, d,J4,2 1.27 Hz, H-4) and 8.31 (IH, d,hA 1.24
Hz, H-2). Bc (50 MHz): 26.62 (C-9), 52.14 (C-7), 132.49 (C-4), 134.08 (C-2),
139.45 (C-3), 145.16 (C-5), 162.47 (C-6), 190.61 (C-8); m/z: 184 (M+, 37.6),169
(M+-Me, lOO) and 153 (M+-OMe, 25.1) (Found 184.0200 CXHg03S requires
184.0194)
ISOPROPYL 5-ACETYL-3-THIOPHENECARBOXYLATE (143)
a_(0'0
S
141b
The general procedure was followed using isopropyl thiophene-3-carboxylate 141b
(200 mg: 1.17 mmol), acetic anhydride (3 ml) and BF3.0Et2 (0.28 011: 333 mg:
2.35 mmol). The temperature was 70°C and the time taken for completion was 2 h.
Purification via column chromatography eluting with light petroleum/ ethyl acetate
(3: I) afforded the isopropyl 5-acetyl-3-thiophenecarboxylate 143 (94 mg:
0.38 mmol 38%) IR vrnax(CHCl3 solution): 1670, 1712, 3026 and 3111 crrr '. OH
(200 MHz; CDCI3): 1.34 (6H, d, Jg,7 6.25 Hz, H-8), 2.57 (3H, S, H-IO), 5.20
(IH, septet,h,g6.28 Hz, H-7), 8.03 OH, d,J4,21.24 Hz, H-4) and 8.30 (IH, d,
h,4 1.24 Hz, H-2). Bc (50 MHz): 21.67 (C-8), 26.63 (C-10), 68.72 (C-7), 130.05
(C-4), 132.48 (C-2), 135.00 (C-3), 139.17 (C-5), 161.5 (C-6) and 190.66 (C-9).
m/z: 212 (M+, 26.9), 169 (M+-C3H7, 2.5) and 153 (M+-OC3H7, 71.3) (Found
212.0481 ClOHI203S requires 212.0507)
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PHENYL 5-ACETYL-3- THIOPHENE CARBOXYLATE (144)
The general procedure was followed using phenyl thiophene-3-carboxylate 141c
(200 mg: 1 mmol), acetic anhydride (3 ml) and BF3.0Et2 (0.2 ml: 238 mg:
2 mmol). The temperature was raised to 50°C and the time taken for completion was
1.5 h. Purification via column chromatography eluting light petroleum/ ethyl acetate
(5: 1) afforded the phenyl 5-acetyl-3-thiophenecarboxylate 144 as white crystals
(132 mg: 0.53 mmol: 55%) IR Vmax (CHCI3 solution): 31672, 1737, 3026 and
3110 crrr l. OH (200 MHz; CDCI3): 2.54 (3H, s, H-12), 7.1-7.46 (5H, m, PhH),
8.12 (IH, d, 14,2 1.21 Hz, H-4) and 8.54 (IH, d, h.4 1.20 Hz, H-2). Oc (50 MHz):
26.67 (C-12), 121.51 (C-8), 126.16 (C-4), 129.56 (C-I0), 132.68 (C-9), 133.45
(C-2), 140.61 (C-3), 145.8 (C-5), 150.34 (C-7), 160.32 (C-6) and 190.58 (C-II);
m/z: 246 (M+, 9.5), 153 (100) and 111 (21.6) (Found 246.0355 CnH I003S
requires 246.0350)
METHYL 5-ISOPROPYL-3- THIOPHENE-CARBOXYLATE (145)
o
r5'OCH3
S
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The general procedure was followed using methyl thiophene-3-carboxylate 1418
(110 mg: 0.7 mrnol), isobutyryl chloride (3 ml) and BF3.0Et2 (0.04 ml: 47.6 mg:
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0.33 mmol). The temperature for the reaction was 50°C and the time taken for
completion was 4 h. Purification by column chromatography eluting with light
petroleum/ ethyl acetate, (5: I) afforded methyl 5-isopropyl-3-thiophenecarboxylate
145 (122 mg: 0.57 mmol: 57%) IR Vmax (CHCI3 soln.): 1664, 1720, 3026 and
3111 crrr+. DH (200MHz: CDCl3): 1.04(6H,d,JIO,96.84 Hz, H-IO), 3.21 (IH,
septet, ]g,1 06.63 Hz, H-9), 3.68 (3H, s, H-7), 7.87 (I H, d, J4,2 1.17 Hz, H-4),
8.12 (IH, d, h,4 1.18 Hz, H-2); DC (50 MHz): 20.57 (C-IO), 36.73 (C-9), 51.95
(C-7), 131.38 (C-4), 133.98 (C-3), 139.118 (C-2), 144.22 (C-5), 162.30 (C-6),
190.24 (C-8) m/z: 212 (M+, 14.3),169 (M+-C3H7,100) and 181 (M+-OMe.4.3%)
(Found M+, 212.0494 C 56.56 and H 5.60% CIOH1203S requires M 212.0507 C
56.60 and H 5.80 %).
ISOPROPYL S-ISOBUTYRYL-3-THIOPHENECARBOXYLATE (146)
o~6'0
S 141b
The general procedure was followed using isopropyl thiophene-3-carboxylate 141b
(500 mg: 2.94 mmol), isobutyryl chloride (3 ml) and BF3.0Et2 (0.7 ml: 83.3 mg:
5.88 mmol). The temperature was 90°C and the time taken for completion was 2 h.
Purification by column chromatography eluting with light petroleum/ ethyl acetate,
(5: I) afforded isopropyl 5-isobutyryl-3-thiophenecarboxylate 146 (365 mg:
1.52 mmol: 51%) IR vrnax(CH2Cb solution): 1713,1732,3062 and 3111 crrr '. OH
(200 MHz: CDCI3): 1.15 (6H, d, }II, 106.84 Hz, H-Il), 1.27 (6H, d, h,,9 6.24 Hz,
H-8), 3.34 (lH, septet, JIO,II 6.85 Hz, H-IO), 5.10 (IH, septet, h,8 6.28 Hz, H-7),
7.98 (IH, d, }4,2 1.21 Hz, H-4) and 8.23 (IH, d, h,4 1.22 Hz, H-2). Oc (50 MHz):
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19.19 (C-l1), 21.81 (C-8), 36.75 (C-IO), 68.57 (C-7), 131.6 (C-4), 134.92 (C-3),
138.88 (C-2), 144.1 (C-5), 161.49 (C-6) and 197.23 (C-9); m/: 240 (M+, 29.8),
197 (M+-C3H7, 91.0),181 (M+-OC3H7, 17.2), 155 (100%) (Found 240.0818,
C 12H1603S requires 240.0820)
PHENYL 5-ISOBUTYRYL-3-THIOPHENECARBOXYLATE (147)
° ~ \___gOoN r-'CI•
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The general procedure was followed using phenyl 3-furoate 141c (380 mg:
1.86 mrnol ), isobutyryl chloride (3 ml) and BF3.0Et2 (0.44 ml: 523 mg:
3.72 mmol). The temperature was 90°C and the time taken for completion was 1.5
h. Purification by column chromatography eluting with light petroleum/ ethyl acetate
(10: 1) afforded phenyl 5-isobutyryl-3-thiophenecarboxylate 147 as a yellow oil
(100 mg: 19.6%); IR vmax(CDCl3 soln.): 1167,1735,3019 and 3112 crrr l , OH
(200 MHz: CDCI3): 1.27 (6H, d, 113,12 6.86 Hz, H-13), 3.44 (IH, septet,112,13
6.84 Hz, H-12), 7.17-7.47 (5H, m, H-8,9 and 10),8.20 (IH, d. 14,2 1.12 Hz, H-4)
and 8.51 (lH, d,}z,4 1.2, H-2). OC (50 MHz): 18.78 (C-I3), 36.91 (C-12), 121.51
(C-8), 126.3 (C-4), 129.42 (C-10), 132.23 (C-9), 133.42 (C-2), 134.2 (C-3), 146.9
(C-7), 150.39 (C-5) 162.3 (C-6)and 197.33 (C-ll). m/z: 274 (M+, 13.7) and 181
(M+-OPh, 100%) (Found 274.0647 CIsHI403S requires 274.0664)
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6.11 SYNTHESIS OF 3,5.DISUBSTITUTED FURANS VIA
FORMYLA TION
GENERAL PROCEDURE FOR FORMYLATION OF FUROATE
ESTERS
To a flask, cooled to O°C, were added phosphorus oxychloride (1.2 equivalents) and
dimethylfonnamide (1.2 equivalents). The resulting mixture was allowed to stand for
20 min. A yellow solid formed and the appropriate ester (I equivalent) was added to
the flask. The temperature was raised to 80T and the resulting mixture was stirred for
the appropriate length of time specified in the individual procedures before being
cooled and poured into a mixture of ice/water. An aqueous solution of potassium
carbonate was added dropwise and the solution extracted with ethyl acetate (3 x
30 ml). The combined organic extracts were then washed with sodium bicarbonate
(3 x 20 ml), brine (3 x 20 ml) and dried over magnesium sulfate. The solvent was
removed in vacuo to leave the crude products as black oils. Purification via column
chromatography eluting with light petroleum/ethyl acetate (5: I) afforded the respective
formylated furoates.
METHYL 5-FORMYL-3-FUROATE (151)
The general procedure for formylation of the furoate esters was followed using methyl
3-furoate 130 (900 mg: 7.14 mmol), phosphorus oxychloride (1.46 g: 9 mmol)
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and DMF (0.74 ml: 0.7 g: 9 mmol). The reaction mixture was heated for 0.5 h.
Purification afforded a mixture of methyl 5-formyl-3-furoate 151 and methyl 2-
formyl-3-furoate in a 10:1 ratio. Total mass isolated was 760 mg (4.9 mmol: 38%).
Data for methyl 5-forrnyl-3-furoate 151:
IR vmax(KBr disc); 1722, 1697,3140 and 3084 cm+. OH(200 MHz; COCl): 3.86
(I H, S, H-7), 7.51 (1H, d, J4,2 0.7 Hz, H-4), 8.19 (I H, d, 12.4 0.62 Hz. H-2) and
9.66 (IH, d, JS,4 0.24 Hz, H-8). Oc(50 MHz); 51.96 (C-7), 119.57 (C-4), 121.36
(C-3), 151.41 (C-2), 153.1 (C-5), 161.91 (C-6) and 177.76 (C-8). m/z: 154 (M+,
49.5) and 123 (M+-OMe, 100%)(Found M+, 154.0261; C7H604 requires
154.0265).
Data for methyl 2-forrnyl-3-furoate:
OH(200 MHz; CDCI3); 3.92 (3H, s, H-7), 6.86 (JH, d, J4.5 1.80 Hz, H-4), 7.25
(IH, S, H-5) and 10.20 (1H, d, J8,4 0.78 Hz, H-8)
ISOPROPYL 5-FORMYL-3-FUROATE (152)
0_.l_0'0
o
131
80<>C
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152
POCI3
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The general procedure for formylating furoate esters was followed using isopropyl 3-
furoate 131 (1.01 g: 655 mmol), phosphorus oxychloride (0.76 mg: 1.26 g:
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8.2 mmol) and dimethylformamide (0.63 ml: 0.6 g: 8.2 mrnol). The reaction was
warmed for 2.5 h before work up in the usual manner. Purification via column
chromatography afforded a mixture of isopropyl 5-formyl-3-furoate 152 and
isopropyl 2-formyl-3-furoate in a ratio of 4: 1.
Data for isopropyl 5-formyl-3-furoate:
Yield 678 mg (3.72 mmol: 28.7%); IR vmax(CHCI3): 1686, 1722,3032 and 3146
ern-I. DH (200 MHz; CDCI3): 0.97 (6H, d, J8,7 6.24 Hz, H-8), 4.83 (I H, septet, J
7,8 6.24 Hz, H-7), 7. 19 (lH, s, H-4), 7.87 (I H, s, H-2) and 9.32 (I H, d, 19,4 0.55
Hz ,H-9). s, (50 MHz): 21.57 (C-8), 68.6 (C-7), 112.78 (C-3), 119.73 (C-4),
151.23 (C-2), 152.98 (C-5), 160.91 (C-6) and 177.68 (C-9). m/z: 182 (M+,14.0),
139 (M+-C3H7, 41.2) and 123 (M+-OC3H7. 93.4). (Found 182.0585 CI)HI004
requires 182.0579).
Data for isopropyl 2-formyl-3-furoate:
JL_{
i«:
5 Q 2 CHQ
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DH (CDCI3: 200 MHz:): 6.52 (lH, d, 14,5 1.76 Hz. H-4), 7.32 (IH, dd, 1S,9 0.9 Hz.
JS,4 1.63 Hz, H-5) and 9.85 (l H, d, JO.81. H-9).
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PHENYL 5-FORMYL-3-FUROATE (153)
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The general procedure for formylating furoate esters was followed using phenyl 3-
furoate 132 (3.8 g: 20 mmol), phosphorus oxychloride (4.66 ml: 7.66 g:
50 mrnol) and DMF (3.86 ml: 3.64 g: 50 mmol). The temperature was raised from
80°C to 100°C and the time taken for completion of the reaction was Ih. Purification
via column chromatography afforded phenyl 5-formyl-3-furoate 153 and phenyl 2-
formyl-3-furoate 2.04 g (38% : 9.4 mmol).
Data for phenyl 5-formyl-3-furoate 153:
IR vrnax(CHCl3 solution): 1696, 1746, 2836 and 3146 cm+. OH (200 MHz: COCl3):
6.73-7.25 (5H, m, H-8, 9 and ]0),7.58 (lH, s, H-4), 8.32 (]H, s, H-2) and 9.62
(IH, s, H-II). OC (50 MHz): 1]9.92 (C-4), 120.95 (C-3), 121.44 (C-B), 126.48
(C-ID), 129.63 (C-9), ]50.03 (C-7), 152.3] (C-2), 153.29 (C-5), 159.96 (C-6) and
177.86 (C-I ]). m/z: 2] 6 (9.1) and] 23 (M+ -OPh, 83.3%) (Found M+, 216.0414 C
66.42, H 3.80% CI2Hg04 requires M, 216.0.422 C 66.66, H 3.70%)
Data for phenyl 2-formyl-3-furoate:
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OH (COCl3; 200 MHz): 7.0 OH, s, H-4), 7.3-7.4 (IOH, m, H-8,9 and 10), 7.6 (I H,
s, H-5) and 10.4 (lH, s, H-II)
GENERAL PROCEDURE FOR VINYLMAGNESIUM BROMIDE
ATTACK ON FORMYL FUROATE ESTERS
To a solution of the appropriate formylated furoate ester (I equivalent) in 30 ml THF
held under nitrogen was added vinylmagnesium bromide (1.2 equivalent) at OT. The
solution was warmed to room temperature and stirred for 12 h. Water (50 ml) was
added and the solution extracted with ethyl acetate (3 x 25 ml), The organic extracts
were combined, washed with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml) and
dried over magnesium sulfate. Solvent was removed under reduced pressure to give
the crude product. Purification via column chromatography eluting with hexane/ethyl
acetate (2: 1) afforded the respective alkylated isomers.
METHYL 5-(1-HYDROXY -2-PROPENYL)-3-FUROATE (156)
o
~OCH'
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The general procedure was followed using a mixture of methyl 5-formyl-3-furoate
151 and methyl 2-formyl-3-furoate (2.89 g: 18.7 mmol) and vinylmagnesium
bromide (22.5 ml: 1.0 M in THF; 22.5 mmol). Purification afforded methyl 5-( 1-
hydroxy-2-propenyl)-3-furoate 156 (1.8 g: 9.8 mmol: 53%) and methyl-2-( 1-
hydroxy-2-propenyl)-3-furoate 159 (180 mg: 0.98 mmol: 5%) as colourless oils.
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Data for methyl 5-( l-hydroxy-2-propenyl)-3-furoate 156:
IR: vmax(CHCI3); 1725 and 3149 crrr l. OH(200 MHz; CDC)3); 3.72 (IH, s, H-7),
5.05 (1H, br d, J8,9 5.82 Hz, H-8), 5.35 (2H, m, H-IO), 5.95 (I H, ddd, Jy,,/{ 5.81
Hz, J9,IOa 10.33 Hz J9,lOb 16.15 Hz, H-9), 6.45 (IH, d, J4,2 0.84 Hz, H-4) and
7.83 (I H, 12,4 0.84 Hz, H-2). Oc(50 MHz); 51.53 (C-7), 67.97 (C-8), 106.29 (C-
4), 116.73 (C-IO), 119.35 (C-3), 136.21 (C-9), 147.33 (C-2), 156.76 (C-5) and
163.66 (C-6). m/z; ]82 (M+, lOO), 155 (71.5), 139 (25.7) and 126 (70.2%) (Found
M+, 182.0571 C9H 1004 requires M, 182.0578).
Data for methyl 2-(l-hydroxy-2-propenyl)-3-furoate 159:
o
IR: vmax(CHCI3); 1720,3088,3136 crrr '. OH(200 MHz; CDCI3); 3.78 (IH, s, H-
7), 4.74 (1H, br d, J8,9 5.31 Hz, H-8), 5.25 -5.45 (2H, m, H-I 0), 6.0 I (I H, ddd,
J9,8 5.63 Hz, J9,lOa 10.32 Hz, J9,lOb 15.9 Hz, H-9), 6.59 (IH, d, J4,5 1.93 Hz, H-
4) and 7.22 (lH, d, J5,4 1.94 Hz, H-5). Oe (50 MHz); 52.03 (C-7), 68.79 (C-8),
110.881 (C-4), 113.84 (C-3), 116.14 (C-IO), 136.13 (C-9), 141.18 (C-5), 162. I
(C-2) and 165.18 (C-6). m/z: 182 (M+, 22.5),155 (13.9),150 (90.7) and 123
(100%) (Found M+, 182.0576 C9H 1004 requires M, 182.0578).
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ISOPROPYL 5-(1-HYDROXY -2-PROPENYL)-3-FUROATE (157)
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The procedure was followed using a mixture of isopropyl 5-formyl-3-furoate and
isopropyl 2-formyl-3-furoate (1.05 g; 5 mmol) and vinylmagnesium bromide
(10.0 ml: 1.0 M solution in THF: 10.0 mmol). Purification afforded isopropyl 5-
(l-hydroxy-2-propenyl)-3-furoate 157 (472 mg: 2.24 mmol: 41%) and isopropyl 2-
(l-hydroxy-2-propenyl)-3-furoate 160 (100 mg: 0.476 mmol: 8%) as colourless
oils.
Data for isopropyl 5-(l-hydroxy-3-propenyl)-3-furoate 157:
IR Vmax (CHCI3): 1144,1712,3034 and 3156 crrr l , OH (200 MHz) (CDCl3): 1.22
(6H, d, ]g,7 6.27 Hz , H-8), 4.86 (lH, septet, 17,86.23 Hz, H-7), 5.05 (IH, br d.
H-9), 5.89 (2H, m, H-I1), 6.48 (tH, s, H-4) and 7.65 (IH, d, 12,40.77 Hz , H-2).
oe (50 MHz): 21.79 (C-8), 68.05 (C-9), 68.1 (C-7), 106.47 (C-4). 116.79 (C-II),
120.22 (C-3), 136.33 (C-IO), 147.25 (C-2), 156.68 (C-5) and 162.92 (C-6). m/z:
210 (M+, 25.7), 168 (38.9), 151 (67.6), 141 (45.9) and 122 (43.9%) (Found
Data for isopropyl 2-(1-hydroxy-3-propenyl)-3-furoate 160:
.....::::: 118
OH
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IR Vrnax (CHCI3); 1724,2984 and 3264 cm! OH (200 MHz; CDCI3); 1.08 (6H, d,
18,7 6.23 Hz, H-8), 4.92 (IH, septet, h,8 6.34 Hz, H-7), 5.12 (2H, m, H-II), 5.69
(lH, br d, 19,10 5.42 Hz, H-9), 5.88 (tH, ddd, JIO,9 5.89 Hz, JIO.lla 10.23 Hz
llO.llb 17.05 Hz, H-10), 6.51 (tH, s, H-4) and 7.73 (IH, s, H-5). m/r: 210 (M+,
43.2), 151 (100) and 139 (66.5%) (Found 210.0882 CIIHI404 requires 210.0891)
PHENYL 5-(l-HYDROXY -2-PROPENYL)-3-FUROATE (158)
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The general procedure was followed using a mixture of phenyl 5-formyl-3-furoate
and phenyl 5-formyl-3-furoate (2.0 g; 9.25 mmol) and vinylmagnesium bromide
(10 ml: 1.0 M in THF; 10 mmol). Purification afforded phenyl 5-(I-hydroxy-2-
propenyl)-3-furoate 158 as a colourless oil; (1.05 g: 4.3 mmol: 46%) IR Vrnax
(CH2CI2 solution): 1740,3024,3082 and 3154 crrr '. OH(200 MHz): 4.26 (IH, br
d, 111,125.8 Hz, H-11), 5.28 (IH, dd, lJ3a,13b 1.07 Hz lna,I2 13.49 Hz, H-13a),
5.38 (1H, dd, J13b,13a 1.10 Hz and J13b,12 10.77 Hz, H-l3b), 6.13 (IH, ddd, 112.11
5.38 Hz, 112,13a 10.31 Hz and J12,13b 16.24 Hz, H-12), 6.74 (lH. 14,2 0.58 Hz. H-
4), 7.10-7.42 (5H, m, H-8,9 and 10) and 8.16 (lH, d, h.4 0.56 Hz, H-2) 0('(50
MHz): 68.22 (C-II), 106.78(C-4), 117.27(C-13), 119.19 (C-3), 121.61 (C-8),
125.98 (C-IQ), 129.47 (C-9), 136.02 (C-12), 148.45 (C-2), 150.96 (C-7), 156.97
(C-5), 161.8 (C-6) m/r: 244 (M+, 8.8) and 151 (100%) (Found M, 244.0742.
CI4HI204 requires 244.0735).
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OXIDATION TO KETONES
SWERN OXIDATION
o o
x
OH 156 o 175
To a flask cooled to -78°C and flushed with nitrogen was added oxalyl chloride
(0.1 ml: 145 mg: 1.14 mmol) followed by CH2CI2 (5 ml). Dimethylsulfoxide
(0.16 ml: 176 mg: 2.25 mmol) in CH2CI2 (2 ml) was slowly added and stirred for
5 minutes before methyl 5-(l-hydroxy-2-propenyl)-3-furoate 156 (135 mg:
0.7 mmol) dissolved in CH2CI2 was added dropwise. The solution turned a murky
grey colour and after 15 minutes triethylamine (0.5 ml: 363 mg: 3.6 mmol) was
added and the solution slowly warmed to room temperature. The resulting mixture
was stirred for 15 minutes and the solution turned purple. On addition of water
(25 ml) an exotherm was observed. The aqueous layer was separated from the
organic layer and was then back extracted with CH2CI2 (2 x 10 ml). The organic
extracts were combined, washed with brine and the solvent removed under reduced
pressure to give an orange solid identified as starting material.
GENERAL PROCEDURE FOR OXIDATION USING MANGANESE
DIOXIDE
Manganese dioxide (10 equivalents) was added to a solution of the appropriate 5-( 1-
hydroxy-2-propenyl)-3-furoate ester (1 equivalent) in light petroleum (10 ml) and
stirred for 48 h. The resulting mixture was then filtered through a pad of Celite® to
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remove the residual manganese dioxide. The solvent was removed in vacuo to leave
the crude product. Purification via column chromatography eluting with light
petroleum/ ethyl acetate (4: 1) afforded the respective oxidised furoates.
METHYL 5-(2-PROPENOYL)-3-FUROATE (175)
o o
OH 156
OCH3 --------.~light petroleum
RT / 48 h o
The general procedure for oxidation was followed using methy I 5-( l-hydroxy-2-
propenyl)-3-furoate 156 (lOO mg: 0.55 mmol) and manganese dioxide (478 mg:
5.55 mmol). Purification via column chromatography afforded methyl 5-(2-
propenoyl)-3-furoate 175 as a white solid (24 mg: 0.13 mmol: 24%); I R
vrnax(CH2Cl2) 1672, 1728, 3064 and 3144 crrr l. OH (200 MHz; CDCI3); 3.79 ( I H,
s, H-7), 5.85 (lH, dd, JlOa,lOb 1.56 Hz, JlOa, 9 10.44 Hz, H-10a), 6.48 (IH, dd,
iJOb,lOa 1.54 Hz, J]Ob,9 17.1 Hz, H-lOb), 6.96 (lH, dd, J9,IOa 10.45 Hz, J9.IOh
17.13 Hz, H-9), 7.46 (lH, s, H-4) and 8.09 (lH, s, H-2). Oc (50 MHz); 51.9 (C-
7),116.97 (C-4), 121.22 (C-3), 130.42 (C-IO), 130.69 (C-9), 150.48 (C-2), 153.21
(C-5), 162.16 (C-6) and 177.79 (C-8). m/z: 180 (M+, lOO), 153 (M+-C2H~, 89.9),
149 (M+-OMe, 78) and 121 (M+-COOMe, 43.8) (Found M+ 180.0420, C 59.9 and
H 4.42% ; C9Hg04 requires M+, 180.0426 C 60.0 and H 4.44%).
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ISOPROPYL 5-(2-PROPENOYL)-3-FUROATE (176)
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The general procedure was followed using isopropyl 5-( I-hydroxy-2-propenyl )-3-
furoate 157 (200 mg: 0.95 mmol) and manganese dioxide (826 mg: 9.5 mmol).
Purification afforded isopropyl 5-(2-propenoyl)-3-furoate 176 as a white solid
(55 mg: 3.75 mmol: 28%) m.p. 42-44°C; IR vrnax(CH2CI2): 1670, 1720,3018 and
3154 cml BH (200MHz: CDCI3) 1.27 (6H, d, Jg,7 6.26 Hz, H-8), 5.14 (IH,
septet, Jts 6.27 Hz, H-7), 5.866 (lH, dd, J Ila,llb 1.58 Hz, Jlla,IO 10.42 Hz, H-
Ila), 6.51 (IH, dd, Jllb,lla 1.57 Hz, Jllb,IO 17.13 Hz, H-Ilb), 6.9 (IH, dd,
JIO,lla 9.75 Hz, JID,llb 17.12 Hz , H-I0), 7.47 (IH, d, J4,2 0.69 Hz , H-4) and
8.08 (lH, d, 12,4 0.69 Hz, H-2). Bc (50 MHz): 21.81 (C-8), 68.7 (C-7), 117.24
(C-4), 122.07 (C-3), 130.44 (C-II), 130.77 (C-tO), 152.41 (C-2), 153.15 (C-5),
161.4 (C-6) and 177.92 (C-9). m/z: 208 (M+, 26.5),166 (36.7),149 (100) and 139
(78.4%).(Found 208.0738 CIIHI204 requires 208.0735).
PHENYL 5-(2-PROPENOYL)-3-FUROATE (177)
OH
light petroleum
RT / 48 h
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The general procedure was followed using phenyl 5-( l-hydroxy-2-propenyl)-3-
furoate 158 (lOO mg: 0.41 mmol and manganese dioxide (356 mg: 4.1 mmol).
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Purification afforded phenyl 5-(2-propenoyl)-3-furoate 177 (20 mg: 0.082 mmol:
20%); IR Vmax (CDCI3 solution): 1672,1744 and 3020 crrr l. 8H (200 MHz): 5.91
(lH, dd, H-13a), 6.55 (lH, dd, H-13b), 6.98 (JH, dd, H-12), 7.07-7.40 (5H, m,
H-8, 9 and 10), 7.60 (lH, s, H-4) and 8.28 (1H, s, H-2) m/z: 242 (16.6) and 149
(100); (Found 242.0583 CI4HIO04 requires 242.0579)
6.12 SYNTHESIS OF 3,5-DISUBSTITUTED THIOPHENES VIA
FORMYLA TION
METHYL 5-FORMYL-3- THIOPHENECARBOXYLA TE
o
~OCH3
S
141b
o
POCI3 .J 7
DMF. ){ _~ 3')- OCH3
OHC 5 S 2
8 1
178
To a flask cooled to O°C was added phosphorus oxychloride (2.16 ml: 3.55 g:
23 mmol) and dimethylformamide (1.79 ml: 1.69 g: 23 mmol ). The yellow
Vilsmeier salt formed which was allowed to stand for 20 minutes. Methyl 3-
thiophenecarboxylate (1.32 g: 9.2 mmol) was added and the solution warmed to
1OO°C for 6 h. The mixture was cooled to room temperature and poured onto an
ice/water mixture (15 g) and potassium carbonate (5 g) added. The solution was then
extracted with ethyl acetate (3 x 30 ml). The combined organic extracts were washed
with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml) and dried in vacuo to give the
crude ester. Purification of the residual oil via column chromatography eluting with
light petroleuml ethyl acetate (4: 1) afforded methyl 5-formyl-3-thiophenecaboxylate
(300 mg: 1.76 mmol: 19%) and methyl 2-formyl-3-thiophene-carboxylate (71 mg:
4.18 mmol: 4.1 %) in a ratio of 4.2: 1.
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Data for methyl 5-formyl-3-thiophenecarboxylate 178:
IR Vrnax (CDCI3): 1671,1720,3042 and 3138 crrr ' OH (200 MHz: CDCl3); 3.83
(3H, s, H-7), 8.08 (lH, d, 14,21.29 Hz, H-4), 8.36 (lH, d h,4 1.29 Hz, H-2) and
9.85 (1H, dd, 18,4 1.34 Hz, 18,2 2.59 Hz, H-8). od50 MHz); 52.16 (C-7), 134.42
(C-3), 136.28 (C-4), 140.31(C-2), 144.2(C-5), 162.08 (C-6) and 183.5 (C-8). m/z:
170 (M+, 52.1),139 (M+-OMe, 100) and III (M+-COOMe, 22.1%) (Found M+,
170.0011; C7H603S requires M, 170.0037).
Data for methyl 2-formyl-3-thiophenecarboxylate 179:
Yield, IR Vrnax (CDCI3): 1666,1724,3052 and 3114 cm-l.oH(200MHz: CDCI3);
3.9 (3H, s, H-7), 7.57 (IH, br s, H-4), 7.59 (lH, d, br s, H-5) and 10.53 (I H, s,
H-8). m/z: 170 (M+, 43.3), 155 (M+-Me, 32.9), 139 (M+-OMe, 39.2) and III
(M+-COOMe, 100%) (Found 170.0024 C7H603S requires 170.0037).
METHYL 5- (I-HYDROXY -2-PROPENYL)3- THIOPHENE-
CARBOXYLATE (180)
o
dOCH3OHC S
178
o
THF
~MgBr Ha
A dry flask was charged with methyl 5-formyl-3-thiophenecarboxylate 178 (500 mg:
3.4 mmol) and THF (20 ml) and cooled to O°C. Vinylmagnesium bromide (3.4 ml:
1.0 M in THF: 3.4 mmol) was added dropwise and the resulting solution warmed to
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room temperature and stirred for 12 h. Water (50 ml) was added and the resulting
solution extracted with ethyl acetate (3 x 25 ml). The combined organic extracts were
washed with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml) and dried over
magnesium sulfate. The solvent was then removed under reduced pressure and the
residual oil purified by column chromatography eluting with light petroleum/ ethyl
acetate (4: 1) affording methyl 5-(l-hydroxy-2-propenyl)-3-thiophene carboxylate 180
(331 mg: 1.67 mmol: 57%) IR Vrnax (CDCI3 soln.) ; 1678, 1720, 3054 and 31 12
crrr+. BH (200 MHz: CDCI3): 3.77 (3H, s, H-1), 5.10(2H, m, H-10), 6.01 (I H,
ddd, 19,8 6.15 Hz, 19,1Oa 10.23 Hz, 19,IOb 16.05 Hz, H-9), 7.26 (IH, d. 14,2 0.74
Hz, H-4) and 7.94 (1H, lzA 1.35 Hz, H-2); Be (50 MHz): 51.8(C-7), 70.69 (C-8),
114.53 (C-4), 116.19 (C-IO), 124.41 (C-3), 132.62 (C-2), 138.80 (C-9), 147.97
(C-5) and 163.3 (C-6) m/z: 198 (M+, 44.9), 183 (M+-Me, 16.5), 167 (M+-OMe,
52.9) and 139 (M+-COOMe, 81.8) : Found 198.0353 C9H IO03S requires M,
198.0350.
METHYL 5-(2-PROPENOYL)-3- THIOPHENECARBOXYLATE (181)
o o
OH 180
light petroleum
RT /48 h o 1
181
To a solution of methyl 5-( 1-hydroxy-2-propenyl)-3-thiophene carboxylate (200 mg:
1mmol) in light petroleum (10 ml) was added manganese dioxide (860 mg: 10 mmol)
and the resulting slurry stirred for 24 h. The mixture was then filtered through a pad
of Celite® to remove the residual manganese diioxide. The solvent was removed in
vacuo to leave the crude product. Tic indicated that there was only one compound
present therfore further purification was not necessary. This gave methyl 5-(2-
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propenoyl)-3-thiophenecarboxylate as a white solid (106mg: 0.5 mmol:53%); m.p.
59-60°C; IR Vrnax (CDCI3 solution): 1660, 1720, 31 12 and 3310 cm+. OH (200
MHz): 3.5 (3H, s, H-7), 5.87 (IH, dd, JlOa, lOb 1.53 Hz, JlOa.9 10.42 Hz, H-IOa),
6.46 (lH, dd, JIOa, lOb 1.53 Hz, J9,IOb 17.0 Hz, H-IOb), 7.02 (IH. dd, J9.IOa 10.42
Hz, J9,IOb17.01 Hz, H-9), 8.06 (lH, d, J4,2 1.20 Hz, H-4) and 8.30 (IH, d, J2,4
1.21 Hz, H-2); Oc (50 MHz): 52.12 (C-7), 129.9 (C-IO), 130.97 (C-4), 132.26 (C-
2), 134.20 (C-3), 139.86 (C-9), 145.2 (C-5), 162.36 (C-6) and 182.25 (C-8); m/z:
196 (M+,15.7), 165 (M+-OMe, 11.5) and 137 (M+-COOMe,11.3%) (Found
196.0198 C9Hg03S requires 196.0194).
6.13 ALTERNATIVE SYNTHESIS TO KETONE (175)
ATTEMPTED FRIEDEL·CRAFTS REACTION USING ACRYLOYL
CHLORIDE
odOMe
o
130
o
X· OMe
o 175
Methyl 3-furoate 130 (500 mg: 3.9 mmol) was added to a stirring solution of
acryloyl chloride (2 ml) and the resulting solution warmed to 70°C. BF3.0El2
(1.0 ml: 1.19 g: 8.45 mmol) was then slowly added and the solution turned black.
Tic using light petroleum/ ethyl acetate (5: 1) as the eluent indicated that a complex
mixture of products had been formed.
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6.14 SYNTHESIS OF DIELS-ALDER ADDUCTS
DIELS-ALDER USING 2,3-DIMETHYLBUTADIENE AND METHYL
5-(2-PROPENOYL)-3-FUROATE
o
OMe
K 16 o
OMe
7
o 175
To a solution of methyl 5-(2-propenoyl)-3-furoate 175 (150 mg: 0.83 mmol) in
CH2C12 (5 ml) in a flame dried flask under a nitrogen atmosphere was added 2,3-
dimethyl-I,3-butadiene (0.14 ml: 101 mg: 1.25 mmol). The resulting solution was
refluxed overnight. The solution was cooled before being diluted with water and
extracted with ethyl acetate (3 x 20 ml). The organic extracts were combined,
washed with sodium bicarbonate (3 x 20 ml), brine (3 x 20 ml) and the solvent
reduced in vacuo to leave the crude product as the residual oil. Purification via
column chromatography eluting with light petroleum/ ethyl acetate (3: I) afforded the
Diels-Alder adduct; 82 mg (0.31 mmol: 37%): IR vmax(CH2Cl2 solution): 1705,
1729,2915 and 3066 crrr l. OH (200MHz, CDCI3): 1.62 (6H, s, H-15 and 16), 1.84
(6H, m, H-IO,13 and 14),3.18 (IH, tt, H-9), 3.90 (3H, s. H-7), 7.40 (IH, d, J4.2
0.69 Hz, H-4) and 8.05 (I H, d, h,4 0.69 Hz, H-2). Oc (50 MHz): 18.78 (C-15),
18.95 (C-16), 25.92 (C-14), 31.20 (C-I3), 33.51 (C-IO), 43.42 (C-9), 51.95 (C-7),
116.15 (C-4), 120.96 (C-3), 123.94 (C-12), 125.29 (C-II), 150.05 (C-2), 152.6
(C-5), 162.41 (C-6) and 192.37 (C-8). m/z: 262 (M+, 33.1), 231 (6.8) and 203
(1.3%). (Found M+, 262.1198 C IsH 1804 requires 262.1205).
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DIELS·ALDER ADDUCT FORMATION WITH 2,3·DIMETHOXY·
BUTADIENE
o oMeO OMe
OMe K ..
o 175 o
183
To a solution of methyl 5-(2 propenoyl)-3-furoate (150 mg: 0.83 mmol) in CH2CI2
was slowly added 2,3-dimethoxybutadiene (0.15 ml: 141 mg: 1.23 mmol). The
resulting solution was refluxed overnight and then cooled, diluted with water (20 ml)
and extracted with ethyl acetate (3 x 25 ml). The combined organic extracts were
then washed with brine (3 x 20 ml), sodium bicarbonate (3 x 20 ml) and the solvent
removed in vacuo. Purification via column chromatography eluting with light
petroleum/ethyl acetate (5: I) afforded the title compound (64 mg: 0.22 mmol: 26%);
bH (200MHz, CDCI3): 2.36 (6H, m, H-IO, 13 and 14),3.18 (IH. m, H-9), 3.55
(3H, s, H-16), 3.57 (3H, s, H-15), 3.90 (3H, s, H-7), 7.40 (IH, d, J4,2 0,69 Hz,
H-4) and 8.06 (lH, d, h,4 0.69 Hz, H-2). be (50 MHz): 23.35 (C- 13), 24.53 (C-
14),24.66 (C-10), 42.66 (C-9), 51.98 (C-7), 57.21,57.33 (C-15 and 16), 116.47
(C-4), 117.03, 121.16 (C-3), 130.77 (C-12), 137.76 (C-11), 150.49 (C-2), 162.25
(C-5), 177.89 (C-6) and 190.00 (C-8). mlz 294 (M+, 11.5), 263 (2.6) and 235
(1.5%) (Found M+, 294.1069 ClSH1806 requires M, 294.1102).
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LEWIS ACID ACCELERATED DIELS-ALDER ADDUCT FORMATION
o o_ _;:_- ..... 15 o OMeOMe
175
To a solution of methyl 5-(2-propenoyl)-3-furoate (90 mg: 0.5 mmol) in CH2CI2
(10 ml) was added I,3-cyclohexadiene (0.1 ml: 84.1 mg: I mrnol) and AICI)
(100 mg: 0.75 mmol). The resulting mixture was refluxed overnight before being
cooled and diluted with water. The solution was then extracted with ethyl acetate (3 x
20 ml) and the combined organic extracts washed with brine (3 x 20 ml) and sodium
bicarbonate (3 x 20 mI). Solvent was removed under reduced pressure and
purification via column chromatography eluting with light petroleum/ ethyl acetate
(4: 1) afforded the desired Diels-Alder adduct 184 (43 mg: 0.16 mmol: 33%) IR
vmax(CHCl3 solution): 1681, 1728, 3026 and 3145 crrr '. BH (CDCI3; 200MHz) 1.7
(4H, m, H-14, and 15 ), 2.58 (tH, m, H-13), 2.85 (IH, rn, H-16), 3.31 (IH, m, H-
10),3.79 (3H, s, H-7), 4.06 (tH, m, H-9), 6.21 (lH, m, H-ll), 6.31 (lH, m, H-
12), 7.34 OH, d, J4,2 0.69 Hz, H-4) and 8.02 (IH, d, hA 0.7 Hz, H-2); Be
(50MHz) 24.18 (C-16) , 25.95 (C- 15), 29.33 (C-Il), 32.77 (C-IO), 46.45 (C-12) ,
49.23 (C-9), 51.90 (C-7), 115.61 (C-4), 120.87 (C-3), 130.90 (C-14) , 134.85 (C-
13), 149.64 (C-2), 152.94 (C-5), 162.43 (C-6) and 194.60 (C-8). m/z: 260 (5.1),
229 (4.1) and 169 (5.4%) (Found M+, 260.1048 CIsHI604 requires M, 260.1048)
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6.15 ALTERNATIVE SYNTHETIC ROUTE TO DIELS-ALDER
ADDUCTS
FRIEDEL-CRAFTS USING METHYL 3-FUROATE
J ~C116
~_~ OMe ~.~
o 15
o
o
182
To a stirring solution of 2,3-dimethylbutadiene (0.68 ml: 500 mg: 6 mmo!) in
CH2CI2 (10 ml) was slowly added acryloyl chloride (2.02 ml: 550 mg: 6 mmol)
and the resulting solution heated to 40°C for I h. The CH2Ch was then removed in
vacuo to leave the acid chloride as a colourless oil. To the oil was added methyl 3-
furoate (250 mg: 1.98 mmol) and the solution warmed to 80°C. BF~.OEt2
(0.47 ml: 0.55 g: 3.93 mmol) was slowly added and the solution turned a black
colour. Tic indicated that product had been formed. Purification by column
chromatography eluting with light petroleum / ethyl acetate (5: 1) afforded the desired
product 182 (121 mg: 0.46 mmol: 23%). Spectroscopic analysis was consistent
with the data obtained for the product 182 obtained previously.
ATTEMPTED FRIEDEL-CRAFTS USING ISOPROPYL 3-FUROATE
0J___6'0
o
131
:rDyCI
x o
O)__
o
o
The method used for generation of the acid chloride between 2,3-dimethybutadiene
and acryloyl chloride was identical to the preceeding reaction. To the resultant oil
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isopropyl 3-furoate (200 mg: 1.3 mmol) was added and the solution warmed to 80uC.
BF3.0Et2 (0.4 ml: 0.46 g: 3.34 mmol) was slowly added and the solution turned
black. Tic indicated that no product had been formed. The reaction temperature was
increased to 100°C but Tic showed again that no product had been formed and only
low running baseline material.
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6.16 SYNTHESIS OF WORTMANNIN DERIVATIVES
ISOLA TION OF WORTMANNIN 34
16
34
Wortmannin was obtained from Talaromyces wortmanii CBS Baarn-Delft (CBS
387.67) as a freeze dried culture. The culture was maintained on 2% malt agar slants
and transferred to Raulin and Thorn (+ 5% extra glucose) still culture (5 I) separated
into roux bottles. Table 6.1 shows the ingedients for the still culture.
INGREDIENT WT
(g)
De-ionised water IL
Glucose 52.5
Tartaric Acid 2.66
Ammonium tartrate 2.66
Di-ammonium hydrogenorthophosphate 0.4
Potassium carbonate 0.4
Magnesium carbonate 0.27
Ammonium sulfate 0.17
Zinc sulfate 0.05
Ferrous sulfate 0.09
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Table 6.1: Ingredients for still culture
The roux bottles were transferred to a room in subdued light for 264 h at 2YC
maintaining a pH of 3.9. The contents of the roux bottles were filtered, the broth
collected and the organics isolated by continuous extraction for 24 h with ethyl
acetate. The ethyl acetate extracts were dried over magnesium sulfate and evaporation
of the solvent in vacuo left the crude wortmannin as a solid. Purification via column
chromatography eluting with light petroleum! ethyl acetate (1: 1) afforded wortmannin
34 as a green solid (2.1 g: 0.46g I-I) mp 238-240°C IR vrnax(CH2Cl2 solution):
1648, 1748, 3140 crrr l. BH(2oo MHz: CDCI3): 0.84 (3H, s, H-18), 1.67 (3H, s,
H-19), 2.15 (3H, s, OAc), 2.51 (2H, m, H-16), 2.70 (lH, m, H-14), 2.85 (2H, m,
H-I2), 2.90 (2H, m, H-I5), 3.28 (3H, s, OMe), 3.37 (2H, dd, J 1.77 and J 11.15
Hz, H-2), 4.72 (IH, dd, J 1.74 and J 7.00 Hz, H-I), 6.09 (IH, ddd, J 2.65, J 7.55
and J 8.67, H-II) and 8.21 (IH,s, H-20). Be (50 MHz); 14.5 (C-18), 20.97
(CH3CO), 22.86 (C-I5), 26.41 (C-I9), 35.65 (C-16), 40.67 (C-IO), 43.98 (C-14),
49.12 (C-I3), 59.12 (MeO), 70.03 (C-Il), 72.78 (C-2), 88.46 (C-I), 114.15 (C-4),
140.29 (C-5), 142.81 (C-9), 144.69 (C-6), 149.50 (C-8), 150.07 (C-20), 157.60
(C-3), 169.49 (CH3CO), 172.59 (C-7) and 216.30 (C-17).mlz 385 (M+-OAc, 1.5)
and 266 (11.8%) (Found M+, C 64.24, H 5.57 C23H2408 requires M, C 64.48, H
5.57% ).
WORTMANNIN.17~.OL (187)
THF
o
MeO ..........AcO,' «,
194
To a flame dried flask flushed with nitrogen were charged Wortmannin 34 (150 mg:
0.37 mmo!) and 10 ml THF before being cooled to O'C. BH3.THF (0.74 ml:
1.0 M solution in THF: 0.74 mrnol) was added slowly dropwise and the resulting
solution kept at O°C for 5 hr. A colour change from orange to yellow was observed.
Water was added and organics were extracted with ethyl acetate (3 x 25 ml), washed
with sodium bicarbonate (3 x 20 ml) and brine (3 x 20 ml). The organic layer was
then dried over magnesium sulfate and the solvent removed under reduced pressure to
give the crude product. Purification by column chromatography eluting with light
petroleum / ethyl acetate (1 :2) afforded the desired product 187as a yellow solid (72
rng;: 0.1 mmol: 48%); IR Vrnax (CHCI3 solution); 1647, 1680, 1750,3026 and 3143
crrr l. ()H (200 MHz); 0.79 (3H, s, H-19), 1.74 (3H, s, H-18), 2.07 (3H, s, OAc),
2.23 (lH, m, H-16), 2.51 (lH, m, H-16), 2.71 (IH, m, H-14), 2.91 (IH, dd, J7.32
and JII.II Hz, H-2), 3.12 (3H, s, CH30), 3.37 (I H, dd, JI.75 and J 11.11 Hz, H-
2),3.80 (IH, t, J 7.84 Hz, H-14), 4.29 (1H, m, H-17), 4.69 (IH, dd, JI.72 and
J7.26 Hz, H-I), 6.04 (tH, rn, H-I1) and 8.17 (lH, s, H-20)· ()c (50 MHz: COCl3);
11.76(C-18), 21.07(C-19), 24.58(C-15), 26.46(C-22), 30.35(C-12), 39.98(C-13),
40.63(C-10), 44.09(C-16), 45.2(C-14), 59.33(CH30), 70.75(C-II), 72.82(C-2),
78.9(C-17), 88.91(C-I), 114.11(C-4), 141.94(C-5), 142.62(C-9), I44.94(C-6),
148.39(C-8), 149.82(C-20), 157.75(C-3), 169.63(C-21) and 172.96(C-7)
WORTMANNIN ENOL ACETATE (188)
p-TsOH o
18o
o
)--OAC
•
MeO,AcO'I.~1 1
2W 1 13
MeO,AcO" »,
20
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To a flame dried flask flushed with nitrogen were charged wortmannin 34 ( 158 mg:
0.39 mmol), isopropenyl acetate (5 ml) and a catalytic amount of para-
toluenesulfonic acid. The resulting mixture was allowed to stir for 24 h at 100°C.
The resulting solution was then extracted with ethyl acetate (3 x 25 ml), washed with
sodium bicarbonate (3 x IOml), brine (3 x 10 ml) and dried over magnesium sulfate.
The residual solvent was then removed under reduced pressure to give the crude
product. Purification was achieved via column chromatography eluting with light
petroleum/ ethyl acetate (I :5) to give wortmannin enol acetate 188 (100 mg: 0.2
mmol: 58%) IR Vrnax (CHCI3 solution); 1646,1680,1752,2970 and 3144 crrr '.
OH (200 MHz; CDCI3): 0.86 (3H, s, H-18), 1.60 (IH. m, H-12). 1.66 (3H, s, H-
19), 2.06 (3H, s, H-21), 2.11 (3H, s, OAc), 2.43 (2H, m, H-15), 2.60 (1H, m, H-
12), 2.85 (1H, m, H-14), 2.98 (1H, m, H-2), 3.13 (3H, s, OMe), 3.39 (1H, m, H-
2),4.61 (IH, m, H-I), 5.54 (2H, m, H-16), 6.03 (IH, m, H-II) and 8.19 (IH. s,
H-20). OC (50 MHz): 16.27 (C-18), 20.998 (C-21), 21.04 (CH3CO). 26.175 (C-
19),30.28 (C-12), 39.25 (C-15), 40.25 (C-lO), 46.07 (C-14), 47.75 (C-l3), 59.32
(MeO), 70.10 (C-II ),72.87 (C-2), 88.52 (C-I), 113 (C-16), 114.11 (C-4), 132 (C-
17),141.44 (C-5), 144.5 (C-6), 142.51 (C-9), 148.03 (C-8), 149.83 (C-20), 155.66
(C-3), 168.67 (CH3CO), 169.95 (C-21) and 172.5 (C-7).
16-METHYLIDENEWORTMANNIN (189)
o
DMF/150CI
1.5 h
MeO ...........AcO,' »,
CH20
NH(CH3h·HC1•
34
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To a flame dried flask under a nitrogen atmosphere was added wortmannin 34
(150 mg: 0.35 mmol), dimethylamine hydrochloride (38 mg: 0.47 rnmol), a
catalytic amount of paraformaldehyde and 10 ml DMF. The resulting solution was
stirred at 150°C for 0.5 h after which it gradually turned black. The solution was
then cooled to O°C and dilute HCI was added dropwise until an acidic pH was
acheived. The solution was then extracted with ethyl acetate (3 x 20m]) and the
extracts combined and washed with water (3 x 10 ml), brine (3 x 10 ml) and dried
over magnesium sulfate. The solvent was then removed under reduced pressure to
give the crude product as the residue. Purification by column chromatography eluting
with ethyl acetate/ light petroleum (5:3) gave 16-methylidenewortmannin 189
(106 mg: 0.24 mmol: 69%); IR Vmax (CDCh solution): 1644,1748,3020 and 3144
crrr+. OH (200 MHz); 0.92 (3H, s, H-18), 1.68 (3H, s, H-19), 2.07 (3H, s, OAe),
2.92 (IH, dd, J 7.00 and 1l.13 Hz, H-2), 3.11 (3H, s, OMe), 3.37 (I H, m, H-2),
4.70 (lH, dd, un, 5.5 (IH, s, H-21), 6.12 (2H, m, H-II) and 8.19 (IH, s, H-
20). Oc (50 MHz); 14.93 (C-18), 20.98 (CH3CO), 26.45 (C-19), 34.05 (C-15)
,36.25(C-12), 40.78 (C-IO),4l.51(C-14),49.45 (C-l3), 59.39 (MeO),69.93 (C-
11),72.82 (C-2), 88.43 (C-I), 114.23 (C-4), 120.71 (C-23), 139.96 (C-5), 142.3
(C-9), 143.96 (C-16), 144.66 (C-6), 149.75 (C-8), 150.00 (C-20), 157.522 (C-3),
169.49 (CH3CO), 172.5 (C-7) and 204.17 (C-17). m/z: 440 (M+, 3.1), 381 (6.2)
and 366 (63.4%) (Found M, 440.1472 C24H2408 requires 440.1471)
ATTEMPTED HYDROGENATION OF 16-METHYLIDENE-
WORTMANNIN
o o
MeO,AcO" ..
x •
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A flask was charged with wortmannin 34 (20 mg: 0.04 mmol) followed by 15 ml
ethyl acetate and a catalytic amount of palladium/carbon catalyst before being flushed
with hydrogen. The resulting solution was allowed to stir for 12 h. The catalyst was
then filtered through a pad of Celite® and the solvent removed under reduced
pressure. Tic indicated that although all starting material was consumed a complex
mixture had been made. The reaction was therefore abandoned.
ATTEMPTED SYNTHESIS OF 17,17-DIMETHYLACETAL
WORTMANNIN
o
x
OMe
OMeMeO---!'cO" ..
o
Wortmannin 34 (150mg 0.35 mmol), a catalytic amount of concentrated sulfuric acid
and 20 ml dry methanol were charged to a flame dried flask held under nitrogen. The
mixture was stirred for 60 h at room temperature. A white precipitate formed and
water (10 ml) was added. The resulting solution was extracted with ethyl acetate (3 x
20 ml) and the combined organic extracts were washed with sodium bicarbonate (3 x
10 ml), brine (3x 10 ml) and dried over magnesium sulfate. The solvent was
removed in vacuo to leave an orange solid as the product. This orange solid was
identified as the starting material.
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6.1 7 ISOLATION OF DEMETHOXYVIRIDIN AND SYNTHESIS OF
PLD-7
ISOLATION OF DEMETHOXYVIRIDIN (35)
o
35
Nodulisporium hinnuleum (lMI catalogue number 214826) was maintained on 2%
malt agar slants at 2Ye. Raulin and Thorn culture medium (with 5% extra glucose -
see Table 6.1) was prepared and transferred to roux bottles and sterilised in an
autoclave. The Nodulisporium hinnuleum was then transferred to the sterile culture
medium and the bottles were tranferred to a room with artificial lighting at 25°C for
350 h. The broth was then decanted from the myceleum. The broth was then
continuously extracted for 24 h with ethyl acetate and the myceleum was soxhlet
extracted for 24 h with ethyl acetate after being freeze dried. As tic indicated that
demethoxyviridin was present in both the extracts of the broth and the myceleum they
were combined and the solvent removed in vacuo. Crude demethoxyviridin was
obtained as the residual oil. Purification via column chromatography eluting with ethyl
acetate/ light petroleum (I .I) followed by recrystallisation from ethyl acetate gave
demethoxyviridin 35 as white crystals. M.p. 149-] S2°C ; IR Vmax (KBr disc): 153(),
]586, ]624, ]673, 1702 and 3439 crrr l. OH (200 MHz: DMSO): 1.55 (3H, m. H-
18),2.6] (2H, m, H-]6), 2.72 (1H, dd, J 5.3 and J ]8.3 Hz, H-2), 3.09 (lH, dd, J
]0.07 and 18.3 Hz H-2), 3.54 (2H, m, H-] 5), 4.33 (I H, m, H-I), 6.09 (1H, br d. J
5.8 Hz, OH), 7.84 (lH, d, J 8.2 Hz, H-] ]),8.59 (IH, d, J 8.2 Hz, H-12) and 8.80
199
(lH, s, H-20). bc(50 MHz: DMSO): 26 (C-18), 29 (C-16), 36 (C-2), 47 (C-15), 71
(C-l), 127, 129(C-ll, 12), 123(C-4), 130, 137(C-8.9), 145, 146(C-13,14), 156
(C-5), 158 (C-6), 173 (C-7), 190 (C-3) and 206 (C-17); m/z: 322. 278, 250, 222,
165,125 (Found M+, 322.0837; C 69.9 and H 4.53% CI9HI405.1/3H20 requires
M+, 32.0879; C 69.7 and H 4.5%)
SYNTHESIS OF PLD 7 (47)
o
o
N
o
Demethoxyviridin 35 (400 mg: 1.24 mmol) and methanesulfonyl chloride (427 mg:
3.72 mmol) were added to a 250 ml round bottom flask followed by pyridine
(20 ml). The resulting solution was stirred for 72 h at room temperature. Water
(200 ml) was added to quench the reaction and the aqueous phase extracted with
diethyl ether (3 x 50 rnl). The organic extracts were combined and washed with
dilute hydrochloric acid (50 ml) and dried over magnesium sulfate. The residual
solvent was removed in vacuo giving PLD 7 47 (174 mg: 0.57 mmol: 46%) M.p.
147-153°C; IRvmax(KBrdisc): 1528, 1586, 1632, 1665 and 1713cm-l. bH(200
MHz: CDCI3): 1.8 (3H, s, H-18), 2.8 (2H, m, H-16), 3.70 (2H, t, J 5.9 Hz, H-15),
6.4 (lH,d, J 10.1 Hz, H-I), 7.7 (IH, d, J 10.1 Hz, H-2), 7.8 and 8.1 (2 x IH, d, J
8.0 Hz, H-Il and 12) and 8.3 (tH, s, H-20); be (50 MHz: CDCI)); 29 (C-16), 36
(C-15), 41 (C-18), 122 (C-4), 124 (C-It) 128 (C-12), 131 (C 9), 132 (C-2), 145,
146 (C-13 and 8), 148 (C-l), 149 (C-20), 152 (C-5), 159 (C-6), 173 (C-7), 180 (C-
200
3) and 207 (C-17); m/z: 304,289,261, 176,97 and 84. (Found M+, 304.0734
CI9HI204 requires 304.0718.
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